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CHAPTER I 
 General Introduction and outline 
of the thesis 
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10 | Chapter I 
1. Breast cancer
Breast cancer (BC) is a heterogeneous disease with different clinical, biological, 
molecular and phenotypical features resulting from accumulation of (epi)genetic 
alterations and/or altered expression of genes 1,2.  The diversity of these genotypes, 
as in all kind of cancers, has been generalized by Hanahan and Weinberg as 
physiologic changes including self-sufficiency in growth signals, insensitivity to 
growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, tissue invasion, metastasis, 
reprogramming of energy metabolism and evading immune destruction that together 
dictate malignant growth 3. Thus, its development is a multi-step process. 
BC is also multi-factorial disease in which environmental factors, life-style and 
individual genetic background play important roles 4. 
2. Epidemiology
According to the latest Press Release (No.223) on December 12 2013 by the 
International Association of Cancer Research (IARC, the intergovernmental agency 
forming part of the World Health Organisation of the United Nations): Breast cancer 
affects some 1.7 million women annually worldwide. It comprised 25.2% of cancers 
diagnosed in women, thus being the most common female cancer (World Cancer 
report 2014). It was estimated that more than 508.000 women died in 2011 (Global 
Health Estimates, WHO 2013). 
Breast cancer incidence rates strongly vary worldwide. Incidence rates are higher in 
more developed countries such as Western Europe (90 new cases per 100.000 
women annually) compared to developing countries like in eastern Africa (30 new 
cases per 100.000). Yet, their mortality rates are comparable (15 per 100.000).   
Although in the developed world the prevention strategies and resources to treat 
breast cancer may be easier available, it seems that industrialization process may 
have a higher impact in cancer incidence. Remarkably the incidence rates for breast 
cancer may increase with level of country income, however this also indicates better 
screening programs as well as aging of this population. 
3. Risk and protective factors
The most important risk factors are female gender, older age, postmenopausal status 
5
, as well as family history (mutations in high penetrance genes, such as BRCA1, 
BRCA2, CHECK2, TP53 and PTEN explain approximately 25% of familial breast 
cancer) 6-9. Factors related to increased or prolonged estrogen exposure have been 
identified as risk factors for BC development and progression i.e. lower age at 
menarche, late birth of first child, later menopause, lack or shorter periods (<12 
months) of breast feeding. Long-term use of contemporary oral contraceptives (OCs) 
DQG FXUUHQW XVH IRU   \HDUV KDV EHHQ UHODWHG WR DQ LQcrease in risk of getting 
premenopausal BC. Similarly, hormonal replacement therapy, specially combined 
estrogen-progestin menopausal therapy has been linked to enhance the risk of getting 
postmenopausal breast cancer 5. 
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As for every disease lifestyle is important and lack or little physical activity is a risk 
factor 10. Other reported lifestyle risk factors include smoking, nightshifts or sleep 
disorders which affect circadian and neuroendocrine rhythms 5,11. 
Environmental factors such endocrine disruptors have shown to cause and/or to be 
linked to strong causality in breast cancer 5. Around 800 chemicals used in daily life 
are known or suspected to be endocrine disruptors 
(http://www.who.int/ceh/publications/endocrine/en/). DDT, PCB, DDE, PAH, PCB and 
BPA are the most important 12-19. Maybe frequent mammographic examinations in 
some cases may increase the risk of getting BC. All this is still a controversial and 
therefore a debated topic 5. 
Protective factors include amongst others the use of turmeric, garlic, as well as 
different vegetables and fruits which are considered chemopreventive, anti-
proliferative, antioxidant and carcinogen-blocking agents which acts by diverse 
mechanisms which are investigated in clinical trials 20, and in cell line models 21-26. 
Additional and more detailed information about risk as well as protective factors can 
be found for instance at the website breastcancer.org (see references for further 
details link27). 
4. Estrogens and Estrogen Receptor (ER)
Estrogens, together with progesterone 28, prolactine 29 and growth hormone 30, play 
an important role in the regulation of proliferation and differentiation of the mammary 
glands. In mouse models, estrogens have been shown to exert a proliferative effect 
on mammary gland epithelial cells either directly or indirectly by neighboring stromal 
cells, through binding to estrogen receptors 30. Thus, estrogens control important 
aspects of reproduction and homeostasis. Estrogens selectively bind to estrogen 
receptors (ER) of which 2 types have been identified: ER-alpha and ER-beta. 
Especially ER-alpha has been associated with carcinogenesis and serves as main 
target for endocrine treatments. Also, loss of ER-beta and TP53 results in breast 
tumorigenesis and cancer progression 31.  
ER acts as ligand-activated nuclear transcription factors 32,33. Once the estrogen binds 
to ER, the receptor dimerizes attracting co-activators and displacing co-repressors 
and then successively bind to specific estrogen response elements within promoter 
regions of estrogen-regulated genes. Some examples of ER co-activators such as 
AIB1 and PELP1/MNAR as well as the ER co-repressors RIP140, LCoR, MTA1, TR2, 
SAFB1/2, FKHR and NCoR have been  reviewed by Dobrzycka et al. 34. Due to these 
co-activators or repressors, expression of ER target genes can be either up- or down-
regulated. 
Additional genomic functions of ER as co-regulator for other transcription factors as 
well as ER non-genomic activities outside the nucleus, at the membrane, in the 
cytoplasm and for ER-beta in the mitochondria have been also described 35,36. 
9,,
9,,,
9,
9
,9
,,,
,,
,
9,,
9,,,
9,
9
,9
,,,
,,
,
12 | Chapter I  

5.    Prognosis 
 
Breast cancer prognosis is strongly related to tumor characteristics such as tumor 
size, tumor grade and axillary lymph node involvement 37,38. Mainly, two different and 
complementary classifications have been used for prognosis: TNM status and tumor 
grade by Bloom and Richardson. TNM classification is based on three clinico-
pathological characteristics: diameter of the tumor (T), involvement of local lymph 
node metastases (N) and presence of distant metastases (M) at time of diagnosis 39. 
Tumor grade classification determined by the Bloom and Richardson system 
categorizes breast tumors in three grades based on the degree of glandular 
differentiation, degree of nuclear atypia and mitotic index into: well differentiated 
(grade I), moderately differentiated  (grade II) or poorly differentiated  (grade III) 40. 
Overall, women with larger breast tumors and/or increasing numbers of positive 
lymph-nodes based on the TNM staging have a worse breast cancer survival 41. 
Likewise, poorly differentiated tumors, i.e. with high tumor grade, correlates with 
worse survival l 42. 
 
Nowadays, most newly diagnosed breast tumors are predominantly found at an early 
disease stage. The majority of tumors (75%) are ER-positive and more often found in 
postmenopausal patients. Whereas ER-negative breast cancer is more frequently 
found (46%) in premenopausal patients and is associated with larger tumors. Despite 
the growth-stimulatory effect of estrogens, exerted by its receptor, breast tumors 
without detectable ER expression tend to grow more rapidly, are less differentiated 
and more aggressive. 
 
6.    Clinical significance of the intrinsic subtypes 
 
Although breast cancer has been described as a heterogeneous disease, it is the 
introduction of high throughput molecular technologies and bioinformatics that 
enabled researchers to more accurately classify breast tumors, based on common 
gene expression patterns 43-45. While general classification has been done on single 
ER protein expression, the multiple gene expression patterns described in the 
landmark study by Perou et al. can distinguish different intrinsic molecular subtypes. 
Initially, these subtypes were classified in four main groups: luminal, HER2-enriched, 
basal-like and normal-like 43. Importantly, these subtypes were maintained among 
GLIIHUHQWPLFURDUUD\SODWIRUPVSDWLHQWV¶series and races 46,47. 
 
Later these subtypes were further refined based on larger sets and more detailed 
gene expression patterns. Luminal breast cancer tumors were ultimately subdivided 
in two groups: Luminal A and luminal B 48,49. Additional characteristics of each of these 
subtypes have been added to better define them 1. For instance, patients with basal-
like tumors, nowadays better known as triple-negative tumors since they generally do 
not express ER, PR, nor HER-2, have the worst overall survival 48. Moreover, luminal 
B compared to luminal A tumors have also a less favorable outcome 48,50.  Bone and 
(to a lesser extend) pleura are the most frequent sites of metastasis of luminal tumors; 
whereas HER-2 and basal-like tumors have more preference to metastasize to the 
brain 51. 
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7.    Treatment and mechanisms of action 
 
Treatment characteristics are defined in terms of response or time. For example, 
therapy given before the surgery is called neo-adjuvant therapy, but when followed 
after surgery it is called adjuvant treatment. When afterwards, the patient has a 
metastasis the given treatment is called first-line therapy and after every relapse will 
be followed by second-, third-, etc.-line therapy. Additionally, the effect of a therapy is 
evaluated based on response or survival analysis. Figure 1 illustrates general terms 
used in clinic for therapy and survival given in scientific publications.  
 
 
Figure 1 Terms used in clinic for therapy and survival. Terms mentioned refer to the moment in which a 
systemic treatment is given (White boxes, upper part); and to survival analysis (Grey boxes, bottom part). 
Survival is specified by their abbreviations: MFS: Metastasis Free Survival and DFS: Disease Free Survival 
are interchangeable; as well as TTP: Time to Progression and PFS: Progression Free Survival. Surgery 
and radiation therapy are local treatments. 
Until 1970 treatment decisions were merely based on clinico-pathological 
characteristics, including tumor size, lymph node status and histological grade. Later 
on, and based on (targeted) treatment possibilities, evaluation of ER, PR and HER2 
protein expression was added and combined in an algorithm. This algorithm is 
available online to assist decision making on adjuvant treatment in early breast cancer 
52
. Generally, luminal tumors express estrogen receptors (ER) and count for 
approximately 75% of all breast cancer tumors. For these ER-positive tumors three 
types of hormonal therapy are currently given: SERMs like tamoxifen, aromatase 
inhibitors (AI), or SERDs like fulvestrant. Although each of these drugs have different 
mechanisms of action, they all aim at in preventing activation of ER and it signaling 
pathway. 
While in premenopausal women, the main source of estrogens (estrone and estradiol) 
is the ovary, in post-menopausal women the estrogens are mainly derived from local 
conversion of circulating androgens (androstenedione and testosterone) by peripheral 
aromatase, predominantly in the adipose tissues. The adrenal glands are the main 
producers of these circulating androgens. However, approximately 10-25% are still 
being produced by the ovaries under the control of the Luteinizing Hormone (LH) 53-
55
. 
Endoxifen and (4-OH)-tamoxifen, the active metabolites of tamoxifen, act as 
competitors of estrogen by irreversible binding to the ER which results in a 
^ƵƌŐĞƌǇ Dd^d^/^WƌŝŵĂƌǇ
dƵŵŽƌ dŝŵĞ
EĞŽͲĂĚũƵǀĂŶƚ ĚũƵǀĂŶƚdƌĞĂƚŵĞŶƚ ϭƐƚͲůŝŶĞ͕ϮŶĚͲůŝŶĞ͙
KǀĞƌĂůů^ƵƌǀŝǀĂů;K^Ϳ
ZĂĚŝĂƚŝŽŶ
ƚŚĞƌĂƉǇ
D&^ͬ&^ ddWͬW&^
9,,
9,,,
9,
9
,9
,,,
,,
,
9,,
9,,,
9,
9
,9
,,,
,,
,
14 | Chapter I  

conformational change but not activation of ER. This then leads to blocking of the 
G0/G1 phase of the cell cycle, which results in the attenuation of cell proliferation 56,57, 
and possible induction of apoptosis 58. 
Unlike tamoxifen, AI reduce local estrogen levels by inhibiting the aromatase enzyme 
responsible for conversion of androgens into estrogens. AI can inactivate aromatase 
enzymes by binding reversibly to heme moiety (like nonsteroidal AI such as letrozole 
or analstrozole) or by permanent binding to the active site of the enzyme (like steroidal 
AI such as exemestane) 59. 
There are two types of aromatase inhibitors approved to treat breast cancer, i.e. 
steroidal and non-steroidal inhibitors. The irreversible steroidal inhibitors, such 
as exemestane, forms a permanent and deactivating bond with the aromatase 
enzyme. On the other hand, non-steroidal inhibitors such as anastrozole 
and letrozole, inhibit the synthesis of estrogen via reversible competition for the 
aromatate enzyme. 
In postmenopausal women, AI have shown very limited improvement over tamoxifen 
in relation to overall survival (OS) 60. In metastatic breast cancer, AI increase time to 
recurrence compared to tamoxifen 60,61 and have replaced tamoxifen as first-line 
treatment for advanced postmenopausal breast cancer 62,63. Although less severe 
than tamoxifen, AI  exhibit side-effects, including bone loss and fractures, rheumatoid 
arthralgia and even possibly effects on lipid metabolism and cognition 64. 
Another therapy used for ER+ tumors, although less common, is Fulvestrant 
(Faslodex®), an estrogen receptor antagonist, inhibiting ER-alfa protein dimerization 
and additionally introduces a conformational change accelerating the proteosomal 
degradation of the estrogen receptor. Its efficacy is similar to other endocrine 
therapies 65,66. Fulvestrant and other SERDs are nowadays considered of treatment 
for MBC patients who acquired resistance to AI-therapy due to specific mutations in 
the ligand binding domain of ESR1 67,68. 
Drugs targeting HER2-positive tumors include: trastuzumab (Herceptin®), a 
monoclonal antibody against HER2; pertuzumab (Perjeta®), a HER2 and HER3 
dimerisation inhibitor; ado-trastuzumab emtansine (Kadcyla®), Herceptin® linked to 
emtansine (a chemotherapeutic agent); and most recently lapatinib (Tykerb®), a dual 
tyrosine kinase inhibitor of both HER2 and EGF receptors, which has been developed 
to expand the options for treating HER2-positive breast cancer patients 69. 
8.    Tumor biomarkers:  gene signatures, microRNAs and liquid biopsy 
Besides single biomarkers, gene signatures, also called gene expression profiles, 
VWDUWHGWRHPHUJHHYHUVLQFHDWWHPSWLQJWR LGHQWLI\ LQGLYLGXDO¶VSURJQRVLVDQG
most optimal personalized treatments. 
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Overall, these expression profiles contribute on one side to reduce over-treatment and 
on the other side to consider alternative (targeted) therapies to treat predicted 
resistant tumors. Gene signatures may include different genes, while in some cases 
these genes enrich for related biological pathways 70. They may contribute to the 
outcome prediction. Nowadays a large number of signatures with prognostic and/or 
predictive value has been proposed to provide additional information next to the 
currently used clinical-pathological features as tumor size and lymph-node status 
rather than to be a replacement 71. 
Most of the signatures were in principle designed to predict recurrence, later on some 
of them were shown to have also predictive value for chemotherapy 72,73, for example: 
MammaPrint®, a 70-Gene signature (which was one of the first FDA approved gene 
expression signatures), predicts high risk of developing metastasis in either ER-
positive or ER-negative early breast cancer patients 74,75. This validated (Raster study 
and Mindact trial) signature showed that patients classified as high risk had benefit 
from chemotherapy when added to endocrine treatment 76 whereas patients at low 
(genomic) risk, but classified at high clinical risk, showed no benefit from 
chemotherapy  77.  
Oncotype DX®, a 21-Gene signature, predicts recurrence in lymph-node negative ER-
positive breast cancer patients treated with adjuvant tamoxifen 78,79. It also identifies 
patients who would benefit of additional chemotherapy 80.  
EndoPredict®, a 12-Gene signature combined with tumor characteristics, scores the 
risk of distant metastasis in early-stage ER-positive, HER2-negative breast cancer 
patients treated with endocrine therapy alone. 81-84.  
Other signatures, besides scoring the risk of distant recurrence 5 to 10 years after 
diagnosis, define patients who can benefit from hormonal treatment and thus may be 
of value in selecting patients for extended hormone therapy 85: 
Prosigna® 58-gene signature (Formerly called PAM50), is already approved by the 
FDA and has the CE mark. This signature, measures the risk of distant recurrence in 
Gene signatures / gene expression profiles 
A gene signature is a specified gene expression pattern that can be strongly 
correlated with clinical and/or tumor characteristics. This may result from a 
comparison between two defined groups based on one specific feature. For 
example, a gene signature defined based on clinical outcome, such as patients 
with good prognosis (no distant metastases >5 years) vs patients with poor 
prognosis (distant metastases <5 years). 
Consequently, the expression pattern has a certain number of up and down-
regulated genes that have a significant and strong correlation with the parameter 
of interest. These signatures are typically used to generate scores. Positive scores 
indicate the number of up-regulated genes in one group is higher compared to the 
number of up-regulated genes in the other group.  
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ER-positive postmenopausal breast cancer patients in early stage who will benefit 
from extended adjuvant hormonal therapy 43,48,86.  
%UHDVW&DQFHU,QGH[-Gene signature, scores the risk of recurrence in early stage 
ER-positive HER2-negative lymph node-negative (NO) and N1 breast cancer 
patients. Additionally, it predicts the benefit from extended endocrine therapy 87-90. 
Additional signatures have been described to predict response to hormonal therapies 
in breast tumors including for tamoxifen and AI 91,92, respectively. Furthermore, the 
prognostic 76-gene signature of Zhang Y. et al., demonstrated for its classified high-
risk patients benefit from adjuvant tamoxifen therapy 93,94. 
MicroRNAs 
Next to mRNA expression signatures, also expression of microRNAs have been 
profiled and evaluated for a relation with disease and treatment outcome. MicroRNAs 
(miRNAs) are a class of small non-protein-coding RNAs, evolutionarily conserved, 
that control gene mRNA expression. This mRNA expression can be either inhibited, 
degraded 95,96 or enhanced 97-100 via sequence-specific interaction of a miRNA with 
the 3' UTR of target mRNA. The mechanism of gene expression control depends on 
the degree of complementarity 101. 
Most of the miRNAs are located in intergenic regions residing predominantly in 
introns, but they can also be found in exons on the antisense strand of defined 
transcription units. MiRNAs can also be located in intragenic regions, having their own 
promoter and being transcribed as independent units 102. 
Deregulation of miRNAs expression occurs and can be due to genomic amplifications, 
deletions and mutations, epigenetic mechanism such as hyper methylation of the 
promotor and importantly due to changes in the tumor microenvironment 103-106.  
Aberrant expression levels of miRNAs have been observed amongst others between 
breast cancer molecular subtypes 107,108 and related with prognosis 109-111 and with 
response to hormonal therapy 112,113. 
Liquid biopsy 
Almost all cancer biomarker and expression signature research discussed above, 
have been performed on tissue biopsies. The last decade, however, also liquid 
biopsies are evaluated as tumor diagnostics tool to enable a more improved and 
personalized cancer treatment.  
Liquid biopsy is a less invasive method to detect in real-time the evolution of breast 
cancer. Liquid biopsies include mainly circulating tumor cells (CTCs) and cell-free 
DNA (cfDNA), although circulating endothelial cells (CECs) 114 or exosomes have also 
been described. Cell-free DNA originates from apoptotic or necrotic cells or viable 
cells which actively secret DNA fragments into the blood stream. Thus, cfDNA from 
normal cells or circulating tumor DNA (ctDNA) from tumor cells can be easily isolated 
and processed from plasma or serum. However, high-throughput and sensitive 
analyses are needed and now available to detect ctDNA. For the characterization of 
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ctDNA, next generation sequencing (NGS) and digital PCR (dPCR) are frequently 
used 115. 
Genomic patterns in cell-free DNA such as somatic single nucleotide variants (SNVs), 
copy number alterations (CNA) and structural variants (SVs) derived from the tumor 
have been already effectively detected. Thus, cell-free DNA is a great tool to monitor 
patients during the course of treatment to improve their therapies based on genomic 
patterns 116-120. CTCs are also available in the blood stream of cancer patients. 
Compared to cell-free DNA, characterization of CTCs, covers RNA and protein 
patterns besides DNA alterations 121-123. Nevertheless, CTCs are less frequent 
present in blood compared to cell-free DNA 124.  
Although the clinical utility of liquid biopsy still needs to be evaluated 125, its use is a 
crucial step towards a more individualized cancer therapy, which will revolutionize the 
ways to select and monitor cancer treatments 115. 
9.    Therapy resistance 
Targeted therapies against the ER, such as tamoxifen or AI, and against HER2, such 
trastuzumab and lapatinib, are proposed to be successful because breast cancer 
patients are stratified based upon these molecular markers or based on subtypes. 
Unfortunately, not all patients respond (de novo resistance) while in the metastatic 
setting, patients who respond initially will eventually relapse (acquired resistance).  
Approximately 40% of the metastatic patients with ER-positive primary breast tumors 
respond to hormonal therapy (antiestrogens or aromatase inhibitors) when given as 
first-line treatment 126. In the adjuvant setting, tamoxifen therapy results in an 11% 
improvement of 10-year survival in lymph node-positive patients, independent of 
menopausal status or age 127. Whereas, of the 60% of early stage breast cancer 
patients that receive chemotherapy in the adjuvant setting, only 2-15% will benefit, 
while all remain at risk of side-effects 127,128. Thus ER as a biomarker is not perfect for 
prediction of treatment outcome. There is also substantial inter-individual variation in 
response to tamoxifen and Aromatase inhibitors. 
10.    Mechanisms of endocrine resistance: Overview 
Several mechanisms have been described to contribute to hormonal resistance 60,129-
131
, but the (dis)function of ER-alpha plays a central role in endocrine therapy 
resistance.  
Loss or modification of ER expression, is the main mechanism of the novo 
resistance to hormonal therapy. Different theories have been proposed to explain the 
loss of ER expression. Epigenetic changes, hypoxia and overexpression of EGFR or 
HER2 have shown to alter the ER transcription and to explain the reduced ER 
expression. Alterations in DNA methylation at CpG islands of the ER promoter, 
usually hypermethylation as well as histone modifications are the main epigenetic 
changes studied 130. An example of histone modifications is the increased expression 
of EZH2, a histone methyl transferase that has been associated with downregulation 
of ER and tamoxifen resistance 132. PR and CDK10 gene methylations have been also 
related to endocrine resistance 130. Additional epigenetic changes have been 
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suggested for their relationship with tamoxifen resistance, including the lack of 
HOXB13 expression in especially a subset of ER-positive tumors seen after 
evaluation of the expression ratio of homeobox protein (HOXB13)/Interleukin-17B 
receptor (IL17BR) 133. 
Mutations in the ESR1 gene such as the A1587G, are also related to hormonal 
resistance and poor survival. This type of mutations present in only 1% of primary 
breast tumors 134, have been observed to arise especially after AI treatment 135,136. 
Ligand-dependent but also independent activation RI (5Į can occur through 
phosphorylation of the ER at specific amino acid sites such as at Ser 118, 104, 
106, 167 and Ser305 through different kinases including GSK-3, ERK1/2 MAPK, 
CDK2 and PKA have been associated with tamoxifen resistance. On the contrary, 
tamoxifen sensitivity has been related to ER phosphorylation at Ser167 and Ser282 
through kinases such as ERK1/2 MAPK, p90RSK, CK2, Akt and mTOR/p70S6K. 
Phosphorylations including Ser118 and Tyr537 have shown a dual effect 137. 
Lack of pioneer factors such FOXA1 have been also shown to be related to 
hormonal resistance in breast cancer. This pioneer factor is required for transcription 
of ER dependent genes, it is needed during the transcription process to let other 
binding proteins access the transcription binding site. Therefore, in the absence of 
FOXA1 cells do not respond to anti-estrogen treatment since the cell growth is not 
ER-alfa dependent 138,139. 
Another mechanism directly related to ER are ER splice variants, which have been 
shown by Groenendijk et al. to explain hormonal treatment resistance. The dominant 
QHJDWLYH(5ĮYDULDQW(5ǻVWDLQVSRVLWLYHIRU(5E\LPPXQRKLVWRFKHPLVWU\ZKLOHLW
classifies Basal-like according to the molecular subtype classification. This splice 
variant lacks a functional response to estrogen and consequently may not respond to 
hormonal therapy 140. 
Mechanisms related to hormonal drug metabolism caused by genetic variants 
might also explain tamoxifen resistance. It has been demonstrated in patients having 
different (*4, *5, *10, and *41) variant CYP2D6 genotypes, that they cannot or poorly 
metabolize tamoxifen into the active metabolite 4-OH-tamoxifen, and therefore those 
patients do not or poorly respond to the therapy 141-143. Inhibition of metabolism of 
tamoxifen might also occur via co-administration of drugs that inhibit CYP2D6, such 
as the selective serotonin re-uptake inhibitors (SSRIs) 144. 
Activation of proliferative kinase pathways can stimulate cancer growth alone or 
in concert with ER signaling and have been related to hormonal resistance. The 
PI3K/AKT/mTOR and the mitogen-activated protein kinase (MAPK) pathways are the 
most frequently altered in cancer and consequently the most studied. These pathways 
as well as its mutual intercommunication are explained below. Additional kinase 
pathways such as the protein kinase A (PKA) and p-21activated kinase-1 (PAK-1) 
have also been related to hormonal (tamoxifen) resistance.  
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11.    PI3K complex, PIK3CA mutation and downstream resulting pathways 
Since the phosphatidylinositol 3-kinase (PI3K) complex was first described, several 
studies have established the central role of PI3K signalling in diverse cellular 
processes critical for cancer progression, including proteins synthesis, growth, 
metabolism, proliferation, cell survival, apoptosis avoidance, motility and 
angiogenesis 145.  
At genomic level, there are three classes of PI3K grouped according to structure and 
function. Class IA PI3K is the one most clearly implicated in human cancer 146. This 
class consists of two main domains: the regulatory and the catalytic domain. The 
regulatory (R) domain is comprised of three genes: PIK3R1, PIK3R2 and PIK3R3 
which encode for p85D, p85E, and p55J respectively. p85D includes three different 
isoforms: p85D, p55D, and p50D. The catalytic (C) domain is comprised by the genes 
PIK3CA, PIK3CB, and PIK3CD, which encode for p110D, p110E, and p110G 
respectively 146-148.   
PIK3CA mutation 
PIK3CA is the most frequent mutated gene in primary breast cancer up to 45%) ϭ. 
Approximately 90% of PIK3CA mutations are clustered at 2 hotspot regions in exon 9 
(E542K and E545K) and exon 20 (H1047R and H1047L) 149,150, encoding the helical 
and kinase domains, respectively.  
PIK3CA mutations have been shown to phosphorylate and therefore activate AKT, 
the main component of the PI3K/AKT/mTOR pathway. The AKT phosphorylation is 
generally observed in exon 20 but not in exon 9 PIK3CA mutants 151. Additional 
downstream evaluated markers such as mTORC1, pS6, p70S6K, p4EBP1 and GSK3 
have not seen to be activated in PIK3CA mutated breast cancer cell lines nor tumors 
1,152,153
.  
PIK3CA mutations have been shown to have different effects on therapy response 
depending on the molecular subtypes. For example, HER2-positive patients harboring 
the PIK3CA mutation show resistance to trastuzumab therapy 154-157. On the other 
hand, the presence of the PIK3CA mutation in ER-positive breast cancer cell lines as 
well as in ER-positive, HER2-negative primary breast cancer patients have been 
associated with sensitivity to adjuvant tamoxifen 153. 
Pathways related with PIK3CA 
In breast cancer, hormonal resistance might also be related to activation of alternative 
proliferative pathways such as the PI3K/AKT/mTOR and the MAPK pathway, induced 
by upstream growth factors through their receptors including the insulin-like growth 
factor (IGF)-1 and IGF1R or the epidermal growth factor (EGF) and EGFR.  Many of 
these pathways probably emerge as ER-independent drivers of tumor growth, survival 
and/or inhibition of apoptosis. 129,137,140,143. 
PI3K/AKT pathway followed by mTOR resulting pathways 
Probably the PI3K/AKT pathway is the one of the best studied. Several components 
of this pathway are often deregulated, including amplification of HER2, loss of PTEN 
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function and PIK3CA amplifications or mutations. Most of the players of this pathway 
are kinases (i.e. enzymes that transfer phosphate from ATP to a specific substrate). 
Here, the cascade of events known until today upon growth factor activation is 
described. The first step is the growth factor binding to its ligand at the extracellular 
level, followed by a dimerization of the receptor making it auto-phosphorylated. The 
dimerization triggers the recruitment of adapter proteins such as IRS1 activating the 
PI3K complex (previously described) to generate PIP3 which triggers AKT 
translocation to the cell membrane.  PTEN and INPP4B reduce the levels of PIP3 in 
the membrane by dephosphorylating PIP3 and PIP2, respectively, thus inhibiting PI3K 
activation 158. 
Once AKT is recruited to the cell membrane it can be phosphorylated by 
phosphoinositide-dependent kinase 1 (PDK1) on threonine at position 308 (Thr308), 
followed by a second phosphorylation on serine at position 473 (Ser473) by the 
downstream mTORC2 complex. Upon activation, AKT dissociates from the 
membrane and then moves to the cytoplasm and the nucleus, where it phosphorylates 
multiple proteins involved in translation, metabolism, proliferation, survival, and 
angiogenesis 131,159.  
When AKT is phosphorylated its downstream target mTOR will be activated 131. This 
mTOR is a serine/threonine kinase which acts as the catalytic subunit of the two 
known mTOR complexes, mTORC1 and mTORC2.  The mTORC2 complex is 
responsible for the AKT phosphorylation on Ser473 (previously described) 160-163. 
AKT also activates mTORC1 through TSC2, consequently two mTORC1 main 
downstream target proteins, 4EBP1 and S6K, will be phosphorylated by mTORC1. 
4EBP1, which is a repressor of mRNA translation, becomes inactive through its 
phosphorylation by mTORC1 164. 4EBP1 can be seen then as a tumor suppressor 
since it represses eIF4E, a molecule responsible for protein synthesis 165. On the other 
hand, mTORC1 activates S6K, which is responsible for ribosomal biogenesis 164. As 
a result, S6K represses IRS-1 via a feedback loop, resulting in a PI3K/AKT pathway 
inhibition 131. 
12. Pathways, signatures and crosstalk 
Different signatures related with the PI3K/AKT/mTOR pathway have been shown to 
predict hormonal (tamoxifen and letrazole) response in the adjuvant setting 153,166. 
Previously, Loi et al. have shown that ER-positive tumors of breast cancer patients 
have high score of the PIK3CA-GS and are associated with longer MFS after adjuvant 
tamoxifen treatment. Their signature is based on the PIK3CA mutation status, mainly 
exon 20 mutations and grade, meaning that patients with a PIK3CA mutation pattern 
have high score of the mentioned signature. The PTEN-loss (Saal signature) was 
developed to represent IHC-detectable PTEN loss in breast cancer 167 while the PI3K 
signature by Creighton is based on a set of genes in which expression was induced 
or repressed by PI3K inhibitors 168. 
The PI3K/AKT/mTOR pathway shares some features with other pathways i.e. the 
mitogen-activated protein kinase (MAPK), also known as the Raf/MEK/ERK pathway, 
both kinase pathways stimulate cell proliferation, through a signaling initiated on 
receptors located on the cell surface and resulting downstream in the activation of 
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nuclear transcription factors 169,170. In human tissues, three major MAPK pathways are 
known, but the most relevant in breast cancer is the one involving MEK1/2 and 
ERK1/2 171. 
It has been shown that PI3K/AKT/mTOR and Raf/MEK/ERK pathways can collaborate 
to maintain cell viability 172. The crosstalk can occur in both directions. For example, 
MAPK signalling can be either reduced by AKT through inhibition of Raf 
phosphorylation 173, or enhanced after inhibition of mTORC1 through a S6K-PI3K 
feedback loop 174. In contrast, alterations in the PI3K/AKT pathway specifically to 
TSC2 and PTEN can be caused by the ERK and p90RSK 175,176 and by Ras 
respectively 177. 
The following links show a general view of the crosstalk between the PI3K/AKT/mTOR 
and the Raf/MEK/ERK pathways: 
http://www.sciencedirect.com/science/article/pii/S0305737213000728 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291999/figure/f3-ijms-13-01886/ 
The complexity of molecular communication between pathways in breast cancer is 
further complicated by interactions of the PI3K/AKT/mTOR and MAPK pathways with 
other cascades, including the important ER pathway 138,169. It has been observed that 
hormones such as estradiol, progesterone, and testosterone can act through G 
protein receptors activating the MAPK pathway 171. 
Thus, estradiol can stimulate cell proliferation either through a non-genomic or 
genomic estrogen receptor effects (increasing the production of growth factors) which 
ultimately will result in more activation of both kinase pathways (PI3K/AKT/mTOR and 
MAPK). Moreover, transcription of growth factors can also be induced by these two 
pathways 170 leading to a feed-back in tumor cells to reactivate signaling cascades. 
13.  In silico modelling and data-bases 
Considering the blooming data era, with millions of public available data, more 
researchers are choosing to work or at least to start their work with the analyses of in-
silico data. It implies less costs and time when compared to wet lab work. Moreover it 
is cost effective and gives the opportunity to further explore others previous efforts. In 
the last decade, several research consortia such as The Cancer Genome Atlas 
(TCGA; https://cancergenome.nih.gov) and the International Cancer Genome 
Consortium (ICGC; https://icgc.org) have evaluated large series of cancers, including 
breast cancer using high-throughput and state-of-the-art technologies to profile each 
individual tumor for its genomic and epigenomic DNA alterations and for expressed  
mRNAs, microRNAs and proteins. All these data are publicly available for the 
research community for in silico exploration, modelling and/or validation.  
14.   Aims and outline of the thesis 
The perception of breast cancer has changed in the last decades. The omics era has 
guided us to a better understanding of the heterogeneity of the disease, allowing us 
to make use of common features to better group patients and hopefully to improve 
SDWLHQWV¶WUHDWPHQWV 
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This thesis is in line with the omics peers and is committed to improve diagnostic tools 
IRU EUHDVW FDQFHUSDWLHQWV¶ WUHDWPHQWDQG WKXVDLPV WR ILQGSRWHQWLDO ELRPDUNHUV WR
predict hormonal treatment responsiveness and/or resistance in advanced ER-
positive breast cancer patients.  
For the mentioned purposes, the thesis firstly presents in chapter II, the effect of the 
PIK3 CA mutation (the most common mutation in breast cancer) in relation to hormonal 
treatment (tamoxifen and AI) outcome in ER-positive metastatic breast cancer 
patients (MBCP), and additionally in relation to prognosis. In this study patients with 
the PIK3 CA mutation are associated with longer time to progression (TTP) after first-
line AI.  
Consecutively, in chapter III, potential biomarkers for sensitivity to AI in ER-positive 
MBCP are proposed based on their relation to the PIK3 CA mutation status by using 
in silico gene and microRNA expression profiles. LRG1 expression is then proposed 
as a potential biomarker for AI treatment outcome independent of luminal A or B 
subtype. 
In chapter IV, altered phosphorylation of proteins as well as altered protein 
expression related to the PIK3CA mutation status is presented in a subtype 
independent manner. In-silico data of cancer related proteins (including the ones in 
the PI3K/AKT/mTOR pathway) are used for this purpose. PIK3CA mutated breast 
tumors are furthermore characterized in an exon independent manner. In TMAs, a 
favorable prognosis is shown for lymph-node negative ER-positive patients with high 
MAPK1/3 phosphorylation in nuclei and in tumor cells. 
Additionally, in chapter V, a different approach to the study the endocrine resistance 
is used. ER-positive patients with inflammatory breast cancer (IBC), an uncommon 
type of breast cancer (#5%), are studied in relation to tamoxifen and AI response after 
adjuvant and first-line therapy. For this, ER-positive IBC patients are selected since 
their response to endocrine treatment is poorer compared to ER-positive non-IBC. 
Low expression of ABAT and STC2 are proposed for adjuvant and/or first-line 
tamoxifen and/or AI resistance biomarkers. 
Finally, in chapter VI, in an exploratory study of cell-free DNA mutations in MBCP 
treated with tamoxifen, different progression markers including PIK3CA mutations are 
identified to contribute to the understanding of tamoxifen response in ER-positive 
breast cancer patients. This study also shows the potential of using liquid biopsies as 
an alternative diagnostic tool to assess disease progression over time in a patient. 
In conclusion, this thesis studies diagnostics/biomarkers involved in hormonal therapy 
resistance aiming at improved precision medicine for metastatic breast cancer 
patients.  
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ABBREVIATIONS  
AI   Aromatase Inhibitors 
AKT   protein kinase B  
BC  Breast Cancer 
BPA  Bisphenol A 
CTC  Circulating Tumor Cells 
CYP2D6 Cytochrome P450 family 2 subfamily D member 6 
DDE  Dichloro-diphenyl-dichloroethylene 
DDT  Dichloro-diphenyl-trichloroethane 
4E-BP1  4E-binding protein 1 
EGFR   Epidermal growth factor receptor 
eIF4e   eukaryotic translation initiation factor 4E 
EZH2  Enhancer of Zeste 2 polycomb repressive complex 2 subunit 
FDA   Food and Drug Administration 
FOXA1  Forkhead box A1 
HER-2   Human epidermal growth factor 2  
IBC   Inflammatory breast cancer  
IGF1R  insulin-like growth factor Receptor 
IHC  Immuno Histochemistry 
INPP4B  Inositol Polyphosphate-4-Phosphatase, type II  
IRS1   Insulin Receptor Substrate 1  
MAPK=ERK Mitogen-Activated Protein Kinase 
MBCP   Metastatic Breast Cancer Patients 
MEK  Extracellular signal-regulated kinases 
MFS   Metastasis free survival  
mTOR  mammalian Target of Rapamycin 
mTORC1 mammalian Target of Rapamycin Complex 1  
NCI   National Cancer Institute 
OS  Overall Survival 
PAH  Polycyclic aromatic hydrocarbons 
PCBs   Polychlorinated biphenyls  
PFS   Progression-free survival 
PIK3CA  Phosphatidylinositol-4,5-bisphosphate3-kinasecatalytic subunit 
alpha 
PIK3CB  Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
beta 
PIK3CD  Phosphatidylinositol-4,5-bisphosphate3-kinase catalytic subunit 
delta 
PIK3CA-GS  PIK3CA gene signature 
PIP2   Phosphatidylinositol4.5-bisphosphate  
PI3K  phosphatidylinositol 3-kinase 
PIP3   Phosphatidylinositol-3,4,5-trisphosphate  
PTEN    Phosphatase and tensin homolog  
P90RSK Ribosomal protein S6 kinase A1 
S6K1   Ribosomal S6 kinase 1 
TMA  TissueMicro Arrays 
TSC2   Tuberous sclerosis complex 2  
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ABSTRACT 
PIK3CA mutations occur frequently in breast cancer, predominantly in exons 9 and 
20. The aim of this retrospective study is to evaluate the PIK3CA mutation status for
its relationship with prognosis and first-line endocrine therapy outcome. PIK3CA exon
9 and 20 were evaluated for mutations in 1,352 primary breast cancer specimens by
SnaPshot multiplex analyses. The mutation status was studied for their relationship
with metastasis-free survival (MFS) in 342 untreated lymph node-negative (LNN)
patients and to time to progression (TTP) in estrogen receptor (ER)-positive patients
with metastatic disease treated with first-line tamoxifen (N = 447) or aromatase
inhibitors (AIs; N = 84). We detected in 423 patients hotspot mutations for PIK3CA
(31 %). Mutations in exon 20 were detected in 251 patients (59 %), with H1047L and
H1047R mutations in 37 (15 %) and 214 (85 %) cases, respectively. Mutations in
PIK3CA exon 9 were discovered in 173 patients (41 %), with E542K and E545K
mutations in 57 (32 %) and 104 (60 %) cases as most prevalent ones. Evaluation of
the untreated LNN patients for prognosis showed no relationship between MFS and
PIK3CA mutations, neither for exon 9 [HR = 1.04 (95 % CI 0.57±1.89), P = 0.90] nor
for exon 20 [HR = 0.98 (95 % CI 0.63±1.54); P = 0.94] when compared to wild-type.
The PIK3CA mutation status was also not associated with treatment outcome after
first-line tamoxifen. On the other hand, patients treated with first-line AIs showed a
longer TTP when having a PIK3CA mutation in exon 9 [HR = 0.40 (95 % CI 0.17±
0.95); P = 0.038] or exon 20 [HR = 0.50 (95 % CI 0.27±0.91); P = 0.024] compared to
wild-types, both significant in uni- and multivariate analysis including traditional
predictive factors. All results remained when only HER2-negative patients were
evaluated for each cohort. PIK3CA mutations in ER-positive tumors were significantly
associated with a favorable outcome after first-line AIs, which needs further
confirmation in other datasets. Mutations were not associated with prognosis in
untreated LNN patients nor predictive outcome after first-line tamoxifen therapy in
advanced disease patients.
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I N T R O D U C T I O N  
The phosphatidylinositol-3-kinase (PI3K) pathway regulates several cellular 
processes critical for cancer progression, i.e., protein synthesis, growth, metabolism, 
proliferation, cell survival, apoptosis, motility and angiogenesis [1]. Since this pathway 
is frequently deregulated in breast cancer, it is an attractive pharmacologic target to 
investigate. The PI3K is a complex of regulatory and catalytic proteins and one of the 
mechanisms of abnormal PI3K pathway activation is through mutations in the 110 kDa 
catalytic protein encoded by PIK3CA or in the 85 kDa regulatory protein encoded by 
PIK3 R 1. PIK3CA is the most frequent (30 %) mutated oncogene in breast cancer 
(http://www.sanger.ac.uk/genetics/CGP/cosmic), especially in ER-positive tumors [2, 
3]. Approximately 90 % of PIK3CA mutations [4], are clustered in two hotspot regions: 
exon 9 (E542K and E545K) encoding the helical domain and exon 20 (H1047R and 
H1047L) encoding the kinase domain [2, 5]. 
PIK3CA mutations may play an important role in the carcinogenesis and development 
of breast cancer and has been correlated with clinical and treatment outcome [6]. 
Several studies presented, however, contradicting results for the relationship between 
PIK3CA mutation status and clinical outcome. Some studies showed no correlation 
between PIK3CA mutations and clinicopathologic variables [4, 7], while others have 
shown a worse prognosis after treatment with HER2-inhibitors for patients with 
HER2+ tumors and PIK3CA mutations [8, 9]. Moreover, PIK3CA alterations are mainly 
present in invasive lobular (46 %) and ductal (22 %) breast carcinoma [10]. In lobular 
tumors, PIK3CA mutations have been found to be associated with tumor size, ER+ 
tumors and poor survival [6, 10], whereas other histological types with a low incidence 
of PIK3CA mutations have shown to be associated with a favorable prognosis [10]. 
Especially tumors bearing exon 20 PIK3CA mutations are related with poor prognosis 
compared to those having wild type PIK3CA and other PIK3CA mutations [11]. Finally, 
whole genome DNA analysis of a cohort of breast cancers revealed that PIK3CA 
mutations occur predominantly in ER-positive breast cancers of the molecular luminal 
subtype, whereas PI3K-pathway activation was especially observed in ER-negative 
basal breast cancers [3]. In this study, however, relationships with clinical and 
treatment outcome were not investigated. 
Breast cancer patients with tumors expressing the ER are treated with endocrine 
therapies, i.e., with tamoxifen or AIs. Unfortunately, not all patients respond (de novo 
resistance) while in the metastatic setting, patients who do initially respond will 
eventually relapse (acquired resistance). Endocrine therapy resistance may occur 
through activation of the PI3K- and MAPK-pathways and/or their downstream targets 
AKT and mTOR [12, 13, 14, 15, 16]. In this respect it is of interest to note that phase 
III clinical trials showed substantial benefit when mTOR-inhibitors were added to AI 
treatment [17]. Also for survival after adjuvant tamoxifen therapy contradicting results 
have been published. Lai et al. [11] showed in a cohort of 152 patients that invasive 
ductal carcinoma with exon 20 PIK3CA mutation had a significant shorter survival 
after adjuvant tamoxifen therapy compared to wild type tumors. On the other hand, 
Loi et al. [18] observed no relation with PIK3CA mutation status but a beneficial 
outcome after adjuvant tamoxifen therapy when applying a PI3K exon 20 gene 
expression signature. 
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To address above contradicting findings, we examined retrospectively the PIK3CA 
mutations in a cohort of 1,352 breast cancer patients to establish the prognostic and 
predictive significance of these mutations in tumors of 342 untreated LNN patients as 
well as 532 ER-positive patients with advanced disease treated with first-line 
endocrine therapy, i.e., tamoxifen (N = 447) or aromatase inhibitors (N = 84). 
Moreover, we correlated patient and tumor characteristics and clinical outcome with 
the PIK3CA mutation status, stratified for helical (exon 9) or kinase (exon 20) domain 
hotspot mutations, respectively. 
PATIENTS 
The Erasmus University Medical Center (EMC; N = 1,031), at Rotterdam, the 
Netherlands Cancer Institute (NKI; N = 159), at Amsterdam, and the Radboud 
University Nijmegen Medical Centre at Nijmegen (N = 77) all located in the 
Netherlands, and the Sint Augustinus Hospital at Antwerpen (N = 85) in Belgium 
participated in this study. Primary breast cancer tissue specimens were collected from 
1,352 female patients with primary or advanced breast cancer that entered the 
hospitals between 1978 and 2007. Patients and tumor characteristics are presented 
in Table 1 for all patients for which information was available and for the three different 
patient cohorts analyzed in this study. 
Follow-up, tumor staging, and response to therapy was defined by standard 
International Union against Cancer (Geneva, Switzerland) classification criteria [19]. 
This retrospective study has been approved by the local medical ethics committees, 
performed in accordance with the Code of Conduct of the Federation of Medical 
Scientific Societies in the Netherlands (http://www.fmwv.nl) and Belgium, and 
reported following the REMARK recommendations [20]. DNA isolated from primary 
breast tumor specimens were evaluated for PIK3CA exon 9 and exon 20 hotspot 
mutation status to assess relationships with patient and tumor characteristics and with 
clinical and treatment outcome. ER, progesterone receptor (PR), and HER2 status of 
the primary tumor tissue specimens were established as described previously [21, 22, 
23, 24]. 
The prognostic value of PIK3CA mutations was assessed in 342 LNN breast cancer 
patients. These patients had no metastatic disease at time of diagnosis and received 
no adjuvant systemic therapy. In addition, ER-positive patients with advanced disease 
treated with first-line tamoxifen (N = 447) or aromatase inhibitors (N = 84) were 
analyzed to determine the predictive value of PIK3CA mutations. Patients treated with 
endocrine therapy were selected based on the following inclusion criteria: Invasive 
ER-positive breast carcinoma; advanced disease deemed not curable by surgery 
and/or radiotherapy for which first-line tamoxifen or AI therapy had been given for at 
least 4 weeks; and frozen (N = 1,193) or paraffin-embedded (N = 159) primary tumor 
specimens were available.  
Detailed patient characteristics for the cohort of tamoxifen treated patients have been 
previously described [25]. The cohort of 84 metastatic breast cancer patients treated 
with first-line AIs received either steroidal (15 exemestane) or non-steroidal AIs (43 
anastrozole, 26 letrozole). Nine of these patients presented with metastatic disease 
at time of diagnosis, 52 patients had modified mastectomy and 23 patients underwent 
breast-conserving   lumpectomy.   Sixty-four  patients   received   adjuvant  endocrine 
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therapy and 17 patients were treated with adjuvant chemotherapy, however, all 
developed metastatic disease that was treated with first-line aromatase inhibitors. 
METHODS 
Multiplex PCR amplification and SnaPshot analysis 
For the detection of mutations, stored DNA was amplified for exons 9 and 20 of 
PIK3CA using earlier published PCR primers [26]. The amplified exons were 
assessed for mutations at the following nucleotide positions (with corresponding 
amino acid changes) G1624 (E542K, Q), G1633 (E545K, Q), A1634 (E545G, A), 
A3140 (H1047R, L) using the SnaPshot® multiplex system (Life Technologies) as 
described previously [26, 27]. All specimens with a mutation or that failed initially, were 
re-analyzed with the SnaPshot to validate the mutation status of the tumor. 
Statistics 
The relationship of mutation status with patient and tumor characteristics was 
investigated using nonparametric methods, i.e., Spearman rank correlations for 
continuous variables and Wilcoxon rank-sum or Kruskal±Wallis and Ȥ2 square test for 
ordered variables. The Cox proportional hazards model was used to compute the 
hazard ratio (HR) in the analysis of metastasis-free survival (MFS) and time to 
progression (TTP). MFS was defined as the time elapsed between the surgery and 
the first distant metastasis. TTP was defined as the time elapsed between initiation of 
endocrine therapy and the first detection of disease progression. In multivariate 
analysis, the predictive value of PIK3CA mutation status was compared to the base 
model of traditional clinicopathological factors for metastatic breast cancer, i.e., age 
at start of therapy, disease free interval, dominant site of relapse and PR and HER2 
status. The HR was presented with its 95 % confidence intervals (95 % CI). Survival 
curves were generated using the Kaplan±Meier method and a log rank test was used 
to test for differences. Computations were done with the STATA statistical package, 
release 12SE (STATA Corp., College Station, TX). All P-values were two-sided and 
P < 0.05 was considered statistically significant. 
RESULTS 
PIK3CA mutation frequencies and clinicopathological features 
We evaluated the DNA of 1,352 primary breast tumor specimens for hotspot mutations 
in the PIK3CA gene using SnaPshot multiplex analysis (Fig. 1a). No hotspot mutations 
for PIK3CA were detected in 928 tumors, here referred to as wild-type, although these 
tumors may harbor mutations outside the analyzed hotspots. For 423 patients a 
mutation in exon 9 or exon 20 (31 %) was discovered. Exon 20 mutations were 
detected in 251 patients (59 %), with a H1047L in 37 (15 %) and a H1047R mutation 
in 214 (85 %) cases. Mutations in PIK3CA exon 9 were detected in 173 patients (41 
%), with E542K and E545K mutations in 57 (32 %) and 104 (60 %) cases, respectively, 
as the most prevalent ones (Fig. 1b). 
Clinicopathological characteristics in relation with PIK3CA status for all patients and 
the three distinguished sub-cohorts of patients are shown in Table 1 and in more detail 
in Supplemental Table S1. PIK3CA mutations, both in exon 9 and 20, are most 
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frequently observed in luminal ER-positive and/or in PR-positive tumors (all P < 
0.001), in agreement with observations by others. Moreover, tumors with an exon 9 
mutation appeared to be smaller (<2 cm; P = 0.009) and tend to metastasize 
preferentially to bone (P = 0.071) than those with a wild-type or exon 20 mutant 
PIK3CA gene. These cohorts included a cohort for prognosis of untreated LNN 
patients and two cohorts for treatment outcome of ER-positive patients with metastatic 
disease treated with endocrine therapy. For the prognostic cohort the PIK3CA 
mutations were predominantly observed in luminal (P = 0.001), ER-positive (P = 
0.007), PR-positive (P < 0.001), and HER2-negative (P = 0.041) tumors. In the 
tamoxifen treated cohort, PIK3CA exon 20 mutations were especially detected in 
postmenopausal women (P = 0.003), whereas for the AI cohort exon 9 and 20 
mutations were overrepresented in PR-positive tumors (P = 0.004). Since HER2 
affects prognosis and response to endocrine therapy, survival analyses in the three 
sub-cohorts below were performed on all tumors (Table 1) and on HER2-negative 
tumors only (Supplemental Table S2).  
Figure 1 PIK3CA mutation frequencies. 
A The frequencies of PIK3CA exon 9 and 
20 mutations as detected in the total cohort 
and in subsets of breast cancer patients. 
Mutations occur more frequently in 
estrogen receptor positive (ER+) 
compared to ER-QHJDWLYH (5í WXPRUV
Lymph node-negative (LNN) breast cancer 
patients that received no adjuvant 
systemic therapy (N = 342) were 
investigated for the prognostic value of the 
PIK3CA mutation status. ER-positive 
breast cancer patients with metastatic 
disease treated with first-line tamoxifen (N 
= 447) or aromatase inhibitors (N = 84) 
were evaluated for a relation between 
PIK3CA mutation status with treatment 
outcome. WT are patients who have no 
PIK3CA hotspot mutation in exon 9 or 
exon 20, defined as wild-type. B The type 
and number of mutations detected in exon 
9 (all starting with E) or in exon 20 
(H1047R, H1047L) for the 423 patients 
with a PIK3CA mutation in their primary 
tumor. 
PIK3CA mutation status and prognosis 
To assess the prognostic value of PIK3CA mutation status, a subset of 342 LNN 
patients who received no adjuvant systemic therapy have been evaluated for the 
relation between mutation status and MFS. No significant differences were observed 
between wild-type and mutated PIK3CA tumors with regard to traditional prognostic 
factors age and menopausal status at diagnosis, tumor size, and grade. No 
association between PIK3CA mutation and MFS was found, neither for exon 9 [HR = 
1.04 (95 % CI 0.57±1.90); P = 0.90] nor for exon 20 [HR = 0.98 (95 % CI 0.63±1.54); 
P = 0.94] when compared to wild-type (Fig. 2a). Since mutations occurred 
predominantly in luminal tumors, the prognostic value was also established in 262 ER-
positive LNN patients of this sub-cohort. Again, for these 262 patients, no association 
A
B
342 untreated LNN
209 ER-1352 All 992 ER+
84 Aromatase Inhibitors447 tamoxifen
WT Exon 9 Exon 20
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between PIK3CA mutation and MFS was found, neither for tumors with exon 9 
mutations [HR = 1.03 (95 % CI 0.55±1.93); P = 0.94] nor for tumors with exon 20 
mutations [HR = 1.04 (95 % CI 0.65±1.66); P = 0.88] when compared to wild-type 
tumors. Mutation status and MFS showed also no relationships in the subsets of (ER-
positive) HER2-negative tumors only (Supplemental Table S2).  
Figure 2 PIK3CA mutation status: Prognosis and treatment outcome after first-line tamoxifen.  
A MFS analysis in 342 LNN breast cancer patients who had no adjuvant systemic therapy as a function of 
PIK3CA mutation status.  
B TTP analysis in 447 ER-positive breast cancer patients with advanced disease treated with first-line 
tamoxifen as a function of PIK3CA mutation status. 
 
PIK3CA mutation status and outcome after first-line tamoxifen therapy 
Next, a subset of 447 ER-positive patients with advanced disease treated with first-
line tamoxifen has been evaluated for the relationship between PIK3CA mutation 
status and treatment outcome. No significant differences were observed between 
PIK3CA wild-type and mutated tumors in relation to traditional predictive factors age 
at start of tamoxifen treatment, dominant site of relapse, disease-free interval and PR. 
The tumors with PIK3CA exon 9 and 20 mutations did not associate with TTP after 
tamoxifen, i.e., for exon 9 [HR = 1.17 (95 % CI 0.87±1.57); P = 0.30] and for exon 20 
[HR = 1.01 (95 % CI 0.78±1.31); P = 0.93] (Fig. 2b). The relationship between PIK3CA 
mutation status and TTP was also not observed in the subset of HER2-negative 
tumors (Supplemental Table S2). The PIK3CA mutation status showed a relation with 
menopausal status at start of therapy in this subset (P = 0.003), which was also 
confirmed by a significant test of interaction (P = 0.010) for exon 20 mutation status 
and menopausal status. For this reason, the mutation status in relation to TTP was 
also evaluated independently for pre- and postmenopausal patients. No associations 
were observed for PIK3CA exon 9 mutations in premenopausal [N = 77; HR = 0.94 
(95 % CI 0.50±1.78); P = 0.85] and postmenopausal [N = 369; HR = 1.22 (95 % CI 
0.87±1.71); P = 0.25] women. The PIK3CA exon 20 mutations, on the other hand, 
showed a significant relation with TTP in premenopausal women [HR = 2.59 (95 % CI 
1.08±6.25); P = 0.034] but not in postmenopausal women [HR = 1.00 (95 % CI 0.76±
1.31); P = 0.99], although exon 20 mutations were especially detected in 
postmenopausal women. 
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PIK3CA mutation status and outcome after first-line aromatase inhibitor therapy 
Finally, the PIK3CA mutation status was evaluated for a relationship with treatment 
outcome in a set of 84 ER-positive patients with advanced disease treated with first-
line AIs. The PR status in this cohort was the only traditional predictive factor for 
metastatic disease that linked to the PIK3CA exon 9 and 20 mutation status (P = 
0.004). Interestingly, patients with a PIK3CA mutation when compared with those 
being wild-type had a prolonged TTP after AI treatment, both for exon 9 [HR = 0.40 
(95 % CI 0.17±0.95); P = 0.038] as well as for exon 20 [HR = 0.50 (95 % CI 0.27±
0.91); P = 0.024] mutations (Fig. 3). These associations between mutation status and 
TTP were still significant when analyzed in the subset of HER2-negative tumors 
(Supplemental Table S2). An explanatory analysis in only patients treated with non-
steroidal AIs (N = 69) demonstrated that the relation between PIK3CA mutation and 
prolonged TTP kept significant, i.e., for exon 9 [HR = 0.27 (95 % CI 0.08±0.88); P = 
0.030] and for exon 20 [HR = 0.45 (95 % CI 0.23±0.87); P = 0.019]. The subset of 
steroidal AI treated patients (N = 15) was too small to draw conclusions. In multivariate 
analysis including age, disease-free interval, dominant site of relapse and PR and 
HER2 status as traditional predictive factors, the association with AI treatment 
outcome remained significant for both exon 9 and exon 20 mutants (see Table 2). 
These significant preliminary findings, however, need further validation in additional 
larger datasets. 
 
 
 
 
 
 
 
 
Figure 3 PIK3CA mutation status and treatment outcome after first-line aromatase inhibitors. TTP 
analysis in 84 ER-positive breast cancer patients with advanced disease treated with first-line aromatase 
inhibitors as a function of PIK3CA mutation status. 
DISCUSSION 
The purpose of this study was to evaluate PIK3CA exon 9 and exon 20 hotspot 
mutations in 1,352 primary breast tumor tissue specimens and to associate the 
mutation status with clinicopathological characteristics and with clinical outcome. 
Using SnaPshot analyses we identified PIK3CA mutations in 31 % of the patients with 
13 % mutations in exon 9 and 18 % mutations in exon 20. The mutations were mainly 
detected in the ER-positive tumors (35 %) compared to the triple-negative tumors (11 
%) (Supplemental Table S1). Moreover, fewer mutated tumors were observed for 
patients with LRR (29 %) compared to those patients with bone metastasis (40 %; N 
= 356, P = 0.056) and to those patients with bone or other distant metastases   (35 %:  
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N = 696, P = 0.17).   The frequency and distribution of PIK3CA hotspot mutations are 
comparable to those reported (Supplementary Figure S1) [3]. 
We evaluated exon 9 (helical) and exon 20 (kinase) domain PIK3CA mutations 
separately since exon 9 mutations have been reported mainly in lobular carcinomas 
and to associate with poor prognosis [28] and AKT-independent downstream 
signaling [29]. Although exon 9 mutations occur less frequent than exon 20 mutations, 
no significant differences were observed for almost all clinicopathological 
characteristics and clinical outcome in the sub-cohorts when stratified for PIK3CA 
exon 9 and 20 mutation status. We only observed in ER-positive tumors that PIK3CA 
exon 9 mutated tumors showed a trend to metastasize more often to bone and are 
smaller when compared to wild-type or exon 20 mutant tumors. 
The PIK3CA mutant tumors in our analyses are mainly of the luminal subtype and PR-
positive (80±83 %) in contrast to only 65 % PR-positive wild-type tumors. Other 
studies observed also significantly more PR-positive tumors in the PIK3CA mutant 
tumor group compared to the PIK3CA wild-type group, i.e., in a meta-analysis in 252 
of the 333 mutant tumors (76 %) versus 374 of the 708 wild-type tumors (53 %) are 
PR-positive [5, 30, 31], respectively. However, presence of PR recently has shown to 
be only prognostic but not predictive for adjuvant tamoxifen therapy [32]. Moreover, 
the uni- and multivariate analyses for TTP after AI treatment in our cohort revealed no 
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significant relationship between PR and outcome and PIK3CA mutation status 
remained independently from PR predictive for response to AI. In line with this, whole-
genome analysis of breast cancers of patients treated with AI in the neoadjuvant 
setting showed that mutations in the PI3K-pathway mainly occur in luminal A breast 
tumors with low recurrence risk [33]. Additionally, invasive ductal and lobular 
carcinomas did not differ in PIK3CA mutation frequencies and distributions in all our 
specimens (Supplemental Table S1). 
Our study shows that patients with a PIK3CA mutation in their tumors do have a 
favorable outcome on first-line AI therapy, whereas PIK3CA mutations are not 
prognostic nor related to first-line tamoxifen outcome. These findings are unexpected 
since somatic mutations in PIK3CA have been shown to activate AKT and induce 
oncogenic transformation of breast cancer cells [34] in vitro [35] and in vivo [36]. 
Additionally, in vitro studies demonstrated that resistance to endocrine therapy might 
be due to activation of the PI3K-pathway and/or it downstream targets AKT and mTOR 
[13, 15, 37]. Moreover, recent phase II and III clinical trials of metastatic breast cancer 
patients treated with tamoxifen or exemestane showed benefit from addition of 
everolimus, an mTOR-inhibitor, further stressing the role of the PI3K-pathway 
activation in endocrine resistance [17, 38]. On the other hand, no improve in 
progression free survival after first-line letrozole plus temsirolimus, also an inhibitor of 
mTOR, was observed in a randomized phase III trial of postmenopausal metastatic 
breast cancer patients [39]. Additionally, mutations in the kinase domain of PIK3CA 
were associated with favorable relapse-free survival and weakly with clinical response 
in a neoadjuvant endocrine therapy trial [40]. Finally, comprehensive reviews of a 
large number of clinical studies regarding PIK3CA mutations in breast carcinomas [2, 
41] indicate that PIK3CA mutations are associated with favorable prognosis in ER-
positive breast cancer. All these studies, however, included lymph node-positive 
and/or (neo) adjuvant treated patients, which may explain why we could not confirm 
this association with prognosis in our study on untreated LNN patients. The 
contradicting findings might also be explained by recent views that PIK3CA mutations 
not always translate into a downstream activated PI3K pathway [3]. A system 
biological approach was applied in this study to reveal a mechanism of action in 
clinical samples, which showed that while PIK3CA mutations are predominantly 
present in luminal breast tumors the PI3K pathway activation mainly occurs in basal-
like tumors. Luminal A PIK3CA mutated tumors in this study were low in PI3K pathway 
activation markers pAKT, pS6 and p4EBP1 and showed less PI3K-gene signature 
activity when compared to basal PIK3CA wild-type tumors. Analyses of down-stream 
PI3K pathway activation might be informative in our sub-cohorts for prognosis and 
tamoxifen, since no relationship with PIK3CA mutation status was observed for these 
cohorts, however, a system biological approach on these two cohorts was not 
applicable because genome wide RNA and/or protein data were not available. 
We investigated primary tumor specimens and related their PIK3CA status with 
treatment outcome for advanced disease, nevertheless, it has been shown that the 
PIK3CA status can differ between primary tumor and metastatic lesions [42]. Biopsies 
of metastatic lesions, however, are often difficult to obtain due to their localization. 
Additionally, serum/plasma-derived circulating free DNA (cfDNA) from a subset of 
metastatic breast cancer patients contained PIK3CA mutations whereas no mutations 
were detected in cfDNA from patients with localized breast cancer [43]. These studies 
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also identified wild-type primary tumors with matched metastatic lesions or cfDNAs 
that harbored PIK3CA mutations [42, 43]. All this indicates that primary disease may 
differ sometimes from metastatic disease with regard to PIK3CA status. It may affect 
slightly our findings and might explain partially differences between our observations 
in metastatic disease from those obtained by others in the adjuvant setting [11, 18]. 
Interestingly, we found that patients with a PIK3CA mutation in primary tumors have 
longer TTP after AI therapy when compared to wild-type tumors whereas there is no 
association with treatment outcome after tamoxifen treatment. The association with 
TTP after aromatase inhibitor therapy remained significant in the subset of patients 
treated with non-steroidal AI (letrozole, anastrozole) and after multivariate analysis of 
the PIK3CA mutation status together with the traditional predictive factors. The 
discrepancy in PIK3CA mutation status relationship with treatment outcome after AI 
and tamoxifen therapy may be of relevance for the choice of treatment of ER-positive 
breast cancer patients. This discrepancy needs further evaluation since the AI-cohort 
is relatively small and because these sub-cohorts were not controlled for differences 
that could affect response to tamoxifen or AI for metastatic disease due to the 
retrospective design of the study. Our analyses indicate, however, that HER2 status 
does not affect the relationships between mutation status and outcome after AI and 
tamoxifen. Moreover, none of metastatic breast cancer patients treated with tamoxifen 
whereas 64 patients treated with AI received adjuvant endocrine therapy, but Cox 
regression analyses for adjuvant tamoxifen in the AI-cohort revealed no significant 
relationship with TTP [HR = 1.66, (95 % CI 0.95±2.89); P = 0.074]. Based on these 
observations we do not believe that adjuvant endocrine therapy could explain the 
differences in response for metastatic disease for our analyzed cohorts of patients. 
In a neoadjuvant study on ER-positive breast tumors, it has been reported that 
everolimus increases the efficacy of letrozole [44]. Tumors with exon 20 PIK3CA 
mutations in this study showed less proliferation based upon Ki67-measurements 
after letrozole therapy compared to wild-type tumors and tumors carrying exon 9 
mutations. Unfortunately, for analyses of overall survival, patients were not stratified 
for PIK3CA mutation status. Endocrine therapy combined with mTOR inhibitors, such 
as everolimus, has also been studied in cell line models. Cell lines harboring the 
PIK3CA mutation are sensitive to this combined therapy, however, cell lines with an 
active PI3K pathway due to PTEN deletions or activating mutations in KRAS or BRAF 
have no additional benefit from this combined therapy [45, 46]. Further studies are 
needed to evaluate treatment opportunities for ER-positive breast cancer patients with 
and without a PIK3CA mutation and PI3K/AKT/mTOR pathway activation. 
CONCLUSIONS 
This study is the first to report that metastatic breast cancer patients with PIK3CA 
mutations in ER-positive primary tumors show favorable outcome after first-line 
aromatase inhibitor treatment. This significant preliminary association should be 
verified in randomized prospective clinical trials to establish predictive significance 
[47]. Moreover, PIK3CA mutations in luminal ER-positive tumors have no prognostic 
value and are not predictive for first-line tamoxifen treatment. 
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ABSTRACT 
Background 
PIK3CA is the most frequent somatic mutated oncogene in estrogen receptor (ER) 
positive breast cancer. We previously observed an association between PIK3CA 
genotype and aromatase inhibitors (AI) treatment outcome. This study now evaluates 
whether expression of mRNAs and miRs are linked to PIK3CA genotype and are 
independently related to AI therapy response in order to define potential expressed 
biomarkers for treatment outcome. 
Materials and methods 
The miR and mRNA expression levels were evaluated for their relationship with the 
PIK3CA genotype in two breast tumor datasets, i.e. 286 luminal cancers from the 
TCGA consortium and our set of 84 ER positive primary tumors of metastatic breast 
cancer patients who received first line AI. BRB Array tools class comparison was 
performed to define miRs and mRNAs whose expression associate with PIK3CA exon 
9 and 20 status. Spearman correlations established miR±mRNA pairs and mRNAs 
with related expression. Next, a third dataset of 25 breast cancer patients receiving 
neo-adjuvant letrozole was evaluated, to compare expression levels of identified miRs 
and mRNAs in biopsies before and after treatment. Finally, to identify potential 
biomarkers miR and mRNA levels were related with overall survival (OS) and 
progression free survival (PFS) after first-line AI therapy. 
Results 
Expression of 3 miRs (miR-449a, miR-205-5p, miR-301a-3p) and 9 mRNAs (CCNO, 
FAM81B, LRG1, NEK10, PLCL1, PGR, SERPINA3, SORBS2, VTCN1) was related 
to the PIK3CA status in both datasets. All except miR-301a-3p had an increased 
expression in tumors with PIK3CA mutations. Validation in a publicly available dataset 
showed that LRG1, PGR, and SERPINA3 levels were decreased after neo-adjuvant 
HIGHLIGHTS 
x Expression of 9 mRNAs and 3 miRs relates to PIK3CA genotype in 2 breast
cancer cohorts.
x All 9 mRNAs and 2 miRs were upregulated in tumors with PIK3CA mutations.
x LRG1 and PLCL1 mRNA levels relate to PIK3CA status irrespective luminal
subtype.
x LRG1 and PLCL1 mRNA levels associate with aromatase inhibitor therapy
outcome.
x LRG1 expression is decreased after neo-adjuvant letrozole treatment.
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AI-treatment. Six miR±mRNA pairs correlated significantly and stepdown analysis of 
all 12 factors revealed 3 mRNAs (PLCL1, LRG1, FAM81B) related to PFS. Further 
analyses showed LRG1 and PLCL1 expression to be unrelated with luminal subtype 
and to associate with OS and with PFS, the latter independent from traditional 
predictive factors. 
Conclusion 
We showed in two datasets of ER positive and luminal breast tumors that the 
expression of 3 miRs and 9 mRNAs associate with the PIK3CA status. Expression of 
LRG1 is independent of luminal (A or B) subtype, decreased after neo-adjuvant AI-
treatment, and is proposed as potential biomarker for AI therapy outcome. 
Abbreviations 
AI, aromatase inhibitors; AKT also known as Protein kinase B (PKB); BC, 
breast cancer; ER, estrogen receptor; FAM81B, family with sequence similarity, 81 
member B; HER2, human epidermal growth factor receptor 2; LRG1, leucine rich 
alpha 2 glycoprotein 1; MBC, metastatic breast cancer; mTOR, mechanistic target of 
rapamycin; PFS, progression free survival; PLCL1, phospholipase C like 1; SNP, 
single nucleotide polymorphism. 
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INTRODUCTION 
Breast cancer (BC) is a heterogeneous disease with different clinical, biological and 
phenotypical features (Koren and Bentires-Alj, 2015). Targeted therapies against two 
critical pathways in BC, the ER and HER2, such as tamoxifen or aromatase inhibitors 
and trastuzumab respectively, are successful when BC patients are stratified based 
upon their ER and HER2 status. Unfortunately, not all patients respond (de novo 
resistance) while in the metastatic setting, patients who do respond will eventually 
relapse (acquired resistance). 
Resistance to ER and HER2 targeted therapies may occur through activation of the 
PI3K pathway and/or their downstream targets AKT and mTOR (Clarke et al., 2015). 
Activation of the PI3K pathway was especially seen in ER negative tumors with 
predominantly amplified but hardly mutated (7%) PIK3CA, whereas mutations in this 
gene are most frequently found in ER positive tumors, up to 52% in luminal BC 
according to Ma et al. (2015) and The Cancer Genome Atlas Network (2012). 
Furthermore, primary tumors of BC patients with PIK3CA mutations were unexpected 
associated with favorable prognosis (Volinia and Croce, 2013) and clinical benefit 
from endocrine treatment (Ramirez-Ardila et al., 2013). Interestingly, PIK3CA mRNA 
was the most prominent gene in a prognostic signature of 30 mRNAs and 7 miRs 
(Volinia and Croce, 2013) established in one of two genome wide integrated 
transcriptome studies performed in BC until now (Buffa et al., 2011; Volinia and Croce, 
2013). The prognostic value of the mRNA component of this signature was confirmed 
on eight BC cohorts and outperformed several well-known RNA predictors, however, 
the predictive value of this signature remains to be established. 
The aim of our current study was to investigate mRNAs and miRs as potential 
predictive biomarkers correlated with PIK3CA genotype and AI therapy outcome. We 
evaluated the genome wide transcriptome of two BC datasets, and established 
overlapping mRNAs and miRs whose expression was related to the genotype of 
PIK3CA. The levels of these mRNAs and miRs were correlated with response to neo-
adjuvant and first-line AI therapy. 
MATERIALS AND METHODS 
Patients and datasets 
This study evaluated two previously published cohorts of breast cancer specimens for 
which PIK3CA genotype and mRNA expression profiles were available. It included a 
cohort of 286 luminal breast cancer patients (TCGA dataset) (The Cancer Genome 
Atlas Network, 2012) and a cohort of 84 ER positive breast cancer patients with 
metastatic disease who received first line aromatase inhibitors (AI dataset) (Ramirez-
Ardila et al., 2013). The TCGA transcriptome data for mRNA and miR were uploaded 
from their database portal (https://tcga-data-nci-nih-gov.eur.idm.oclc.org/), and 
evaluated for only luminal specimens (based on PAM50 classification) with wildtype 
PIK3CA or with an exon 9 or exon 20 mutation for this gene. 
The AI dataset included ER positive breast cancer patients from 3 institutes (Erasmus 
University Medical Center (EMC), Rotterdam; Netherlands Cancer Institute (NKI), 
Amsterdam; Sint Augustinus Hospital, Antwerpen). Patient characteristics, medical 
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ethics board approval, code of conduct, report criteria, and therapy response criteria 
for this cohort have been described previously (Ramirez-Ardila et al., 2013). Briefly, 
the patients received either steroidal (15 exemestane) or non-steroidal AI (43 
anastrozole, 26 letrozole). PIK3CA status and mRNA expression profiles were 
established by SnaPshot® multiplex assays (Life technologies) (Ramirez-Ardila et al., 
2013) and 44k mRNA oligoarrays (Agilent Technologies) (Jansen et al., 2013), 
respectively. The miR expression profiles were obtained for 768 probes (671 unique 
miRs) with Human MicroRNA Array v2.0 fluidic cards (Taqman Low Density Arrays, 
TLDAs) from Life Technologies according to the manufacturer's protocol. Expression 
data are deposited at NCBI GEO, with accession number GSE41994 for mRNAs 
(Jansen et al., 2013) and GSE78870 for miRs. 
In addition, we evaluated a third dataset of 25 breast cancer patients who received 
neo-adjuvant letrozole, available at NCBI GEO with accession code GSE59515 
(Turnbull et al., 2015). This neo-adjuvant dataset contains the transcriptome of 
primary tumor biopsies taken before and after 2 weeks and after 3 months treatment. 
Data analyses 
The TCGA set mRNA levels were median centered by gene while the mature/star miR 
strand levels were normalized to reads per million mapped miRNAs. The AI set mRNA 
levels were quantified and normalized using Agilent Feature Extraction software 
(Agilent, Santa Clara, CA, US). The miRNA TLDAs generated Ct values which were 
normalized against the median Ct value of the TLDA. All mRNA and miR expression 
data were log2 transformed and evaluated using BRB ArrayTools, Version 4.5.0-
Beta_1 (June 2015) (http://linus.nci.nih.gov.eur.idm.oclc.org/BRB-ArrayTools.html). 
BRB class comparison was performed when at least 80% expression data points were 
available in the AI set. The expression data in the TCGA set were available for all the 
samples. A P value <0.005 and <0.05 after 100,000 permutations was considered 
significant for mRNAs and miRs, respectively. The integrated evaluation of miR±
mRNA pairs was performed using the following databases: miRTarbase, mirSel, 
miRecords (V.4 ± Apr 27-2013), Ingenuity Pathway Analysis (IPA®) integrated with 
TarBase V.5.0. Pathway analyses were performed using (IPA®) and DAVID 
(https://david.ncifcrf.gov). 
Statistics 
Computations were performed with the STATA statistical package, release 13 
(STATA Corp., College Station, TX). All P values were two sided and P < 0.05 was 
considered statistically significant. Bonferroni multiple test corrections were also used. 
Briefly, relationships between PIK3CA genotype, clinic-pathological factors and 
miR/mRNA expression levels were investigated using nonparametric methods, i.e. 
Spearman rank correlations for continuous variables and Wilcoxon rank sum or 
Kruskal Wallis and chi square test for ordered variables. The Cox proportional hazard 
model was used in univariate analysis to compute the hazard ratio (HR) for PFS. The 
HR was presented with its 95% confidence intervals (95% CI). Survival curves were 
generated using the Kaplan±Meier method and a log rank test was applied to test for 
differences. PFS was defined as the time elapsed between initiation of first line AI 
therapy and the first detection of disease progression. miRs and mRNAs considered 
statistically significant in univariate analysis were included in a multivariate stepdown 
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analysis to determine the strongest independent predictive biomarkers. Finally, these 
potential predictive biomarkers were added to the base model of traditional clinic-
SDWKRORJLFDOIDFWRUVIRUPHWDVWDWLFEUHDVWFDQFHULHDJHDWVWDUWWKHUDS\±
70 or >70 years), disease-free interval (0±24 or >24 months), dominant site of relapse 
(Local regional relapse vs bone vs visceral), PR-status (negative or positive), and 
HER2-status (negative or positive, based on Target-Print HER2 mRNA classification). 
RESULTS 
PIK3CA genotype and transcriptome profiles 
The class comparison algorithm of BRB Array tools was used to identify differentially 
expressed mRNAs and miRs between PIK3CA wildtype and PIK3CA mutated ER 
positive (luminal) primary breast cancer specimens. This analysis revealed 119 and 
111 unique differentially expressed mRNAs (P < 0.005) in the TCGA and AI dataset, 
respectively (Figure 1, Supplemental Table S1). The majority of genes showed 
increased expression in tumors with a PIK3CA mutation in both datasets, i.e. 69% 
(82/119) in the TCGA dataset and 84% (93/111) in the AI dataset. Likewise, 17 and 
31 unique miRs were differentially expressed between PIK3CA wild type and mutated 
tumors (P < 0.05) in the TCGA and AI datasets (Figures 1, Supplemental Table S2). 
About half of the miRs showed increased expression in PIK3CA mutated tumors for 
the TCGA, i.e. 9 miRs in TCGA [53% (9/17)] and 16 miRs [52% (16/31)] in the AI 
dataset were upregulated.  
The 119 and 111 identified mRNAs were examined with Ingenuity® Pathway Analysis 
(IPA) to establish regulated signaling pathways in both datasets. Not surprising IPA 
revealed Estrogen as the only common significant up stream regulator for a subset of 
JHQHVERWKLQWKH$,GDWDVHW3YDOXH (íDQGWKH7&*$GDWDVHW3YDOXH 
(í 6XSSOHPHQWDO )LJXUH 6 $GGLWLonal pathways were not found to be 
enriched (based on the IPA and DAVID analyses). 
Breast cancer PIK3CA mutation specific transcriptome 
To obtain a PIK3CA mutation specific transcriptome independent of the cohort 
studied, we selected the overlapping potential biomarkers between both the TCGA- 
and AI-dataset (Supplemental Figure S2). In total 9 mRNAs (CCNO, FAM81B, LRG1, 
NEK10, PGR, PLCL1, SERPINA3, SORBS2 and VTCN1; Supplemental Table S3) 
and 3 miRs (hsa-miR-205-5p, hsa-miR-301a-3p and hsa-miR-449a) were related with 
PIK3CA genotype in both datasets. Interestingly, all biomarkers except one (miR-
301a-3p) showed increased expression in PIK3CA mutated ER positive (luminal) 
breast cancer (Figure 2). Since the TCGA dataset contains both luminal A and B 
samples, the 12 potential biomarkers associated with PIK3CA status were further 
evaluated for the relationship between their expression and luminal A or B subtype. 
The expression of LRG1, PLCL1, SERPINA3, CCNO and miR-449a were confirmed 
after multiple testing correction to be independent of subtype (Table 1). Moreover, the 
levels of these 5 biomarkers were in both TCGA- and AI-dataset not correlated with 
MKI67 levels, a gene significantly upregulated in luminal B compared to luminal A 
subtype. This again indicates that LRG1, PLCL1, SERPINA3, CCNO and miR-449a 
expression are independent from luminal subtype 
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F i g u r e 1  Wo r kf l o w u sed  t o  d i sco ver  d i f f er en t i al l y exp r essed  m R N A s an d  m i R s w h en  an al yz ed  b y 
PIK3CA m u t at i o n  st at u s. A  TCGA dataset (publicly available data from the TCGA consortium). B  AI 
dataset. *Known mRNAs indicates mRNAs with gene names annotated according to platform GPL6480 
updated in Nov 16, 2014 (http://www-ncbi-nlm-nih-gov.eur.idm.oclc.org/geo/query/acc.cgi?acc=GPL6480); 
**known miRs indicates miRs annotated according to miRbaseV20; ***unique mRNAs or miRs with the 
highest P-value indicate those cases in which at least two probes for an annotated mRNA or miR name 
were found differentially expressed. We selected the probe with the highest P-value. 
BRB class comparison analyses between PIK3CA mutants and wild types
&ULWHULD3)&
100.000 Permutations
< 20% missing values 
&ULWHULD3)&
100.000 Permutations
<20% missing values
Only known* and unique 
mRNAs with the highest P-
value remained***
Only known** and unique 
miRs with the highest   P-
value remained***
A
BRB class comparison analyses between PIK3CA mutants and wild types
&ULWHULD3)&
100.000 Permutations 
&ULWHULD3)&
100.000 Permutations 
B A I - d at aset  
84 primary tumors of MBC patients treated with first-line Aromatase inhibitors:
25 P I K 3 C A  m u t an t s(8 exon 9 and 17 exon 20) vs 59 wild- types
17814 Unique mRNAs        965 miRs (1222) sequences       
TCGA-dataset
286 luminal A and B breast tumors from the TCGA consortium:
102 PIK3CA mutants (45 exon 9 and 57 exon 20) vs  184 wild- types
17 unique differentially 
expressed miRs (8 down- and 9 
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Figure 2 Differentially expressed mRNAs and miRs when analyzed by PIK3CA mutation status. 
Volcano plots of differentially expressed mRNAs (top side) and miRs (bottom side) in the TCGA dataset 
(left side) and in the AI dataset (right side) analyzed by PIK3CA genotype. The vertical dotted lines indicate 
the threshold for a relative expression fold change (FC) of breast cancer PIK3CA exon 9 or exon 20 mutated 
tumors compare to PIK3CA wild types. The horizontal dotted lines represent the threshold of a P value. 
The blue dots in the upper sides are significantly upregulated (on the right) and down regulated (on the left) 
in PIK3CA mutants. Overlapping mRNAs and miRs in both datasets are labeled and indicated in red dots. 
The volcano plots are based on number of probes (see Figure 1 for details). 
Integrated analyses of common miRs and mRNAs 
Since miRs can regulate expression of specific target genes, the expression of the 
common 9 mRNAs and 3 miRs were checked for their statistical relationship by 
spearman correlation in both the TCGA- and AI-dataset. This exploratory analysis 
resulted in 14 miR±mRNA pairs with a P < 0.05, including 6 pairs still significant after 
multiple testing correction (Supplemental Table S4). These 6 miR±mRNA pairs were 
explored in different miR databases to identify putative mRNAs targeted by our miRs, 
and demonstrated only PGR as target of miR-205-5p in the miRSel database 
(Sempere et al., 2007). Highest correlations in the TCGA and AI dataset, i.e. rs = 0.69 
and 0.78, were observed between subtype independent expression of CCNO and 
miR-449a, possibly due to their chromosomal co-localization on 5q11. 
Additionally, expression levels of the 9 mRNAs were also correlated with each other 
(Supplemental Table S5), and showed coregulatory expression for 12 mRNA pairs in 
both datasets after multiple testing correction. Ingenuity identified TP73 for the LRG1-
SERPINA3 pair and STAT3 for the PGR-SERPINA3 pair as their common 
transcription regulator, respectively. 
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PIK3CA mutation specific transcriptome before and after neo-adjuvant AI 
therapy 
Next, above identified potential biomarkers were analyzed on the third neo-adjuvant 
dataset to establish whether their expression levels change after letrozole treatment 
(Figure 3). Expression in the before treatment biopsies were only significantly 
decreased for VTCN1 in the 8 clinical non-responders when compared to the 17 
clinical responders. On the other hand, expression levels for LRG1, PGR, and 
SERPINA3 were decreased after 2 weeks treatment and attenuated up to 3 months 
therapy when compared to the pre-treatment levels (Figure 3A). The downregulation 
for these 3 genes during neo-adjuvant letrozole therapy was only observed in patients 
with clinical response but not in those without clinical response, as exemplified for 
LRG1 (Figure 3B). 
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Figure 3 Gene expression alterations in primary tumor biopsies before and after AI treatment from 
patients who received neo-adjuvant AI therapy. The figure illustrates the results after validation in the 
publicly available NCBI GEO-dataset GSE59515 including 25 breast cancer patients who received neo-
adjuvant letrozole therapy. The cohort contained a subset of 17 patients with and a subset of 8 patients 
without clinical response after AI-treatment. The dataset contains the expression profiles of primary tumor 
biopsies before and after 2 weeks and 3 months treatment from these patients. A presents the median 
expression levels and P-values measured before treatment for the 2 patient subsets (Mann±Whitney P-
values) and before and after 2 weeks and 3 months AI-treatment for all patients (Kruskal Wallis P-values). 
The Kruskal Wallis test was also performed on each subset of patients separately. B is a boxplot illustrating 
LRG1 expression levels before and after treatment in both patients with and without clinical response to 
neo-adjuvant letrozole. 
PIK3CA mutation specific transcriptome and hormonal therapy outcome 
The PIK3CA genotype linked potential biomarkers were further evaluated for their 
relationship with OS for 272 patients of the TCGA-dataset and with PFS for 75 MBC 
patients who received first line AI and for whom both expression and clinical data were 
available. Expression of LRG1, PLCL1, SERPIN A3 and miR-301a-3p was related with 
OS, based on all therapies that the patients had received (Table 1). In addition, 
expression levels of all biomarkers except miR-205-5p were significantly (P < 0.05) 
related to PFS (Figure 4A). Only the expression of miR-301a-3p was linked to therapy 
resistance whereas expression of all other biomarkers was associated with response 
to AI. The 11 potential biomarkers that associated with therapy outcome, were each 
further evaluated along with traditional predictive factors, the base model. In this 
multivariable analyses eight factors were independent from the base model (Table 1) 
and these were combined for a stepdown analysis. Since we know that PIK3CA 
mutations correlate with PFS in our cohort, as reported by us (Ramirez-Ardila et al., 
2013), a stepdown including PIK3CA status was analyzed to reveal variables that 
outperformed the PIK3CA status correlation with PFS, i.e. are more strongly 
correlated with PFS. Performing the stepdown analysis with and without PIK3CA 
status resulted in similar findings, i.e. only FAM81B (P < 0.001), LRG1 (P = 0.001) 
and PLCL1 (P = 0.013) were independent biomarkers associated with AI therapy 
outcome in MBC patients (Figure 4B). Interestingly, LRG1 and PLCL1 expression was 
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shown to be related to PIK3CA independently of the luminal subtype. The observed 
association with PFS for these 2 potential biomarkers is illustrated in Kaplan Meier 
survival curves in Figure 4C±D. Finally, we investigated the expression of LRG1 and 
PLCL1 in our dataset of 101 MBC patients who received first line tamoxifen, however, 
no significant relationship with tamoxifen outcome was observed for both genes (data 
not shown). 
 
Figure 4 Relation to PFS after first line AI treatment. A Forest plot summarizing univariate analyses in 
75 MBC patients in relation to PFS after first line AI treatment. Traditional factors are not included here. 
The variables in red remained significant in multivariate analysis after stepdown analyses and corrected for 
traditional factors. (#) indicates dichotomized variable, all others are continuous variables. All variables are 
up-regulated in PIK3CA mutants except for miR-301a-3p. (*) indicates variables which are subtype 
independent, i.e. had no significant relationship (P > 0.004) with subtypes after Bonferroni multiple-testing 
correction. B Steps followed to identify independent potential biomarkers related to PIK3CA status and 
independent of subtype C±D. PFS analyses in 75 ER positive breast cancer patients with advanced disease 
treated with first line AI as function of C PLCL1 expression and D LRG1 expression. 
 
P<0.05 
Corrected for 
Traditional factors
(P>0.004) after 
Bonferroni 
multiple-testing 
correction 
Subtype 
independent 
based on the 
TCGA-dataset
1. LRG1        P=0.001
2. PLCL1      P=0.013
3. FAM81B   P=<0.001Stepdown 
analysis 
P<0.05 
1. LRG1   P=0.006
2. PLCL1  P<0.001
(Table 1)
1. LRG1    P=0.139
2. PLCL1  P=0.0126
(Table 1)
B
Logrank P <0.001
0.00
0.20
0.40
0.60
0.80
1.00
0
Cu
m
u
la
tiv
e 
pr
op
or
tio
n
19
56
9
39
4
23
1
14
9 24 36
Numbers at risk:
High LRG1 expression
Low LRG1 expression
PFS in months
0
7
18
High LRG1
Low LRG1
Logrank P =0.02
38
37
15
23
7
14
2
5
0.00
0.20
0.40
0.60
0.80
1.00
0 12 24 36
Cu
m
u
la
tiv
e 
pr
op
or
tio
n
Numbers at risk:
High PLCL1 expression
Low PLCL1 expression
PFS in months
PIK3CA mutants #
hsa-miR-449a *
hsa-miR-205-5p
hsa-miR-301a-3p
NEK10
PLCL1 *
LRG1 *
SERPINA3
PGR
CCNO *
FAM81B
SORBS2
VTCN1
ID
0.45 (0.24, 0.82) 0.010
0.93 (0.87, 0.99) 0.022
0.93 (0.84, 1.04) 0.209
1.30 (1.01, 1.68) 0.043
0.76 (0.65, 0.90) 0.001
0.61 (0.46, 0.81) 0.001
0.69 (0.55, 0.87) 0.002
0.82 (0.70, 0.97) 0.020
0.84 (0.74, 0.95) 0.006
0.84 (0.73, 0.96) 0.010
0.82 (0.73, 0.92) <0.001
0.69 (0.56, 0.86) 0.001
0.84 (0.73, 0.97) 0.021
HR (95% CI) P-value
1.1 10
A
DC
High PLCL1
Low PLCL1
9,,
9,,,
9,
9
,9
,,,
,,
,
9,,
9,,,
9,
9
,9
,,,
,,
,
LRG1 mRNA associates with PIK3CA genotype and AI therapy outcome | 63

D IS C U SS IO N  
In this study, the transcriptome of a TCGA cohort of 286 luminal A and B tumors from 
BC patients and our cohort of 84 ER positive primary breast tumors from patients who 
developed metastatic disease were stratified by PIK3CA genotype. In both datasets 
we demonstrated 1 miR with decreased and 2 miRs and 9 mRNAs with increased 
expression in tumors with a PIK3CA hotspot mutation. Evaluation of these biomarkers 
in the neo-adjuvant dataset showed that expression of 3 mRNAs decreased after 
letrozole therapy. Multivariate analyses, including clinico-pathological factors and 
molecular tumor subtypes, revealed LRG1 and PLCL1 as independent potential 
biomarkers for PFS after first line AI therapy. All our findings indicate that high LRG1 
expression levels hallmark primary breast cancer with PIK3CA mutations and 
treatment response after neo-adjuvant and first-line AI-therapy. 
The majority of differentially expressed mRNAs in both datasets had an increased 
expression in PIK3CA mutated tumors. In addition, we found 6 miR±mRNA pairs with 
significant related expression levels in both datasets after Bonferroni multiple 
correction test. Negative correlations have been generally reported since miRs control 
gene expression by mRNA degradation and/or translation inhibition (Bartel, 2004). 
However, most of our miR±mRNA pairs showed a positive correlation. Dvinge et al. 
indicated that the BC miRNA±mRNA landscape was dominated by positive 
connotations, and suggested co-transcriptional modules, especially in ER+ samples 
(Dvinge et al., 2013). 
The established PIK3CA mutation specific potential biomarkers were previously linked 
to breast cancer, PI3K pathway and/or endocrine therapy. For example, PGR 
belonged to the regulated genes after PI3K inhibition (Bosch et al., 2015), whereas 
S E R PINA3 was part of activated PI3K signatures (Loi et al., 2010). SERPINA3 was 
identified as biomarker for estrogen regulation in response to neoadjuvant AI therapy 
(Miller and Larionov, 2010), whereas SNPs for NEK10 (Milne et al., 2014) and VTCN1 
(Tsai et al., 2015) were linked to BC susceptibility. Moreover, miR-449a expression 
was increased in luminal BC compared to the other subtypes (Dvinge et al., 2013) 
and its tumor suppressor activity was regulated by PI3K (Liu et al., 2015). The 
upregulated expression of miR-205 and miR-449a in tumors with a PIK3CA mutation 
was shown to suppress the epithelial mesenchymal transition (EMT) in BC and liver 
cancer, respectively (De Cola et al., 2015) (Chen et al., 2015a). Interestingly, miR-
205-5p directly targets HER3 receptor, involved as well in EMT, inhibiting the PI3K 
pathway activation respectively (De Cola et al., 2015). In contrast, the down regulated 
miR-301a-3p in tumors with PIK3CA mutation, was shown to increase the EMT in 
laryngeal neoplasm (Lu et al., 2015) and to target in BC especially genes involved in 
T cell related processes (Dvinge et al., 2013). Combining results in BC cell lines on 
PIK3CA status obtained from the COSMIC database 
(http://cancer.sanger.ac.uk/cell_lines) and on miR-301a-3p expression described by 
Ma et al. (2014) suggest that BC cell lines with PIK3CA mutations have decreased 
miR-301a-3p expression compared to wild types. 
Although all 9 mRNAs and 2 miRs associated with PIK3CA genotype and PFS in 
MBC, only PLCL1, LRG1, CCNO, SERPINA3 and miR-449a were not related with 
luminal subtypes A and B. Furthermore, mRNA expression of FAM81B, PLCL1, and 
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LRG1 remained as independent potential biomarkers for PFS after first line AI 
treatment once stepdown analyses and multivariate analysis with well-known clinical 
traditional factors are performed. 
Thus, we propose PLCL1 and LRG1 as potential luminal subtype independent 
biomarkers that associate with PIK3CA genotype and first line AI treatment outcome. 
PLCL1 and LRG1 have so far not been linked with BC and PIK3CA genotype. PLCL1 
encodes for phospholipase C like 1, also known as PRIP 1, which has been suggested 
to be involved in insulin induced GABA(A) receptor functioning (Fujii et al., 2010) and 
in gonadotropin secretion (Matsuda et al., 2009). Interestingly, CA2+ and 
phospholipase C signaling was recently indicated as one of the over represented 
canonical networks in ER positive BC (Ellis et al., 2012). LRG1 (encodes for leucine 
rich alpha 2 glycoprotein 1) was proposed as a metastasis suppressor in 
hepatocellular carcinoma (HCC) since exogenous recombinant human LRG1 protein 
inhibited migration and invasion of HCC cells in vitro (Zhang et al., 2015). Moreover, 
LRG1 was shown as potential biomarker for detection of cancer in urine and/or serum 
such as epithelial ovarian, lung and colon cancer (Chen et al., 2015b; Ivancic et al., 
2014; Smith et al., 2014; Wu et al., 2015). In endometrial carcinoma patients LRG1 
expression was related to poor prognosis (Wen et al., 2014). Our transcriptome 
analyses of tumor biopsies before and after neo-adjuvant letrozole showed decreased 
expression upon treatment for LRG1, PGR, and SERPINA3. These 3 genes were also 
reported within the top 150 differentially expressed genes between pre- and 2 weeks 
post anastrozole neo-adjuvant treatment (Dunbier et al., 2013). All this suggest that 
alterations in LRG1 levels may be used as readout for a response to AI. Further 
studies in BC are needed to resolve the relationship of PLCL1 and LRG1 with PIK3CA 
mutation and AI therapy response. 
In conclusion, we used mRNA and miR expression and identified 9 mRNAs and 3 
miRs overlapping between ER positive and luminal A and B tumors in relation to 
PIK3CA mutation status. The expression of 2 genes, LRG1 and PLCL1, was shown 
to be independent of subtype and related to PFS after first line AI treatment in MBC 
patients. Expression levels of LRG1, but not PLCL1, were shown to decrease 
significantly after treatment in patients with clinical response to neo-adjuvant letrozole. 
Since our analyses were based on PIK3CA genotype, and given the high frequency 
of PIK3CA mutations, this exploratory study provides potential novel biomarkers for 
PFS after first line AI treatment. These results need to be validated in future studies. 
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ABSTRACT 
Introduction 
While mutations in PIK3CA are most frequently (45%) detected in luminal breast 
cancer, downstream PI3K/AKT/mTOR pathway activation is predominantly observed 
in the basal subtype. The aim was to identify proteins activated in PIK3CA mutated 
luminal breast cancer and the clinical relevance of such a protein in breast cancer 
patients.   
Materials and methods  
Expression levels of 171 signalling pathway (phospho-)proteins established by The 
Cancer Genome Atlas (TCGA) using reverse phase protein arrays (RPPA) were in 
silico examined in 361 breast cancers for their relation with PIK3CA status. MAPK1/3 
phosphorylation was evaluated with immunohistochemistry on tissue microarrays 
(TMA) containing 721 primary breast cancer core biopsies to explore the relationship 
with metastasis-free survival.  
Results  
In silico analyses revealed increased phosphorylation of MAPK1/3, p38 and YAP, and 
decreased expression of p70S6K and 4E-BP1 in PIK3CA mutated compared to wild-
type luminal breast cancer. Augmented MAPK1/3 phosphorylation was most 
significant, i.e. in luminal A for both PIK3CA exon 9 and 20 mutations and in luminal 
B for exon 9 mutations.  In 290 adjuvant systemic therapy naïve lymph node negative 
(LNN) breast cancer patients with luminal cancer, high MAPK phosphorylation in 
nuclei (HR= 0.49; 95% CI, 0.25-0.95; P=0.036) and in tumor cells (HR= 0.37; 95% CI, 
0.18-0.79; P=0.010) was related with favorable metastasis-free survival in multivariate 
analyses including traditional prognostic factors. 
Conclusion  
Enhanced MAPK1/3 phosphorylation in luminal breast cancer is related to PIK3CA 
exon-specific mutations and correlated with favorable prognosis especially when 
located in the nuclei of tumor cells. 
Keywords: PIK3CA mutations, MAPK1/3 phosphorylation, luminal breast cancer, 
tissue microarray, Metastasis free survival (MFS). 
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INTRODUCTION 
The Cancer Genome Atlas (TCGA) data on breast cancer have shown that the 
PIK3CA mutation frequency could rise to 45% in luminal A tumors compared to only 
9% in basal tumors [1]. Remarkably, the reverse protein phase array (RPPA) data of 
this study demonstrated that phosphorylation of AKT, S6 and 4EB-P1, typical markers 
of PI3K pathway activation (PI3K-AKT signalling pathway in KEGG: 
http://www.genome.jp/kegg-bin/show_pathway?hsa04151) were highly expressed in 
basal-like and HER2 molecular subtypes and correlated strongly with INPP4B and 
PTEN loss, and with PIK3CA amplification. Moreover, protein and mRNA signatures 
of PI3K pathway activation were enriched in basal-like over luminal A breast cancers 
[1].  
Mutations in PIK3CA occur predominantly in two hotspot regions, i.e. in the helical 
and kinase domains encoded by exon 9 and 20, respectively. COSMIC, the catalogue 
of somatic mutations in cancer 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) reported so far 2745 
missense mutations for PIK3CA in breast carcinomas, which were located in exon 9 
and more frequently in exon 20.  
It has been reported that the PIK3CA mutation status between primary and 
corresponding metastatic disease can be discordant [2]. Interestingly, single cell 
PIK3CA mutational analyses revealed heterogeneity in circulating tumor cells and 
metastases compared to primary breast tumors [3]. Additionally, different treatment 
responses have been observed for the distinct molecular subtypes in relation to 
PIK3CA mutation status. For example, prolonged survival was observed in ER-
positIve early disease patients treated with adjuvant tamoxifen and in advanced 
disease patients treated with first-line aromatase inhibitors for those with PIK3CA 
mutant tumors [4], [5]. In contrast, PIK3CA mutations in HER2+ patients were linked 
to trastuzumab therapy resistance [6], [7], [8]. This resistance might be due to co-
occurrence of both oncogenes or to tumor cell heterogeneity with underrepresented  
trastuzumab responsive HER2+ clones.  
In order to understand the apparent disconnection in breast cancer between genetic 
activation through PIK3CA oncogenic driver mutations and its downstream 
PI3K/AKT/mTOR signalling cascade, we evaluated in especially luminal tumors 
pathway proteins for their relation with PIK3CA mutations. Therefore, TCGA in silico 
RPPA-database of 171 cancer related (phospho) proteins from 361 breast cancer 
specimens were stratified by type of PIK3CA mutation and molecular subtypes. 
Expression or phosphorylation of seven proteins correlated significantly with PIK3CA 
status in luminal breast cancer. Phosphorylated MAPK1/3, as most significant 
upregulated protein, was further explored on TMAs containing 721 primary breast 
cancer specimens, including a subset of luminal tumors from 290 systemic untreated 
LNN patients, to address the prognostic value of this phosphorylated kinase (Figure 
1). 
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Figure 1 Overview of the study 
design. Figure 1A. In-silico data 
used from the TCGA consortium to 
identify potential biomarkers (protein 
expression and/or phosphorylation 
patterns related to the PIK3CA 
mutation status adjusted for 
subtype. Figure 1B. Tissue 
microarrays data used to explore the 
subcellular localization of the 
discovered potential biomarker 
phospho-MAPK1/3 and its 
correlation with subtypes, PIK3CA 
mutation status and prognosis. 
Abbreviations: IHC: 
Immunohistochemistry; TMA: Tissue 
microarrays; LNN: Lymph Node 
Negative. 
 
MATERIALS AND METHODS 
Databases and software packages 
 
We have used the quantified expression of 171 cancer-related proteins and 
phosphoproteins by RPPA of 403 primary breast cancer specimens available from 
TCGA (see Supplemental table S1). The data used by us were deposited [1] and can 
be retrieved at TCGA portal at https://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm. The tumors were selected based on 
their known PIK3CA mutation status and molecular subtype [9]. Of the 403 tumors, 
366 specimens with a single PIK3CA mutation within the hotspot in exons 9 or 20 or 
wild-type were selected for further analyses, excluding tumors with PIK3CA double 
mutations. Five additional specimens were excluded, because 4 samples belonged 
only to the normal-like subtype and one specimen lacked subtype classification. In the 
remaining 361 tumors, either mutant (N=94) or wild-type (N=267) for PIK3CA, the 
protein expression and phosphorylation levels were analyzed irrespective of 
molecular subtype as well as stratified by subtype (using the PAM50 classification) 
(Figure 2).  
A
290 luminal LNN 
breast tumors: 
relation with 
prognosis
B
D
is
co
ve
ry
Ex
pl
or
at
io
n
TMA-dataset 
Breast tumors N=721
TCGA-dataset
Reverse Phase Protein Array for breast tumors
N=361
Phosphorylation of MAPK1/3
In silico data analysis:
Discover proteins/phosphoproteins related to the 
PIK3CA mutation status irrespective of 
molecular subtypes (Figure 2-3, Table 1)
95 tumors: relation with 
the PIK3CA mutation 
(Mutants N=32, wild-
types N= 63)
Explore phospho-MAPK1/3 staining for 
subcellular location and tumor cell heterogeneity 
and relationship with molecular subtypes 
(Figures 4- 8, Tables 2-3)    
526 Luminal breast tumors
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Figure 2 Data analysis flowchart to discover potential protein biomarkers for breast cancer. The 
figure shows the detailed criteria used to identify the association of the PIK3CA mutation with the protein 
expression and phosphorylation patterns using Reverse Phase Protein Array (RPPA) in silico data from the 
TCGA consortium on 361 breast tumors and 171 proteins or phosphoproteins. 
RPPA on 171 proteins/phosphoproteins
361 breast tumors: 
Subtypes: (236 Luminal: 147 luminal A, 89 luminal B, 44HER2+ and 81 Basal-like)
PIK3CA mutation status:  (Exon 9, exon 20 mutant, N=94) or (wild-type, N=267)
60 proteins/phosphoproteins (Supplemental table S1)
Univariate analysis related to the PIK3CA mutation  
15 proteins/phosphoproteins (Table 1) 
Multi-regression analysis  including  each subtype as 4 additional variables 
besides the PIK3CA mutation status
5 proteins/phosphoproteins affected by the PIK3CA mutation specifically in exon 9 or 20
9 proteins/phosphoproteins affected by the PIK3CA mutation
in the luminal A and/or B subtype (P < 0.05 for PIK3CA mutation status and        
P > 0.05 for their luminal A and/or B subtype)
7 proteins/phosphoproteins affected by the PIK3CA mutation with Fold Change 
(P<0.05):
236 Luminal breast tumors (147 lumininal A and 89 luminal B)
Protein expression  of:
NF2, 4E.BP1, Rad51, p70S6K and FAK
Phosphorylation of: 
MAPK1/3, 4E.BP1, p38 and YAP
Phosphorylation of: 
MAPK1/3, 4E.BP1, p38 and YAP 
Protein expression  of:
4E.BP1, p70S6K and FAK 
Phosphorylation of: 
MAPK1/3, p38 and YAP
Protein expression  of:
4E.BP1 and p70S6K
Phosphorylation of: MAPK1/3
1 phosphoprotein affected by the PIK3CA mutation in both exons: 9 and 20
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Data analyses and statistics  
 
Differences between groups were examined with a two-WDLOHGVWXGHQW¶VW-test or when 
not normally distributed with the Mann-Whitney test. Multiple linear regression 
analyses were performed on the protein expression and phosphorylation levels to 
establish their relationships with the PIK3CA genotype and molecular subtypes. The 
residuals of the regression analyses were afterwards checked for their constant 
variance by the Breusch-Pagan/Cook-Weisberg test for heteroscedasticity and for 
their normality. In multiple linear regression analyses, the PIK3CA wild-type basal 
subtype was used as reference to which the other subtypes and their PIK3CA status 
were compared. Proteins significant after these regression analyses were 
subsequently investigated for their relationship with PIK3CA genotype in luminal A 
and B specimens and also for their associations with exon 9 and exon 20 mutations, 
separately. The protein expression and phosphorylation levels were visualized with 
boxplots to illustrate the levels in luminal A and B PIK3CA wild-type or mutant with the 
levels obtained in basal wild-types (Figure 3).  
 
The Cox proportional hazard model was used in univariate analysis to compute the 
hazard ratio (HR) for metastasis-free survival (MFS). The HR was presented with its 
95% confidence intervals (95% CI). Survival curves were generated using the Kaplan±
Meier method and a log rank test was applied to test for differences. MFS was defined 
as the time elapsed between the date of diagnosis and the date of distant metastatic 
relapse. In multivariate analysis, the biomarker was added to the base model of 
traditional prognostic factors for early breast cancer disease, i.e., age at diagnosis, 
menopausal status, tumor size, and tumor grade. Analyses were executed in STATA 
statistical package, release 14 (STATA Corp., College Station, TX). All P-values were 
two-sided, P<0.05 were considered statistically significant.  
 
Immunohistochemistry and evaluation of MAPK1/3 phosphorylation 
 
Tissue microarrays (TMAs) of formalin-fixed, paraffin-embedded primary breast 
cancer specimens were described previously [11], and were immunocytochemically 
stained according to the procedures previously applied by us [10], [11]. Briefly, tissue 
samples were used from patients with primary operable breast cancer between 1985 
and 2000. This TMA contained a cohort of 817 patients.  Tumors were included for 
analyses if histologic subtype, Bloom-Richardson score for tumor differentiation 
grade, estrogen and progesterone receptor status (ER, PgR), HER2/neu, epidermal 
growth factor receptor (EGFR) and cytokeratin 5 (CK5) status were available. Above 
selection criteria resulted finally in the evaluation of triplicate tissue core biopsies from 
721 patients with primary breast cancer. These included 526 luminal breast tumors 
amongst other subtypes, of which 290 were from lymph node negative patients who 
received no (neo)adjuvant systemic therapies as described previously (van der Willik 
et al., AJCR 2016). This retrospective study with coded tumor tissues was approved 
by the Erasmus MC medical ethics committee at Rotterdam, The Netherlands (MEC 
02.953). TMAs were stained with the primary rabbit polyclonal antibody for MAPK1/3 
phosphorylation at 1:200 dilution (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
Antibody #9101 from Cell Signaling  
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Figure 3  ✣✥✦✧★✩✪ al t er at i o✪✫ i✪ PIK3CA exo n - sp eci f i c mutated luminal breast cancer. Differential 
phosphorylation and expression of 5 proteins due to PIK3CA mutation status but not molecular subtype as 
established in the multi-regression analysis (Table 1). The figure presents fold changes (FC) and P-values 
of non-parametrical Mann Whitney tests for MAPK1/3, p38 and YAP phosphorylation and expression of 
p70S6K and 4E-BP1 in luminal A and B breast cancer with exon 9 or exon 20 PIK3CA mutations. 
 
Technology). The antibody was incubated overnight at 4 °C after 20 minutes antigen 
retrieval at pH6.0. Subsequently, the TMA-slides were incubated with a secondary 
antibody (Rabbit Envision+ System, HRP (DAKO)) and staining was visualized using 
diaminobenzidine (DAB).  
 
Both nuclei and cytoplasm were scored for MAPK1/3 phosphorylation by two 
independent observers with regard to staining intensity and to the estimated 
proportion of tumor cells with positive nuclei and/or cytoplasm within a core biopsy. 
These scores were categorized to explore staining pattern differences. Negative 
versus positive staining was evaluated for both nuclei and cytoplasm separately, and 
combined since a subset of specimens showed heterogeneity in tumor cell staining 
(see figure 4). Positive staining was specified for its intensity (weak, moderate, strong) 
and/or proportion of staining. To have enough cases for proper evaluation, groups 
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P= 0.0018
Luminal A
Exon 20 Mutants
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P= 0.0106
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were taken together to obtain more robust categories. For that reason, negative and 
weak staining were combined into one category (weak), and moderate and strong 
staining into another category (strong). In a similar way, the categories for proportions 
were dichotomized into less than 20% positivity (low) versus more than 20% positive 
nuclei or cytoplasm (high).  
 
PIK3CA mutation analysis 
  
PIK3CA status were established by SnaPshot® multiplex assays (Life technologies) 
as described previously [5]. For only 105, of which 95 luminals, out of the 721 cases,  
(sufficient) DNA was available from the TMA core biopsies to identify PIK3CA exon 9 
and exon 20 mutations. 
 
RESULTS 
Protein expression and phosphorylation related to PIK3CA genotype and 
molecular subtypes 
 
Student t-test or Mann-Whitney test analyses of proteins in 361 tumors, showed that 
60 proteins had significant differences in expression or phosphorylation levels 
between tumors mutant (N=94) or wild-type (N=267) for PIK3CA (Supplemental Table 
S1). Of these 60 proteins, 15 protein changes were significant (P<0.05) in multiple 
linear regression analyses for PIK3CA status when molecular subtypes were taken 
into account (Figure 2, Table 1). 
 
To identify protein alterations correlated with mutation and not with subtype, only 
proteins were studied further for which expression level or phosphorylation status was 
affected by the PIK3CA mutation status and not significantly by subtype. Of the 15 
proteins, the residuals of 11 proteins showed that the assumptions for constant 
variance (4 failed test for heteroscedasticity) were valid allowing extrapolation of 
findings (Table 1). Subsequently, 9 proteins had P values <0.05 for PIK3CA mutation 
status and P>0.05 for luminal A and/or B subtypes (Table 1). Of these, MAPK1/3 
phosphorylation and NF2 expression had significant different levels between PIK3CA 
wild-types and mutants irrespective of molecular subtype. 
 
The other proteins were differentially expressed or phosphorylated due to PIK3CA 
status and subtype when compared to the wild-type basal subtype. Only significant 
for PIK3CA mutation status and independent of subtype in luminal B were the altered 
levels for Rad51 expression and 4E-BP1 expression and phosphorylation, and in 
luminal A the p38 and YAP phosphorylation and expression of p70S6K and FAK. The 
applied (non)parametric tests have demonstrated significant proteins alterations in the 
TCGA dataset. For the findings on p70S6K, however, these may not be extrapolated 
due to test limitations and/or assumptions.  
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Table 1 Protein alterations in breast cancer related with PIK3CA genotype irrespective of molecular 
subtype.  
Phosphorylation and expression levels of 171 proteins measured with reverse phase protein arrays (RPPA) 
obtained from the TCGA database, were evaluated for their relationship with PIK3CA genotype and 
molecular subtype. Student t-test and Mann-Whitney test analyses defined protein alterations that are 
significantly related to PIK3CA status in all 361 tumor specimens. Multiple linear regression evaluated 
protein levels in relation to PIK3CA status combined with molecular subtype and used the wild-type basal-
like subtype as reference. Only 15 protein alterations were significant for PIK3CA mutation status after 
linear regression. Of these, 9 proteins were of interest because their levels were altered due to PIK3CA 
(P<0.05) but not by luminal subtype (P>0.05). 
a
 P-value based on Mann-Whitney test.  
b
 residuals failed test for heteroskedasticity.  
c
 residuals failed test for normality. 
 
 
PIK3CA genotype related protein alterations in luminal breast cancer 
The altered expression and phosphorylation levels of the 9 selected proteins were 
further investigated in the luminal subsets, i.e. 147 luminal A and 89 luminal B tumors 
(Supplemental Table S2). Two proteins, i.e. NF2 and RAD51, showed no significant 
fold changes in this luminal subset when evaluated for all mutants together, and were 
excluded from further analyses. In PIK3CA mutated specimens compared to wild-type 
specimens significant fold changes were observed for the remaining 7 proteins with 
increased MAPK1/3 phosphorylation seen in luminal A and B cancers, decreased 4E-
BP1 expression and phosphorylation in luminal B tumors, and decreased p70S6K and 
FAK expression and increased p38 and YAP phosphorylation in luminal A typed 
specimens. 
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Protein expression and phosphorylation related to PIK3CA exon 9 and 20 
mutations 
 
Five of the 7 proteins altered in the luminal subset, all but FAK expression and 
phosphorylation of 4E-BP1, were significantly related to exon specific mutations when 
compared to wild-type counterparts (Figure 3, Supplemental Table S2).  
Tumors with PIK3CA exon 9 hotspot mutations had increased MAPK1/3 and YAP 
phosphorylation and decreased p70S6K expression in luminal A, and only increased 
MAPK1/3 phosphorylation in luminal B (Figure 3). Tumors harboring exon 20 
mutations had increased MAPK1/3 and p38 phosphorylation in luminal A and 
decreased expression of p70S6K in luminal A while only 4E-BP1 was decreased in 
luminal B. The differences in phosphorylation observed in our in silico analyses for 
p38 and YAP in relation to exon-specific PIK3CA mutations, have not been yet 
reported by others to our knowledge. 
 
Tumor cell heterogeneity and subcellular localization of MAPK1/3 
phosphorylation 
  
Protein functioning is not only defined by their expression and phosphorylation status, 
but may also depend on (sub)cellular localization. The RPPA findings, as described 
above, however, do not reveal which cell types and cellular compartments express 
proteins. To address this disadvantage, we examined MAPK1/3 phosphorylation for 
tumor cell heterogeneity and its subcellular localization in TMAs containing core 
biopsies of 721 primary tumor tissue specimens (Figures 4 & 5). 
Immunohistochemical staining for MAPK1/3 phosphorylation was performed, since it 
was the most significant protein alteration seen in PIK3CA exon 9 mutant luminal A 
and B tumors and in exon 20 mutant luminal A tumors (Figure 3).  
Our TMA biopsies showed heterogeneity in staining patterns for MAPK1/3 
phosphorylation as illustrated by the examples of figure 4 and quantified in figure 5. 
Moreover, MAPK1/3 phosphorylation was especially seen in the luminal and HER2 
intrinsic subtypes, whereas tumors of the basal subtype had somewhat less staining 
of especially nuclei (Figure 6). 
 
The MAPK1/3 phosphorylation staining revealed besides tumors with no and >80% 
positive tumor cells, also tumors with 11% to 80% tumor cells with MAPK1/3 
phosphorylation in their cytoplasm (18% in Figure 5D) and in their nuclei (32% in 
Figure 5B). These findings suggest heterogeneity in a subset of specimens containing 
both tumor cell populations positive as well as negative for MAPK1/3 phosphorylation. 
Additionally, Figure 4 indicates heterogeneity in subcellular phosphorylation of 
MAPK1/3, which is confirmed by the staining distributions for proportions and 
intensities between nuclei and cytoplasm, respectively, as illustrated in Figures 5E 
and 5F. For example, cases with no cytoplasmic MAPK1/3 had weak to strong nuclear 
MAPK1/3 staining (Figure 5F) in up to 100% of the nuclei (Figure 5E). Overall, the 
staining proportion and intensity for MAPK1/3 phosphorylation was significantly 
heterogeneous (both Chi-square test P<0.001) when compared between nuclei and 
cytoplasm.  
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Fig u re 4  Phosphorylate d  MAPK1/3 staining patterns e x a m p les defined by intensity and proportion 
of MAPK1/3 phosphorylated tumor cells. Figure 4A Negative for both nuclear and cytoplasmic. Figure 
4B Negative for nuclear and 100% moderate cytoplasmic intensity. Figure 4C 70% weak nuclear and 80% 
moderate cytoplasmic intensity. Figure 4D 100% strong for both nuclear and cytoplasmic intensity. Figure 
4E 100% strong nuclear and 100% moderate cytoplasmic intensity. 
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Figure 5 MAPK1/3 phosphorylation immunohistochemical staining evaluation. Tissue microarrays 
containing primary breast tumor core biopsies from 721 breast cancer patients were evaluated for nuclear, 
cytoplasmic and tumor cell MAPK1/3 phosphorylation. The figures present the percentage (above each 
bar) and number of cases (bottom values) for nuclear (Figure 5A, 5B) and cytoplasmic staining (Figure 5C, 
5D) defined by intensity (Figure 5A, 5C) and by proportion (Figure 5B, 5D).  
Additionally, it illustrates the number of cases comparing MAPK1/3 phosphorylation between cytoplasmic 
and nuclear staining for proportion (Figure 5E) and for intensity (Figure 5F). 
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Figure 6  MAPK1/3 phosphorylation in relation with intrinsic subtypes analysed in 721 primary breast 
tumors. The figures present the percentage (above each bar) and number of cases (bottom values) for 
nuclear (Figure 6A, 6B), cytoplasmic (Figure 6C, 6D) and cellular staining (Figure 6E, 6F) defined by 
proportion (Figure 6A, 6C, 6E) and by intensity (Figure 6B, 6D, 6F). The intrinsic subtypes were defined by 
ER, PgR, HER2/neu, EGFR and Cytokeratin 5 staining and classified as described previously by us (PMID: 
27186402) as luminal (positive for ER and/or PgR, negative for HER2/neu), Her2 (positive for HER2/neu) 
and basal (positive for EGFR and/or Cytokeratin 5, negative for ER, and HER2/neu). P-values are based 
on Chi-square test. 
 
MAPK1/3 phosphorylation staining and PIK3CA mutation 
 
MAPK1/3 phosphorylation was also evaluated in a subset 95 luminal breast cancers 
with known PIK3CA genotype, including 32 tumors with PIK3CA exon 9 (n=9) or exon 
20 mutations (n=23). No significant differences between PIK3CA mutants and 
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wildtypes were observed for staining proportion and intensity of nuclei and cytoplasm, 
when analysed separately or combined (Figure 7).  
 
 
Figure 7 MAPK1/3 phosphorylation in relation to PIK3CA mutation status analyzed in 95 available 
luminal breast tumors. The figures present the percentage (above each bar) and number of cases (bottom 
values) for nuclear (Figure 7A, 7B), cytoplasmic (Figure 7C, 7D) and cellular staining (Figure 7E, 7F) 
defined by proportion (Figure 7A, 7C, 7E) and by intensity (Figure 7B, 7D, 7F). No association was found 
for subcellular localization of MAKP1/3 phosphorylation with PIK3CA mutation status. P-values are based 
on Chi-square test. 
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Clinical relevance of subcellular localization of MAPK1/3 phosphorylation in 
breast cancer tissue specimens 
 
Logrank tests for trend were evaluated to determine whether MAPK1/3 
phosphorylation staining intensity and proportion were related with MFS (Table 2). 
These tests demonstrated a relationship with MFS in especially luminal tumors for 
nuclear and tumor cell MAPK1/3 phosphorylation for both staining intensity and 
proportion. In contrast, cytoplasmic staining was associated with MFS in only 2 of 9 
analyses. 
 
MAPK1/3 phosphorylation staining patterns were evaluated for their prognostic value 
in a cohort of luminal primary breast tumors from 290 LNN patients who did not receive 
(neo)adjuvant systemic therapy. Kaplan-Meier survival curve analyses and the 
logrank tests for trend showed that only nuclear and tumor cell staining were related 
with MFS in this cohort (Table 2 & Figure 8). The Kaplan-Meier analyses 
demonstrated that high (>20% in Figure 8A) as well as strong (Figure 8D) nuclear 
MAPK1/3 phosphorylation associate with favorable survival. Similar results were 
obtained for tumor cell staining (Figures 8C and 8F) but not for cytoplasmic staining 
(Figures 8B and 8E).  
 
Uni- and multivariate analyses for MAPK1/3 phosphorylation staining patterns were 
performed for this cohort of 290 LNN patients (Table 3). Staining patterns in 
multivariate analyses were compared to the base model of traditional prognostic 
factors which included age, menopausal status, tumor size, Bloom-Richardson 
differentiation grade and progesterone receptor status. Only high nuclear and tumor 
cell stain staining proportions were independent from the traditional factors and 
associated with favorable survival. MAPK1/3 phosphorylation in more than 20% of 
nuclei was associated with longer MFS compared to no or less than 20% of positive 
nuclei (HR=0.49; 95% CI: 0.25-0.95;P=0.036). Similarly, in specimens with staining in 
more than 20% of both nuclei and cytoplasm, MAPK1/3 phosphorylation was also 
related with favorable MFS (HR=0.37; 95% CI: 0.18-0.79; P=0.010). 
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Figure 8 Subcellular localization of phosphorylated MAPK1/3 and its prognostic significance. 
Kaplan Meier curve analyses for MFS in luminal primary breast tumors of 290 (neo) adjuvant systemic 
therapy naïve LLN patients shows that high (Figure 8A) and strong (Figure 8D) nuclear MAPK1/3 
phosphorylation correlates with favorable prognosis. No correlation was observed for cytoplasmic 
phosphorylated MAPK1/3 regarding staining proportion (Figure 8B) and intensity (Figure 8E). Finally, 
nuclear and cytoplasmic staining combined (cellular staining) was associated with favorable prognosis 
when defined by proportion (Figure 8C) as well as by intensity (Figure 8F). Abbreviations: MFS: Metastasis-
free survival; LNN: Lymph Node Negative.  
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DISCUSSION 
 
This study aimed to reveal proteins downstream PI3K with altered phosphorylation or 
expression levels in luminal breast cancer with PIK3CA exon 9 and/or exon 20 
mutations. Our in silico analyses of publically available RPPA data showed in luminal 
A and B tumors with PIK3CA mutations an increased phosphorylation of MAPK1/3, 
p38 and YAP and decreased expression of p70S6K and 4E-BP1. We showed that 
MAPK1/3 phosphorylation was the most significant protein upregulated in PIK3CA 
exon 9 mutated luminal A and B tumors and in PIK3CA exon 20 mutated luminal A 
tumors. Our immunohistochemical staining of MAPK1/3 phosphorylation on TMAs 
demonstrated tumor cell heterogeneity in subcellular location, staining intensity and 
proportion. We demonstrated that high MAPK phosphorylation in especially the nuclei 
of tumor cells correlated with favorable prognosis.  
 
We investigated protein changes detected by RPPA to identify alterations specific for 
luminal breast cancer specimens with a PIK3CA exon 9 or exon 20 mutation. 
Mutations in PIK3CA, next to TP53, occur most frequently in breast cancer. TP53 
mutations and PI3K/AKT/mTOR pathway activation are particularly observed in breast 
cancer of the basal subtype [1]. The PIK3CA mutations, however, are predominantly 
observed in ER-positive tumors and have been shown to be present in approximately 
27% of luminal B up to 45% in luminal A specimens [1]. Above considerations were 
taken into account in our in silico analyses using a multi-regression model combining 
PIK3CA status and molecular subtype. These analyses helped to identify alterations 
related to the PIK3CA mutation status in a (luminal) subtype independent way. 
Although 15 protein changes had a significant relation with PIK3CA mutation status, 
only 9 of these were not correlated with luminal A and/or B subtypes. These 9 proteins 
were further explored within the subset of 236 luminal specimens for the relation with 
exon-specific PIK3CA mutations. This subsequent in silico evaluation demonstrated 
just 5 of these 9 protein alterations to be PIK3CA exon mutation specific in luminal A 
and/or B tumors, including increased phosphorylation of MAPK1/3, p38 and YAP and 
decreased expression of p70S6K and 4E-BP1. Future investigations are needed to 
validate our in silico results in other subsets. 
 
Differences in protein phosphorylation patterns in relation to PIK3CA mutations have 
been reported for human cancer cell line models. It was shown that somatic knock-in 
of both KRAS and PIK3CA mutations in human breast epithelial cells was 
accompanied by increased MAPK1/3 phosphorylation, MAPK pathway activation, and 
tumor formation in immune-comprised mice [12]. Moreover, it was shown that 
phosphorylation of MAPK1/3 resulted in an activation of the protein and translocation 
from the cytoplasm to the nucleus [13]. We could not evaluate this translocation of 
MAPK1/3 upon phosphorylation with the available RPPA data from the TCGA 
consortium, since the RPPA was performed on protein lysates of cancer tissue and 
not on protein lysates of nuclear and cytoplasmic fractions. Therefore, we performed 
an immunohistochemical staining for MAPK1/3 phosphorylation on TMAs containing 
core biopsies of breast cancer specimens. These stainings enabled us to establish 
the subcellular location of MAPK1/3 phosphorylation and to examine tumor cell 
heterogeneity. Our results detected in 32% of cases nuclear MAPK1/3 
phosphorylation for only a subset of tumor cells (ranging from 20% to 80%). This 
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suggests that MAPK activation is not always seen in all tumor cells for a substantial 
subset of breast cancers.  
 
Importantly, high MAPK1/3 phosphorylation in nuclei was related with favorable 
prognosis in our cohort of LNN luminal breast cancer specimens. Others have stained 
tissue microarrays for MAPK1/3 phosphorylation in breast cancer to determine either 
the relation with PI3K or with clinical outcome. Nuclear MAPK1/3 phosphorylation was 
investigated on 563 estrogen receptor positive primary tumors from patients 
participating in a randomized trial of 1 to 3 years adjuvant tamoxifen [14, 15]. One 
study showed that at baseline both PIK3CA exon 9 and 20 mutated specimens have 
higher MAPK1/3 phosphorylation levels compared to wild-types [14]. Although this 
association with PIK3CA mutations was not confirmed in our TMA cohort, this is 
explained by the small number of cases for which the PIK3CA status could be 
determined. The other study demonstrated a trend between tamoxifen response and 
MAPK1/3 phosphorylation [15]. Additionally, nuclear and cytoplasmic MAPK1/3 
phosphorylation were also studied in large well-characterized breast cancer series to 
investigate its biological and clinical significance [16, 17]. This study showed that 
nuclear MAPK1/3 phosphorylation was associated with better outcome, especially in 
tamoxifen-treated cases. All these immunohistochemical studies in large cohorts of 
(luminal) breast cancer specimens confirm in part our in silico findings in relation to 
PIK3CA mutation [18] and our TMA findings that nuclear MAPK1/3 phosphorylation 
correlates with favourable outcome [16, 17]. Future prospective studies are needed 
to verify above retrospective findings and to establish MAPK1/3 phosphorylation as 
biomarker.  
  
In conclusion, we have explored several methods combining in silico multivariate 
analyses and immunocytochemistry on luminal breast cancer specimens. We have 
shown that PIK3CA mutated breast tumor specimens are characterized in an exon 
dependent manner by increased MAPK1/3 phosphorylation. The observed 
relationships in clinical specimens indicate that the phosphorylation of MAPK1/3 and 
its subcellular localization might associate with clinical outcome. Considering the high 
prevalence of PIK3CA mutations in breast cancer, our findings will aid in the design 
of future studies to evaluate and/or target downstream effectors of the PIK3CA 
mutation. Our findings indicate that MAPK1/3 phosphorylation may play an important 
role as a target downstream effector in luminal breast cancer patients with a PIK3CA 
mutation.  
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HIGHLIGHTS 
ABSTRACT 
Background 
3DWLHQWVZLWK(VWURJHQ5HFHSWRUĮ-positive (ER+) Inflammatory Breast Cancer (IBC) 
are less responsive to endocrine therapy compared with ER+ non-IBC (nIBC) 
patients. The study of ER+ IBC samples might reveal biomarkers for endocrine 
resistant breast cancer. 
Materials & methods 
Gene expression profiles of ER+ samples from 201 patients were explored for genes 
that discriminated between IBC and nIBC. Classifier genes were applied onto clinically 
annotated expression data from 947 patients with ER+ breast cancer and validated 
with RT-qPCR for 231 patients treated with first-line tamoxifen. Relationships with 
metastasis-free survival (MFS) and progression-free survival (PFS) following adjuvant 
and first-line endocrine treatment, respectively, were investigated using Cox 
regression analysis. 
Results 
A metagene of six genes including the genes encoding for 4-aminobutyrate 
aminotransferase (ABAT) and Stanniocalcin-2 (STC2) were identified to distinguish 
22 ER+ IBC from 43 ER+ nIBC patients and remained discriminatory in an 
independent series of 136 patients. The metagene and two genes were not prognostic 
in 517 (neo)adjuvant untreated lymph node-negative ER+ nIBC breast cancer 
patients. Only ABAT was related to outcome in 250 patients treated with adjuvant 
tamoxifen. Three independent series of in total 411 patients with advanced disease 
showed increased metagene scores and decreased expression of ABAT and STC2 
to be correlated with poor first-line endocrine therapy outcome. The biomarkers 
remained predictive for first-line tamoxifen treatment outcome in multivariate analysis 
including traditional factors or published signatures. In an exploratory analysis, ABAT 
and STC2 protein expression levels had no relation with PFS after first-line tamoxifen. 
Conclusions 
This study utilized ER+ IBC to identify a metagene including ABAT and STC2 as 
predictive biomarkers for endocrine therapy resistance. 
Keywords 
Inflammatory breast cancer; Endocrine therapy resistance; Metastatic disease; ABAT; 
STC2. 
x ER+ inflammatory breast cancer (IBC) can be used as endocrine therapy
resistance model.
x Molecular characterization revealed ABAT and STC2 as ER+ IBC
discriminatory genes.
x ABAT and STC2 are novel biomarkers for tamoxifen resistance in advanced
breast cancer.
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INTRODUCTION 
Breast cancer is the most prevalent form of cancer in women in the United States and 
Europe (Torres-Arzayus et al., 2010). The majority of patients with breast cancer bear 
tumors expressing detectable levels of the Estrogen Receptor (ER). For these 
patients, targeted therapies are available including strategies directed at the receptor 
itself, such as tamoxifen and fulvestrant. In addition, estrogen deprivation offers 
another therapeutic strategy that can be achieved by ovarian ablation, or LHRH 
analogs, in the premenopausal patient, or with aromatase inhibitors (AIs) in the 
postmenopausal setting. These therapies are highly effective; adjuvant endocrine 
therapy has been shown to reduce mortality from ER+ breast cancer to the same 
degree as adjuvant chemotherapy (Early Breast Cancer Trialists' Collaborative, G, 
2005). Unfortunately, part of the patients with ER+ breast cancer show de novo 
resistance to endocrine therapy, whereas others initially benefit but ultimately relapse 
due to acquired endocrine resistance (Leary et al., 2010). Predicting, modulating 
and/or restoring endocrine responsiveness remain important clinical priorities for 
which molecular targets are urgently needed. 
Inflammatory breast cancer (IBC) is a rare (׽5%) but aggressive form of locally 
advanced breast cancer. At time of diagnosis, virtually all patients with IBC have 
lymph node metastases and 1/3 of the patients have metastases in distant organs. As 
a consequence, the prognosis for patients with IBC is dismal (Dawood et al., 2011; 
Dirix et al., 2006). Analysis of the Surveillance, Epidemiology and End Results 
(SEER)-database revealed that IBC is characterized by atypical clinicopathological 
features (Dawood et al., 2011), including frequent absence of ER protein expression 
(Hance et al., 2005). Our research group and others have shown that this IBC-specific 
clinicopathological profile is corroborated at the molecular level by a distinct gene 
expression profile (Bertucci et al., 2004; Van Laere et al., 2007a; Van Laere et al., 
2005). Exploration of this gene expression profile led to the discovery of pronounced 
activation of the transcription factor NFkB in IBC (Lerebours et al., 2008; Van Laere 
HWDODQGPRUHUHFHQWO\WRWKHREVHUYDWLRQWKDW7*)ȕ-signaling is repressed 
(Van Laere et al., 2008). Furthermore, we demonstrated that the IBC-specific 
expression profile harbors the molecular traits of aggressive tumor cell behavior in 
general (Van Laere et al., 2008), including stem cell biology (Van Laere et al., 2010). 
As such, we consider IBC, although occurring rarely, as a suitable example to 
elucidate mechanisms responsible for tumor cell dissemination, metastasis and drug 
resistance in breast cancer in general. 
The majority (depending on the reference up to 66%) of patients with IBC lack ER 
protein expression, but ER+ tumor samples from patients with IBC exist. Clinically, 
patients with ER+ IBC are less responsive to endocrine treatment as compared to 
patients with other forms of ER+ breast cancer. In light of molecular heterogeneity and 
our previous results, we reasoned that studying ER+ IBC focusing on endocrine 
treatment response might provide new insights into molecular resistance mechanisms 
of endocrine therapy. In the current study, we evaluated expression profiles from 
patients with ER+ IBC and nIBC. The purpose of this study was 1) to identify 
differentially expressed genes between IBC and nIBC, 2) assess their accuracy to 
predict ER+ IBC, and 3) to define their relationship with endocrine therapy response 
in clinical samples. Discriminatory genes were identified by gene expression arrays, 
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of which two genes remained deregulated in an independent series of ER+ samples 
between patients with and without IBC. When applied onto clinically annotated 
expression series from patients with ER+ breast cancer treated with endocrine 
therapy either in the adjuvant or advanced setting, decreased expression of these two 
genes were linked with poor responsiveness to endocrine therapy. These two genes 
when validated with quantitative real-time PCR for mRNA expression and with 
immunohistochemistry for protein expression, demonstrated predictive value only at 
the mRNA level. 
MATERIALS AND METHODS 
Study design and patient samples 
The present study describes a retrospective analysis performed in accordance with 
the Code of Conduct of the Federation of Medical Scientific Societies in the 
Netherlands, Belgium and France, and is reported following the REMARK 
recommendations (McShane et al., 2006). The local medical ethics committees have 
approved the study. Follow-up, tumor staging, and response to therapy was defined 
by standard International Union Against Cancer (Geneva, Switzerland) classification 
criteria (Hayward et al., 1978). Samples were recruited from the Translational Cancer 
Research Unit (TCRU, Antwerp, Belgium), the Institut Poali-Calmettes (IPC, Marseille 
France), the Erasmus Medical Center (EMC, Rotterdam, the Netherlands) and the 
Netherlands Cancer Institute (NKI, Amsterdam, the Netherlands). The ER-status of 
WKHWXPRUVZDVHVWDEOLVKHGE\LPPXQRKLVWRFKHPLVWU\SRVLWLYHWXPRUFHOOVRU
(,$  IPROPJ SURWHLQ DQG WRJHWKHU ZLWK DGGLWLRQDO FOLQLFRSDWKRORJLFDO
characteristics have been described before for each of the series (Bekhouche et al., 
2011; Desmedt et al., 2007; Jansen et al., 2013; Kok et al., 2009; Loi et al., 2008; 
Reijm et al., 2014; Schmidt et al., 2008; Van der Auwera et al., 2010; Van Laere et 
al., 2007b; Wang et al., 2005). 
The mRNA-datasets used in this study are presented in Table 1 and includes ER+ 
IBC-subsets (I±II), endocrine treated subsets (III±VI), and untreated lymph node-
negative (LNN) patients (VII±IX). 
9,,
9,,,
9,
9
,9
,,,
,,
,
9,,
9,,,
9,
9
,9
,,,
,,
,
Low ABAT and STC2 in ER+IBC and endocrine resistance in advanced disease | 95

The discovery and test phase incorporated 2 patient series with ER+ IBC: a) a 
discovery series (I) of 65 samples from patients with and without ER+ IBC retrieved 
from the TCRU (E-MTAB-1006) and b) an independent test series (II) of samples from 
136 patients with and without ER+ IBC that received adjuvant treatment, retrieved 
from IPC. Samples from patients with ER+ IBC in series I (N = 22) and series II (N = 
39) were selected by strictly adhering to the consensus diagnostic criteria (Dawood et 
al., 2010). 
To evaluate discovered genes for their relationship with endocrine treatment outcome, 
4 additional data sets (III±VI) were incorporated of patients with ER+ breast cancer 
treated with endocrine therapy for primary and advanced disease: 3 data sets (IV±VI) 
of 411 metastatic breast cancer patients in total from EMC, NKI and TRCU; and 1 
data set with primary breast cancers of 250 patients (III). The data set of 411 patients 
with advanced ER+ breast cancer treated with first-line therapy contained three 
subsets, one of 96 patients treated with tamoxifen (IV) and one of 84 patients treated 
with aromatase inhibitors (AIs) (V), and one of 231 patients treated with tamoxifen and 
profiled using RT-qPCR for dedicated genes (VI). The RT-qPCR data set was used 
as an independent validation series for the genome-wide expression series. All 
samples in these cohorts were classified according to the Recurrence Score (RS) 
(24), the Genomic Grade Index (GGI) (25). For each of these patient series tumor size 
and histological grade were recorded, in addition to age and menopausal status at 
start of therapy, dominant site of relapse and disease-free interval for the RT-qPCR 
data set. To assess the prognostic value of the discovered genes, we incorporated 
also 3 series (VII-IX) of ER+ tumors from 517 LNN breast cancer patients, who did 
not receive any type of adjuvant systemic therapy. Details regarding the application 
of the above classifiers are provided in the Supplementary data file, Tables A.1 and 
A.2. 
The discovered predictive genes were also evaluated for their protein expression 
pattern in a tissue microarray including cores of ER-positive primary tumor specimens 
from a cohort of advanced breast cancer patients who have been treated with first-
line tamoxifen previously described (Reijm et al., 2014). A subset of 110 ER-positive 
tumors were explored for their protein staining, i.e. the number of positive cells and 
the staining intensity, and a staining IHC-score was calculated to evaluate the 
relationship between IHC-score and progression-free survival. 
METHODS 
RNA isolation and (genome-wide) expression profiling 
RNA isolation for the samples retrieved from each of the participating centers (TCRU, 
EMC, NKI and IPC) and quality control was done as described before (Bekhouche et 
al., 2011; Jansen et al., 2005, 2013; Kok et al., 2009; Van Laere et al., 2007a). 
Genome-wide expression profiles were available from Affymetrix HGU133A or 
HGU133plus2 platforms (I±III, VII±IX) and 44k mRNA oligoarrays of Agilent 
Technologies (IV±V). 
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Expression analyses were verified by RT-qPCR (series VI) and were performed for 
WKH ³,%&-OLNH´ JHQHV LHABAT, ADAMDEC1, CLEC7A, ETS1, ITK and STC2) to 
discriminate between IBC and nIBC, for the Recurrence Score genes (i.e. AURKA, 
BAG1, BCL2, BIRC5, CCNB1, CD68, CTSL2, ERBB2, ESR1, GRB7, GSTM1, MKI67, 
MMP11, MYBL2, PGR and SCUBE2) and for a panel of reference genes (i.e. HMBS, 
HPRT1, TBP and B2M). Assay details are provided in Supplementary Table A.1. The 
cDNA synthesis, quantification and the methodology to ensure PCR specificity have 
been described previously (Sieuwerts et al., 2005; van Agthoven et al., 2009). RT-
T3&5ZDVSHUIRUPHGLQD0[35HDO-Time PCR System (Agilent, Amsterdam, 
The Netherlands) using the TaqMan-based gene expression assays from Applied 
Biosystems/Life Technologies and SYBR-based intron-spanning forward and reverse 
primer combinations for the other genes. Levels of the target genes, expressed 
relative to the reference genes were quantified as follows: mRNA target = 2(mean Ct 
UHIHUHQFHJHQHVíPHDQ&WWDUJHWJHQHV
. 
Expression levels of each series (Supplementary Table A.2) were normalized and 
subsequently harmonized for cross-platform evaluation and robust regression 
analyses. To accomplish harmonization of series, Hampel'S M-Estimators were 
calculated in SPSS (version 20) for all series and applied to establish the 
harmonization factor for the genes in each series when using series I as reference 
(Supplementary Table A.3). 
Comparative analysis or ER+ IBC and nIBC expression profiles 
Global differences in gene expression between samples from patients with and 
without ER+ IBC in the discovery series were analyzed using the global test (Goeman 
et al., 2004) and Principal Component Analysis (PCA). Using the PAM50-algorithm, 
each sample in the discovery series was classified according to the molecular 
subtypes, ER activity, and Risk-Of-Relapse (ROR) models based on the molecular 
subtypes alone (ROR-S) or in combination with cell proliferation (ROR-P), as 
described before (Ellis et al., 2011). In addition, the Recurrence Score (RS) (Paik et 
al., 2004) and the HOXB13/IL17RB gene expression ratio (Jansen et al., 2007; Ma et 
al., 2006) were calculated. 
Biomarker discovery analysis 
We performed Prediction Analysis of Microarrays (PAM) (Tibshirani et al., 2002) to 
identify a series of biomarkers able to discriminate ER+ IBC from ER+ nIBC samples. 
The discovery series were randomly divided into training sets of 40 samples and test 
sets of 25 samples to obtain 10 gene signatures, which were compared to identify 
common classifiers. In total six classifier genes were shared between these 10 gene 
signatures, i.e. ABAT, ADAMDEC1, CLEC7A, ETS1, ITK and STC2. PCA was 
performed onto the ER+ IBC discovery and validation series to evaluate the 
discriminatory performance of all genes and of the six common classifier genes 
together. Mutual relationships between these common classifier genes and ER were 
investigated using the Ingenuity Pathway Analysis (IPA) software. 
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Construction of an ER+ IBC-like metagene 
The thus identified six genes ABAT, ADAMDEC1, CLEC7A, ETS1, ITK and STC2 
were combined into an ER+ IBC-like metagene. The regression coefficients of each 
of the genes obtained within the discovery series were used to calculate a score for 
the metagene in all other series. This metagene score was evaluated as biomarker 
representing the signature of above six genes. 
Diagnostic evaluation of biomarkers and classifiers 
The IBC discovery and test sets (series I & II) were used to assess the predictive 
potential of the biomarkers to identify IBC and nIBC. The biomarkers were evaluated 
as continuous variables with Receiver Operator Characteristic (ROC) analyses using 
the STATA statistical package. The ROC analyses were performed to define Area 
Under Curves (AUC) and assess the discriminatory potential of the biomarkers. Next, 
ROC analyses were used to select cutoffs with optimal sensitivity and specificity. 
These cutoffs generated dichotomized biomarkers which were subsequently explored 
as classifiers using distribution dot-plots created in STATA and evaluated for their 
diagnostic effectiveness by SISA (http://www.quantitativeskills.com/sisa/). The 
distribution dot-plots illustrated the performance and the number of false 
positives/negatives when applying the cutoffs. The SISA tool established for the 
classifiers their accuracy, sensitivity, specificity and Youden's Index of the predictions. 
Survival analysis of biomarkers and classifiers 
The biomarkers were evaluated for their relationship with survival using Cox 
regression analyses in two ways: as a continuous variable or dichotomized to a 
WKUHVKROGDVFODVVLILHUWRGLVWLQJXLVK³,%&-OLNH´DQG³Q,%&-OLNH´)RUWKHDVVHVVPHQWRI
the relationship with first-line therapy outcome in advanced disease, Progression-Free 
Survival (PFS), defined as the time elapsed between initiation of endocrine therapy 
and the first detection of disease progression, was considered as endpoint. PFS was 
censored at 36 months. For the assessment of the relationship with prognosis and 
adjuvant therapy in early disease, Metastasis-Free Survival (MFS) was used as 
endpoint and defined as the time elapsed between the date of diagnosis and the date 
of distant metastatic relapse. Multivariate Cox regression analyses were performed 
on each of the endocrine treated advanced disease subsets for PFS (series IV±VI). 
The models included the biomarkers as continuous variable on the one hand and the 
published signatures for the Recurrence Score or the GGI on the other hand. 
Additional multivariate analyses were performed with the base model of clinic-
pathological factors including age and menopausal status at start of therapy, dominant 
site of relapse, disease free interval (DFI), and the mRNA expression levels of ER 
(ESR1), PR (PGR), and HER2 (ERBB2). All data computations were done with the 
STATA statistical package version 12.0. All P-values are two-sided and P < 0.05 was 
considered statistically significant. 
Tissue microarrays and immunohistological and evaluation 
Tissue microarrays (TMAs) of formalin-fixed, paraffin-embedded primary breast tumor 
specimens were prepared and immunohistochemically stained according to the 
procedures described previously (Reijm et al., 2014). The staining was performed with 
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the primary monoclonal antibody against ABAT (HPA041690) and STC2 
(HPA045372; Atlas Antibodies AB, Stockholm, Sweden). The antibodies were 
incubated for 1 h (1:100 dilution) after 20 min antigen retrieval at pH6.0. Subsequently, 
the TMA-slides were incubated with a secondary antibody and staining was visualized 
using diaminobenzidine (DAB). ABAT and STC2 protein staining was scored for 
quantity and intensity. Staining was grouped into standardized categories for the 
percentage of staining positive cells (0%, 1±20%, 21±50%, 51±75%, or 76±100% of 
positive cells) and for staining intensity (negative, weak, moderate, strong). 
Subsequently, the scores for quantity and intensity were multiplied to generate a 
staining IHC-score. Based on the IHC-score, a specimen was classified as negative 
or positive for ABAT and STC2 protein expression. 
RESULTS 
Comparative analysis of ER+ IBC and nIBC expression profiles 
Using global test analysis and PCA, we observed that ER+ samples from patients with 
and without IBC exhibited significant differences in their expression profiles that led to 
segregation of IBC and nIBC samples in the PCA plot of the discovery series (Figure 
1A). Evaluation of the Recurrence Score, the HOXB13/IL17RB expression ratio and 
PAM50-derived scores for molecular subtypes, ER activity, risk of relapse models 
(ROR-S and ROR-P), indicated decreased ER signaling and sensitivity to endocrine 
treatment for ER+ samples from IBCs compared to those of nIBCs (Figure 1B). 
Figure 1 IBC discriminatory genes. Evaluation of IBC and nIBC in the discovery series I (Figure 1A±B) and 
of ER+ IBC discriminatory genes (ABAT, ADAMDEC1, CLEC7A, ETS1, ITK, STC2) (Figure 1C). Figure 1A 
illustrates the Principle Component Analyses of the tumor samples by their gene expression profiles. Red 
dots denote ER+ IBC samples, blue dots denote ER+ nIBC samples. The centroids for both tumor 
A
B
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SKHQRW\SHVDUHLQGLFDWHGLQEODFNDQGODEHOHGUHVSHFWLYHO\³&HQWURLG,%&´DQG³&HQWURLGQ,%&´3&$IRU
the common 6 classifier genes showed an expected segregation of ER+ samples from patients with and 
without IBC on the 2D scatter plot representation of the 1st (X-axis) and the 2nd (Y-axis) principal 
component. Class label permutation analyses (applying 100 class label permutations) demonstrated that 
the centroids of the ER+ samples from patients with and without IBC are significantly segregated (Observed 
Euclidean distance = 4.555, average expected Euclidean distance = 0.890; P < 0.010). Figure 1B presents 
the results on PAM50 analyses, Recurrence score, and HOXB13/IL17RB. For PAM50, the percentage 
Luminal A-type tumors in IBC and nIBC is provided in addition to the ROR-S, ROR-P and ER activity scores. 
The ER activity score ranges from negative to positive, with negative values indicating repressed ER 
activity. In addition, the RS and the HOXB13/IL17RB gene expression ratio are provided for both tumor 
types. The reported P-values result from the comparison of the IBC and nIBC groups with respect to these 
variables. Figure 1C depicts the network obtained for the 6 IBC discriminatory genes together with the 
estrogen receptor-ĮESR1) when evaluated with Ingenuity Pathway Analyses. This exploratory analysis 
revealed interactions with hormone receptor signaling, inflammation, cell survival, epidermal growth factor 
VLJQDOLQJ VWHPFHOO VLJQDOLQJ DQG 7*)ȕ VLJQDOLQJ LQGLFDWLQJ D SRWHQWLDl involvement for each of these 
biological features in endocrine resistance. The molecules are color-coded red if the corresponding gene 
is overexpressed in ER+ IBC samples and green if the corresponding gene is repressed in ER+ IBC 
samples. Uncolored nodes are added by the software. Solid lines signify direct gene±gene interactions, 
whereas broken lines represent indirect relationships that may require secondary effectors not depicted in 
the network. All connections are supported by at least one published report or from canonical information 
stored in the Ingenuity Pathway Knowledge Base.  
 
Biomarker discovery analysis 
As shown above, ER+ IBC samples exhibited molecular characteristics of resistance 
to endocrine therapy, making their gene expression profiles a potential source for 
biomarker discovery. Using PAM on 10 alternatively composed training sets of 40 
randomly selected ER+ samples from the discovery set (series I), we generated 10 
distinct gene signatures distinguishing IBC from nIBC samples. Application of these 
gene signatures onto corresponding series of the 25 left-out samples revealed an 
average sensitivity of 89% (range 71%±100%), specificity of 80% (range 67%±100%) 
and test error rate of 18% (range 0%±28%). These 10 gene signatures had 6 
overlapping genes: ABAT, ADAMDEC1, CLEC7A, ETS1, ITK1 and STC2. Relative to 
nIBC, ABAT and STC2 expression levels were decreased in IBC whereas the levels 
of the remaining 4 genes were increased (Table 2 and Figure 2). Exploratory IPA 
analysis was performed to investigate mutual relationships between the 6 classifier 
genes and ER (Figure 1C) and suggested their potential involvement in endocrine 
therapy resistance. 
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Figure 2 Receiver Operator 
Characteristics (ROC) 
Analyses. The ROC-analyses 
generate Area Under Curve 
(AUC) values presented in 
Figure 2A as measure for the 
discriminatory potential of the 
individual genes to predict 
IBCs and nIBCs correctly 
within the test (series II) 
compared to the discovery 
(series I). Factors with AUC (or 
their intervals) value 0.5 are 
not informative. The results 
show as illustrated with ROC 
plots in Figure 2B that AUCs 
for only the metagene, ABAT 
and STC2 are discriminatory 
and comparable for the 
discovery and test. 
 
 
 
 
 
 
 
 
 
Area Under Curve (AUC)A
AUC series I: 0.90 (95%CI: 0.82-0.97)
AUC series II: 0.62 (95%CI: 0.52-0.72)
AUC series I: 0.13 (95%CI: 0.04-0.21)
AUC series II: 0.37 (95%CI: 0.27-0.47)
AUC series I: 0.20 (95%CI: 0.10-0.31)
AUC series II: 0.33 (95%CI: 0.23-0.43)
Metagene in IBC discovery (I) and test (II)
B
STC2 in IBC discovery (I) and test (II)ABAT in IBC discovery (I) and test (II)
Chi2 P-value <0.001
Chi2 P-value = 0.095Chi2 P-value <0.001
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Diagnostic effectiveness of biomarkers and classifiers 
Next, these six genes were evaluated for their potential to distinguish IBC from nIBC 
in an independent subset of patients with and without IBC (series II). Only the AUCs 
for the metagene score, ABAT, and STC2 were discriminatory and comparable in both 
the discovery and test cohort (Figure 2). The ROC AUCs of these three biomarkers 
were further explored to establish optimal classifier cutoffs. Distribution dot-plots in 
the discovery cohort were used to verify the ER+ IBC classification thresholds, which 
ZHUHVHWIRUWKHPHWDJHQHVFRUHDWDQGIRUERWKABAT and STC2 DW)LJXUH
3A, C and E). The classifiers, however, exhibited moderate diagnostic effectiveness 
with regard to ER+ IBC prediction, since only a maximum of 64% accuracy was 
achieved within the test (Figure 3B, D and F).  
Figure 3 Dot-plots and diagnostic effectiveness. This figure represents dot-plots and the diagnostic 
performance of the biomarkers in the discovery and test series for IBC and nIBC (series I and II). The 
metagene scores and expression levels of ABAT and STC2 measured in the discovery (series I) were 
evaluated in dot-plots to explore the defined thresholds that classify samples as IBC-like or nIBC-like. The 
diagnostic effectiveness of the biomarker IBC classification were evaluated in the independent test (series 
II). 
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Biomarkers in early disease: prognosis and adjuvant tamoxifen 
The metagene score, ABAT, and STC2 were subsequently evaluated as continuous 
variable for their relationship with MFS with regard to prognosis and outcome after 
adjuvant tamoxifen (Table 3). The prognostic value was determined on three series 
of in total 517 (neo)adjuvant systemic treatment naïve patients with ER+ LNN breast 
cancer (series VII±IX). None of the biomarkers, assessed by microarrays, were 
prognostic when evaluated for all 517 patients. The biomarkers were also evaluated 
in 250 ER+ patients treated with adjuvant tamoxifen (series III). Decreased expression 
of ABAT (HR = 0.73; 95% CI = 0.61±0.87; P = 0.001) showed a significant correlation 
with poor MFS in these tamoxifen treated patients, whereas STC2 and the metagene 
score had no association with MFS after tamoxifen. 
     
Biomarkers and first-line endocrine therapy for advanced disease 
 
The metagene score, ABAT, and STC2 were also evaluated for their relation with PFS 
on microarray based series of patients with advanced disease treated with first-line 
tamoxifen (IV, N = 96) or aromatase inhibitors (V, N = 84), and validated with RT-
qPCR on an independent series of patients treated with first-line tamoxifen (VI, N = 
231). As continuous variables, increased metagene scores and decreased expression 
of ABAT and STC2 were correlated with poor treatment outcome in all three series of 
patients, except for STC2 in series IV (Table 3). As classifiers, apart from STC2 in 
series IV, all three biomarkers showed significant associations with PFS for all series 
in the Kaplan±Meier survival analyses (Figure 4). 
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Figure 4 Kaplan±Meier Analyses for outcome after endocrine treatment. The metagene, ABAT and 
STC2 as IBC/nIBC classifiers and their relation with PFS as measure for treatment outcome in advanced 
disease after first-line tamoxifen (series IV and VI) and aromatase inhibitors (series V). 
 
Biomarkers and published signatures 
 
The biomarkers were compared for their relation with PFS in advanced disease 
(series IV, V, VI) with published signatures for Recurrence Score and GGI (Table 4).  
When compared to Recurrence Score and GGI only ABAT remained significantly 
associated with PFS in all series (except for GGI in series V). In contrast, the 
metagene score and STC2 were only independent from Recurrence Score and GGI 
in AI-treated patients (series V). In summary, especially ABAT expression levels were 
independently associated with PFS when compared to published signatures 
separately and validated with RT-qPCR. 
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Biomarkers and clinicopathological predictors 
 
Multivariate analyses were performed by adding the biomarkers separately to a base 
model of traditional clinicopathological factors for endocrine therapy in advanced 
disease (Table 5). The model included age, menopausal status, dominant site of 
relapse, disease-free interval and mRNA expression levels for ESR1, PGR, and 
ERBB2. These multivariate analyses showed that low ABAT levels were significantly 
related with poor PFS in the series of 96 patients treated with tamoxifen (series IV  
(HR = 0.78, P = 0.027)), whereas high metagene scores (HR = 1.24, P = 0.005) and 
low STC2 levels (HR = 0.79, P = 0.011) were associated with poor PFS in the series 
of 84 patients treated with AI (series V). All three biomarkers were independently 
related with PFS in the RT-qPCR validation series of 231 patients treated with 
tamoxifen (series VI). 
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Biomarkers and protein expression 
 
In an exploratory study, ABAT and STC2 protein expression were examined in 110 
ER-positive primary breast cancer specimens (Figure 5A). Evaluation of quantity and 
intensity separately showed for both proteins no significant relationships with PFS 
(Supplementary Figure 1). The quantity and intensity scores were multiplied to 
generate an IHC-score for the staining and classified 77 specimens (69%) as ABAT-
positive and 78 specimens (70%) as STC2-positive (Figure 5B). These dichotomized 
IHC-scores were not related with PFS, i.e. not for ABAT (HR = 0.79; 95% CI = 0.51±
1.23; P = 0.30) and not for STC2 (HR = 0.93; 95% CI = 0.60±1.44; P = 0.74). 
Figure 5 ABAT and STC2 protein expression. The expression of ABAT and STC2 protein was evaluated 
with immunohistochemistry in 110 ER-positive primary tumor specimens of advanced breast cancer 
patients treated with first-line tamoxifen. In Figure 5A representative samples are shown for ABAT and 
STC2 staining in IBC and nIBC patients. Figure 5B demonstrates the staining categories for quantity, 
intensity, and IHC-scores, and the distribution of IHC-scores for ABAT and STC2. The IHC-scores were 
dichotomized into positive and negative scores, identifying 77 ABAT-positive and 78 STC2-positive 
specimens. Both ABAT and STC2 protein expression had no relationship with progression free survival. 
 
DISCUSION 
 
Inflammatory breast cancer is a rare (׽5%) but highly aggressive form of locally 
advanced breast cancer with an elevated invasive and metastatic potential. It is 
characterized by clinical and pathological characteristics atypical for breast cancer in 
general, amongst others a low frequency of ER positivity. In the past, we showed that 
the molecular portrait of IBC indeed contained fingerprints of aggressive tumor cell 
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behavior in breast cancer in general (Van Laere et al., 2008). Patients with IBC 
bearing ER expressing tumor cells constitute approximately 30% of all IBC cases and 
endocrine treatment in these patients is observed to be poorly effective. The molecular 
profile of samples from patients with ER+ IBC could provide additional hints towards 
unraveling the molecular biology associated with resistance to endocrine treatment. 
In this study, we demonstrate that, at least at the molecular level, ER+ IBC is 
characterized by features associated with endocrine resistance. For instance, the 
recurrence score and the HOXB13/IL17RB gene expression ratio are both 
significantly elevated in ER+ IBC compared with ER+ nIBC. Several studies have 
shown that elevated levels for both parameters are highly predictive of endocrine 
therapy resistance (Dowsett et al., 2010; Jansen et al., 2007; Ma et al., 2004; Paik et 
al., 2004). In addition, application of the PAM50-algorithm (Tibshirani et al., 2002) 
revealed a remarkably low frequency of Luminal A-type samples, which are shown to 
be more frequently responsive to endocrine treatment compared with their Luminal B-
type counterparts. This hypothesis is supported by the observation that samples from 
tumors with a Luminal B-phenotype frequently exhibit high Recurrence Scores (Fan 
et al., 2006). 
 
Using repetitive prediction analysis to obtain robust predictors, we identified a 
metagene of six genes consisting of ABAT, ADAMDEC1, CLEC7A, ETS1, ITK and 
STC2 to discriminate ER+ IBC from ER+ nIBC samples within the discovery series. 
These biomarkers were each verified and demonstrated that only the metagene and 
the genes ABAT and STC2 remained predictive in the test series. The metagene is a 
slightly better predictor than the single genes, however, its performance in the other 
series was largely dictated by ABAT and STC2. It is intriguing that ABAT and STC2, 
as 2 genes not yet linked to inflammation, discriminate between ER+ IBC and nIBC. 
A role in the inflammatory response, however, is less likely to be established since 
both ABAT and STC2 are down-regulated in IBC compared to nIBC. 
 
Recently, both ABAT and STC2 were described in the 100 rules used in the Absolute 
Intrinsic Molecular Subtyping (AIMS) (Paquet and Hallett, 2015). AIMS enables 
subtyping from gene expression profile at mRNA expression levels of an individual 
sample without the need of large, diverse, and normalized datasets. These findings 
indicate that both genes are highly relevant in molecular subtyping. Moreover, the 
molecular subtyping of breast cancer becomes more and more important in the clinical 
management of patients. The results of our study may therefore contribute with regard 
to endocrine treatment decision making. 
 
Although our study demonstrated only that both ABAT and STC2 are just biomarkers, 
literature suggests for both a role in ER signaling. ABAT (MIM: 137150) has been 
identified as a luminal-like gene with an ER-binding site within 20 kb distance from the 
transcription start site (Krijgsman et al., 2011). This gene is incorporated in Agendia's 
BluePrint assay, an 80-gene molecular subtyping profile developed in 200 breast 
cancer specimens and validated in four independent cohorts. ABAT encodes for 4-
aminobutyrate aminotransferase, an enzyme responsible for the catabolism of 
gamma-aminobutyric acid (GABA), which might be involved in the hormonal 
regulation and pathogenesis of breast cancer (Opolski et al., 2000). Moreover, 
comparative metabolomics demonstrated alterations in glutamine and beta-alanine 
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metabolism along with low ABAT H[SUHVVLRQZLWKVKRUWHQHGVXUYLYDOLQ(5DQG(5í
breast cancer (Budczies et al., 2013). 
 
Bouras and colleagues have shown that STC2 (MIM: 603665) as an estrogen 
responsive gene is co-expressed with ER (Bouras et al., 2002). In fact, independent 
studies have indeed shown that STC2 is a dynamic marker of estrogen-driven 
pathway activation and that constitutive expression after serum withdrawal negatively 
affects breast cancer cell growth, cell viability and cell migration (Raulic et al., 2008; 
Urruticoechea et al., 2008)). Therefore, reduced expression of STC2 in breast cancer 
cells enables survival and cell growth in the absence of estrogen, thereby contributing 
to endocrine treatment resistance. Of note, in a recent effort to redefine the molecular 
portraits of IBC on an extended series of 137 samples, repressed STC2 expression 
levels were observed in IBC in a molecular subtype-independent manner (Van Laere 
et al., 2010). Future studies are needed to provide functional evidence that ABAT and 
STC2 are mechanistically involved in endocrine therapy response. 
 
Based upon above considerations and findings we evaluated ABAT and STC2 further 
in different datasets to determine their relationship with prognosis and treatment 
outcome to adjuvant and first-line endocrine therapy (i.e. tamoxifen and aromatase 
inhibitors). Both biomarkers were not prognostic, whereas only decreased levels of 
ABAT were associated with shorter MFS after adjuvant tamoxifen. In the advanced 
disease setting, decreased expression of ABAT and STC2 characterized patients with 
reduced PFS under either tamoxifen- or AI-based endocrine therapy. Particularly in 
patients treated with first-OLQH WDPR[LIHQ WKHVH ³(5 ,%&-OLNH´ SUHGLFWRUV ZHUH
associated with sensitivity to endocrine treatment in an independent data set profiled 
with an alternative technology. The latter is important as it proves that determination 
of ABAT and STC2 expression levels is also applicable with standard PCR 
WHFKQRORJLHV PDNLQJ WKH ³EHQFK-to-EHGVLGH´ WUDQVLWLRQ PRUH IHDVLEOH :H DOVR
explored whether ABAT and STC2 protein expression might be applicable as 
predictive biomarkers in immunohistochemical assays, however, our findings showed 
no relationship with tamoxifen outcome. 
 
Combining these biomarkers with clinico-pathological factors in multivariate analyses 
demonstrated that ABAT remained significantly associated with response to 
tamoxifen in two independent patient series, whereas the metagene and STC2 was 
only independent within the qRT-PCR validation. Moreover, only ABAT remained 
independent predictive for tamoxifen in both patient series when combined with the 
published signatures Recurrence Score and GGI. All these multivariate analyses on 
different patient series summarized indicate ABAT as a robust predictor for the 
response to tamoxifen. 
 
In conclusion, this study has identified an increased metagene score and decreased 
expression of ABAT and STC2 in IBC, and correlated the metagene and low 
expression of the genes with poor tamoxifen treatment outcome in the advanced 
setting as shown with qRT-PCR in an independent validation. ABAT and STC2 protein 
expression were not informative with regard to treatment outcome. Further studies on 
the classifier genes are needed to elucidate the mechanism of therapy resistance. 
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ABSTRACT 
The aim was to identify mutations in serum cell-free DNA (cfDNA) associated with 
disease progression on tamoxifen treatment in metastatic breast cancer (MBC). Sera 
available at start of therapy, during therapy and at disease progression were selected 
from 10 estrogen receptor (ER)-positive breast cancer patients. DNA from primary 
tumor and normal tissue and cfDNA from minute amounts of sera were analyzed by 
targeted next generation sequencing (NGS) of 45 genes (1,242 exons). At disease 
progression, stop-gain single nucleotide variants (SNVs) for CREBBP (1 patient) and 
SMAD4 (1 patient) and non-synonymous SNVs for AKAP9 (1 patient), PIK3CA (2 
patients) and TP53 (2 patients) were found. Mutations in CREBBP and SMAD4 have 
only been occasionally reported in breast cancer. All mutations, except for AKAP9, 
were also present in the primary tumor but not detected in all blood specimens 
preceding progression. More sensitive detection by deeper re-sequencing and digital 
PCR confirmed the occurrence of circulating tumor DNA (ctDNA) and these 
biomarkers in blood specimens. 
Keywords: breast cancer, tamoxifen therapy, targeted next generation sequencing, 
cell-free DNA, disease progression 
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INTRODUCTION 
It is increasingly appreciated that the genetic make-up of tumors forms one of the 
main determinants for outcome to systemic treatments in cancer patients [1]. There is 
also accumulating evidence that primary tumor characteristics can greatly differ from 
those of the metastases [2]. This may underlie the relatively poor association of 
molecular characteristics of primary tumors with outcome in MBC. It is therefore likely 
that genetic variants important for treatment decision making should be determined in 
specimens from metastatic tumor rather than from primary tumor tissue. In addition, 
the genetic constitution of a tumor lesion is not fixed but constantly changes, in 
particular under treatment pressure. As novel DNA mutations can cause resistance to 
systemic treatments, longitudinal monitoring of these mutations during treatment is 
crucial to detect resistance at an early stage and, if possible, to adjust treatment based 
on the emerging mutations. 
DNA from primary and metastatic tumor cells can be detected as cfDNA in the 
peripheral blood of cancer patients. This cfDNA is therefore a very attractive tool to 
establish mutational changes occurring in tumor cells in a minimal invasive manner. 
Its great promise in this respect was recently reviewed [3]. For example, in patients 
with metastatic KRAS wild-type colorectal cancer treated with an anti-EGFR antibody, 
blood analyses showed that the appearance of KRAS mutants, conferring resistance 
against anti-EGFR antibodies, preceded progressive disease with up to 10 months 
[4]. Likewise, in breast cancer patients mutations in the estrogen receptor (ESR1) 
have been hardly detected in primary tumors but are currently frequently reported in 
plasma from patients with metastatic disease that acquired resistance to aromatase 
inhibitor therapy [5-8]. In the current study, we aimed to identify tumor-specific 
mutations in cfDNA that associate with disease progression on tamoxifen in MBC. 
RESULTS 
Detection of DNA changes 
As we were interested in cfDNA mutations that potentially associate with treatment 
outcome in a particular patient, we characterized DNA changes in serum taken at 
disease progression in 10 MBC patients who received first-line tamoxifen 
(Sumpplementary Table S1) . After applying our selection criteria on called variants, 
18 cfDNA changes were identified at disease progression which were not detected 
in normal tissue DNA nor reported by the 1000 Genome database. Of these, 3 
variants were only seen in blood specimens and not in the corresponding primary 
tumor whereas 15 variants were also detectable in the primary tumor. Twelve DNA 
changes in 6 patients were shown to associate with treatment outcome (Figure 1) Of 
these, 9 tumor-specific DNA changes were present at disease progression and in 
the primary tumor but not in all blood specimens preceding progression (Table 1) 
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Figure 1 Study design and discovered DNA changes. Targeted ion-PGM (re-)sequencing was 
performed on DNA isolated from primary tumors and blood specimens from 10 metastatic breast cancer 
patients who received tamoxifen as first-line therapy. Cell-free '1$FI'1$ZDVLVRODWHGIURPȝOVHUXP
taken at start (Ss), during therapy (St) and at disease progression (Sp). Analysis revealed 12 biomarkers 
including 9 single nucleotide variants (SNVs) detected at progression and in primary tumor but not in all 
preceding blood specimens. The SNVs originating from the primary tumor are presented in red when only 
seen at Sp, in green when seen at Ss and Sp, and in blue when seen at St and Sp. 
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Pathogenic somatic single nucleotide substitutions 
 
The 12 DNA changes included 5 synonymous and 7 non-synonymous SNVs. Almost 
all algorithms predicted the missense SNVs for CDH1, PIK3CA and TP53 (p.V41G; 
p.R148G) as pathogenic and for AKAP9, CREBBP and SMAD4 predominantly as not 
pathogenic (Supplementary Table S2). Moreover, the SNVs in PIK3CA and TP53 
have been reported as cancer-specific mutations. 
 
Re-sequencing at 1% detection limit of missense SNVs 
 
Next the identified non-synonymous SNVs were selected for re-sequencing since only 
these translate into amino acid changes, which might alter the biological function of 
the encoded protein and as a result might affect clinical outcome. All specimens were 
re-sequenced for 1 missense SNV found in blood only and 5 missense SNVs found 
in primary tumors at diagnostic levels, i.e. higher than 10%. The re-sequencing 
confirmed the initial results for AKAP9 p.H562Q in patient 1, CREBBP p.E1321X in 
patient 6, SMAD4 p.Y353X, TP53 p.V41G, and PIK3CA H1047L in patient 7, and 
TP53 p.R148G in patient 8. Moreover, PIK3CA exon 20 re-sequencing identified 
another SNV, i.e. p.H1047R. This SNV was seen at disease progression and all other 
blood specimens of patient 1 and in the primary tumors of patients 1, 2, and 7 
(Supplementary Table S3). 
 
Digital PCR evaluation at 0.05% detection limit of PIK3CA mutations 
 
The re-sequencing results for PIK3CA were verified by digital PCR using mutation-
specific assays (Supplementary Table S3). The p.H1047L mutation was evaluated 
and confirmed in all specimens of patients 7 and 10, but was additionally seen in 
serum at start of therapy of patient 10. The p.H1047R mutation was evaluated in all 
primary tumors as well as in blood specimens of patients 1 and 2. Digital PCR 
confirmed the occurrence of this mutation in all evaluated blood specimens and 
primary tumors, except in the primary tumor of patient 7. 
 
cfDNA mutations and disease development 
 
For patient 1 additional blood specimens available between diagnosis of primary 
tumor and metastatic lesions were evaluated by NGS and digital PCR (Figure 2). Re-
sequencing demonstrated AKAP9 and PIK3CA mutations at similar magnitudes in 
blood specimens taken around the occurrence of metastatic lesions. It also detected 
PIK3CA mutant reads in blood preceding the metastasis, however, in less than 10 
reads. Digital PCR confirmed this PIK3CA mutation in blood taken 6 years after 
diagnosis of primary disease but two years before diagnosis of metastatic lesions. At 
the time metastatic lesions were recognized, the blood had a large number of copies 
with this mutation, which dropped after 2 months of first-line tamoxifen therapy, but 
increased towards therapy resistance after 6 months treatment. 
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Figure 2 cfDNA missense mutations and disease development. The AKA❁9 and PIK3CA mutations of 
patient 1 were evaluated in blood specimens during the course of disease. Sera collected five years after 
clinical diagnosis of breast cancer were evaluated by ion-PGM resequencing and for PIK3CA in duplicate 
by digital PCR (dPCR). The p.H1047R mutation was observed at low magnitude in blood taken five years 
after diagnosis of primary disease and already two years before radiological diagnosis of metastatic lesions. 
Although sometimes low numbers of PIK3CA mutant copies were detected, all were independently 
observed after ion-PGM resequencing and in two separate digital PCR reactions. All proportions except for 
the sample at 5y11m were above the limit of detection. 
 
DISCUSSION 
 
This exploratory study is to our knowledge the first to report on sequential monitoring 
of serum cfDNA in a homogenous setting of MBC-patients receiving first-line 
tamoxifen therapy. In total 12 variants for 6 patients were identified in cfDNA at 
disease progression, including 3 variants that were only found in blood specimens but 
not in the primary tumor and 9 variants detected in corresponding primary tumor but 
not in all blood specimens preceding progression. Because of their putative biological 
relevance, we confirmed the identified missense mutations by re-sequencing and by 
digital PCR. 
 
Out of these, missense mutations in PIK3CA, TP53, SMAD4 and CREBBP were 
present both at time of progression and in the primary tumor. COSMIC reported 
Amount cfDNA (in ng) in 1ml serum 17.6 20.4 6.2 30.8 23.2 17.1 16.1
Proportion (in %) 0.00% 0.00% 23.35% 1.02% 7.22% 1.85%
mutant/total reads (0/7,055) (0/6,285) (2021/8,653)(70/6,842) (534/7,392) (215/11,604)
mutant copies/ml serum 0 0 22 1 4 1
Proportion (in %) 0.00% 0.00% 21.65% 3.79% 9.72% 8.83%
mutant/total reads (3/2,564) (2/3,229) (1577/7,285)(177/4,671) (358/3,682) (463/5,243)
mutant copies/ml serum 0 0 20 3 5 4
Proportion (in %) 0.00% 1.19% 2.38% 45.15% 5.88% 28.48% 18.62%
mutant/total copies (0/125) (1/134) (3/115) (189/424) (3/60) (19/73) (14/76)
mutant copies/ml serum 0 1 3 42 4 15 9
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mutations in breast cancer most frequently in PIK3CA and TP53 while occasionally in 
CRE B B P and S M AD 4  with our variants for the latter two genes not earlier described. 
Mutations in all these genes have been found in hormone-resistant breast cancer [9]. 
The presence of PIK3CA and TP53 mutations in longitudinally collected blood 
specimens correlated with treatment outcome to PI3K-inhibitors and aromatase 
inhibitors and was associated with the clinical course of disease [10, 11]. CREBBP 
and SMAD4 encode proteins that bind to ER as co-activator [12] and co-repressor 
[13], respectively, suggesting a putative role in endocrine therapy resistance [13, 14]. 
However, the effect of the CRE B B P stop-gain mutation revealed in our study remains 
to be established. The SMAD4 p.Y353X stop-gain mutation resides within the MH2 
domain, a mutational hotspot [15] related to a loss of function, detrimental for TGFb 
signaling, and poor disease outcome [16]. Importantly, above variants at time of 
progression likely reflect only tumor load in the blood. The AKAP9 p.H562Q missense 
mutation was not seen in the primary tumor and might have been missed due to tumor 
cell heterogeneity. Alternatively, this mutation might originate from metastatic lesions 
or acquired due to treatment pressure. Variants in AKAP9 have been described 
repeatedly in COSMIC and as SNPs associated with increased breast cancer risk 
[17], but the particular variant found here has not yet been reported. It is currently 
unknown whether, and if so, to which extent, all missense mutations actually 
contribute to resistance against tamoxifen. Many of the mutations are probably 
bystander mutations due to genomic instability. Therapy resistance, however, may 
select for tumor cells with specific mutations adapting these cells to the hostile 
environment, resulting in the survival of fittest and ultimately driving tumor progression 
[18]. 
 
Our study differs from previous studies using ion-PGM targeted NGS on cancer tissue 
and liquid biopsies to identify tumor-specific DNA changes. Earlier studies [19±21] 
evaluated 200 amplicons of the commercially available hotspot cancer panel whereas 
we examined fifteen-fold more amplicons. These studies detected mutations in both 
plasma and tissue for 27 of 34 cancer patients [20], or like our study, in half of the 
cancer patients [19, 21] and evaluated plasma specimens collected within a 16 month 
time-frame after primary tumor tissue was obtained. We instead sequenced and 
identified mutations in minute cfDNA amounts isolated from serum collected at least 
3 years after diagnosis of primary disease. Mutations in low DNA amounts might be 
missed due to the limited number of genomic equivalents present and corresponding 
higher limit of detection. Retrospective studies, such as our own, collected mainly 
limited blood quantities which will often result in minute cfDNA amounts available for 
DQDO\VLV)XUWKHUPRUHRXUVHUXPVDPSOHVKDYHEHHQVWRUHGDWí&IRUPRUHWKDQ
18 years, demonstrating that long-term stored routinely collected sera are suitable for 
cfDNA isolation and subsequent molecular characterization. 
 
To define ctDNA mutations in blood associated with disease progression on tamoxifen 
treatment, we screened for biomarkers seen at progression and the corresponding 
primary tumor but not in all preceding blood specimens in a particular patient. The 
mutation detection in blood depends on cfDNA quantities, with these quantities 
changing in time and reflecting tumor load in the course of disease. Our study showed 
overall no significant differences in blood cfDNA yields at different time-points, 
however, most mutations were detected in patients with the highest DNA yields at 
9,,
9,,,
9,
9
,9
,,,
,,
,
9,,
9,,,
9,
9
,9
,,,
,,
,
Cell-free DNA mutations as biomarkers in BC patients receiving tamoxifen | 121

progression. Deeper re-sequencing confirmed the presence of the 6 missense SNVs 
in specimens of individual patients in which they were initially reported and absence 
from those which initially lack them. It also discovered an additional PIK3CA mutation, 
and examination of sequence reads revealed that the p.H1047R mutation was 
originally present in respective specimens but not called due to stringent settings, 
indicating that current thresholds are suboptimal for rare variant detection in cfDNA 
[19, 22]. Digital PCR independently identified both PIK3CA mutations in blood 
specimens at higher frequencies than revealed by NGS and in additional specimens 
and as proof-of-principle even in blood taken years before diagnosis of the metastatic 
lesions. 
 
In conclusion, our study demonstrates that targeted ion-PGM sequencing of cfDNA is 
applicable to discover mutations in archived serum samples. Deeper re-sequencing 
and digital PCR analyses enables more sensitive detection and monitoring of specific 
mutations in sequential blood specimens even in samples stored for over 18 years 
and in minute amounts of cfDNA. Further studies are warranted to investigate whether 
detection of ctDNA in tamoxifen-treated metastatic breast cancer patients can be used 
to detect disease progression at an early stage and whether the identified variants 
play a role in tamoxifen resistance. 
 
MATERIALS AND METHODS 
 
Materials and methods are described briefly below, details are found in the appendix. 
 
Patient and sample collection 
 
This retrospective study investigated fresh frozen primary tumor tissue and sequential 
sera taken from 10 MBC patients who received tamoxifen as first-line therapy for 
distant metastatic disease (Figure 1). Blood specimens were selected at start of 
tamoxifen therapy (Ss), during therapy (St), and at disease progression (Sp). From 6 
patients formalin fixed paraffin embedded (FFPE) macro-dissected normal tissue was 
available and analyzed. The study was approved by the medical ethics committee 
(MEC 02.953), performed according to the Code of Conduct of Medical Scientific 
Societies (www.federa.org/codes-conduct) and followed REMARK guidelines where 
possible [23]. Clinicopathological characteristics are presented in Supplementary 
Table S4. 
 
DNA isolation, quantification, and sequencing 
 
DNA from tumor and normal tissue specimens was extracted as described previously 
[24, 25]. The MagnaPure Compact nucleic acid isolation kit (Roche Diagnostics) was 
applied to isolate cfDNA from 400 ȝO VHUXP'1$ \LHOGV DQG FRQFHQWUDWLRQVZHUH
quantified with a Qubit® 2.0 fluorometer (Thermo Scientific). The cfDNA input amounts 
of each sample were used to establish the genomic equivalents and limits of detection 
for subsequent molecular analyses (Supplementary Tables S5 and S6). 
Semiconductor sequencing was performed using the Ion Torrent Personal Genome 
Machine (Ion-PGM) and consumables, kits, software packages and protocols 
provided by the manufacturer (Thermo Scientific). Briefly, 10 ng tissue DNA and 
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minute amounts cfDNA (range: 165-573 pg) were used as input for library preparation 
and sequenced with a custom-made gene panel. Ion AmpliSeq Library Preparation 
Kit 2 and Ion PGM Template OT2 200 kit were applied to generate libraries and 
templates, respectively. Ion Sequencing Kit v2 was used for sequencing on an Ion 
318 chip. 
 
C u s t o m  g e n e  p a n e l 
 
The 45-gene panel (Supplementary Table S2) included the most frequently mutated 
genes for breast, colon, prostate and ovarian cancer reported in the catalogue of 
somatic mutations in cancer (Cosmic Release 67; 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Thirty-nine genes were 
sequenced for all exons, 6 oncogenes for hotspot exons only. In total 3,106 amplicons 
(i.e. 1,242 exons; ׽255kb) were sequenced up to a read depth of 5,000x. 
 
B io - in f o r m a t ic s  f o r  v a r ia n t  d e t e c t io n  a n d  e v a lu a t io n  
 
Raw data analyses, base calling and alignment were performed using Torrent Suite 
v4.0. Somatic low stringency filtering was applied in Variant Caller v4.16 (VC) to detect 
DNA changes when compared to reference genome hg19 (build 37). Variants were 
annotated by a custom pipeline including ANNOVAR 
(openbioinformatics.org/annovar) within Galaxy (galaxyproject.org). Only exonic 
variants with frequencies of 1% or higher and above the cfDNA-specific limit of 
detection were selected. Uniquely identified variants and those found in sequenced 
normal DNA or reported within the 1000-Genome database were excluded. These 
variants had to be sequenced without strand bias at a read depth of 100x or more and 
showing at least 10 mutant reads. Integrative Genomics Viewer (IGV) 
(http://www.broadinstitute.org/igv) was used for manual examination. Identified SNVs 
were evaluated with different in silico algorithms to predict the pathogenicity of the 
SNV on protein function. These tools are embedded in ANNOVAR and included SIFT, 
PolyPhen2, MutationTaster, FATHMM, GERP++, SiPhy and PhyloP [26]. 
 
R e - s e q u e n c in g  a n d  d ig it a l P C R  a n a ly s is  
 
Exons of selected non-synonymous SNVs were re-sequenced for all specimens by 
ion-PGM after independent library preparation up to 100,000 reads depth, and 
evaluation was performed similar to the initial analysis. The PIK3CA genotype was 
verified with Taqman p.H1047L- and p.H1047R-specific assays and the 
4XDQW6WXGLR ' 'LJLWDO 3&5 V\VWHP 7KHUPR 6FLHQWLILF 5HDFWLRQ PL[WXUHV
LQFOXGLQJWXPRURUVHUXP'1$DQG4XDQW6WXGLR''LJLWDO3&50DVWHU0L[ZHUH
loaded on digital PCR chips with 20,000 wells, and cycled under standard conditions 
IRUF\FOHV4XDQW6WXGLR'DQDO\VLV6XLWHGHWHUPLQHGWKHSURSRUWLRQPXWDQW
and wild-type templates. 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
Breast cancer is the most common cancer in women and second most common 
cancer worldwide, with nearly 1.7 million new cases diagnosed in 2012 (World Cancer 
Research Fund) 1. The 5-year survival rate of early stage BC is 80-90%, particularly 
in many countries with advanced medical care. However it is dropping to 24% when 
diagnosed at a more advanced stage http://www.wcrf.org/int/cancer-facts-
figures/data-specific-cancers/breast-cancer-statistics.  
Breast cancer is more common after menopause. Most breast cancer subtypes are 
hormone-related with approximately 75% of breast cancer cases being ER-positive 2. 
Cancer is a disease of the DNA and the most prevalent mutation in (ER-positive) 
breast cancer is PIK3CA (see Introduction). Moreover, genomic studies have also 
shown that ER-positive breast cancers are of the luminal subtypes. For metastatic 
breast cancer (MBC) the most common site of metastasis is bone 3.  
Anti-hormonal therapy (antiestrogens and/or aromatase inhibitors) used for ER-
positive breast cancer patients will eventually fail in almost 50% of the ER-positive 
breast cancers 4. In the advanced setting, up to 60% of patients do not respond to 
anti-hormonal first-line therapy. Moreover, almost all metastatic patients and 
approximately 40% of patients receiving adjuvant treatment eventually relapse 5,6.  
For over 40 years the selective estrogen receptor modulator tamoxifen, which 
competes with the natural ligand for binding to the estrogen receptor, has been key 
for premenopausal breast cancer therapy. Moreover, in the adjuvant setting, 
tamoxifen has been shown to decrease breast cancer recurrence risk and death. 
7DPR[LIHQ ELQGV WR (5Į DQG SHUPLWV UHFHSWRU GLPHUL]DWLRQ EXW LQGXFHV
conformational changes which differ to those induced by estrogens.  
For 20 years, another treatment of ER-positive breast cancer is used: aromatase 
inhibitors (AI). The mechanism of action for aromatase inhibitors prevents estrogen 
synthesis, consequently depriving the receptors from their natural ligand. AI are 
mostly effectively used in postmenopausal women.  
In general cancer patients do not die from their primary tumor but they die of the 
metastases that are no longer responding to therapy. Relevant for this discussion and 
my thesis aims is that the objective response rate to endocrine therapy for ER-positive 
MBC is only 20-40% with a median duration of approximately 8-14 months 7. This 
shows a clear and urgent need to recognize biomarkers able to identify patients who 
will or will not benefit from the therapy. As such, for those patients, unnecessarily 
exposure to undesirable adverse events of (anti-hormonal) therapy can be avoided. 
Consequently, this thesis aimed to find potential biomarkers of prediction to anti-
hormonal treatment resistance in advanced ER-positive breast cancer patients. 
Predictive markers, however, are also often prognostic. By definition, the ideal 
predictive biomarker must have a sensitivity predictive value with no prognostic 
value 8.  
For the purpose to find potential biomarkers that predict anti-hormonal treatment 
resistance in advanced ER-positive breast cancer patients different approaches were 
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followed. Almost all approaches included evaluation of publicly available in silico 
datasets for ER-positive and/or luminal breast cancer. These datasets were mainly 
used for independent validation of biomarkers, however, we have used the in silico 
datasets for discovery in our analyses of mRNAs and miRs and of protein expression 
and phosphorylation as described in Chapters III and IV, respectively.  The starting 
point and focus of this thesis is ER-positive/luminal MBC with PIK3CA mutations, the 
most prevalent mutation in breast cancer as mentioned before. 
PIK3CA mutations: Its relationship with and relevance for endocrine treatment 
outcome 
 
In Chapter II, PIK3CA hotspot mutations were investigated in 1352 primary breast 
tumors for its relationship with prognosis and endocrine treatment outcome. We were 
the first to report for MBC, and as shown in this chapter, that PIK3CA mutations in 
ER-positive primary tumors associate with favourable outcome on first-line 
aromatase inhibitors. Moreover, PIK3CA mutations in our cohort were not 
prognostic nor predictive for outcome on tamoxifen. 
Regarding endocrine therapy response in the (neo-)aduvant setting, others have 
shown for adjuvant AI treatment that PIK3CA mutations in exon 20 9 also associates 
with a favourable outcome, whereas mutations in exon 9 are not related with outcome 
10
. With regard to tamoxifen treatment, contradicting findings in the adjuvant setting 
have been reported. In one study PIK3CA mutations and a PI3K-gene expression 
signature were related with favourable outcome on tamoxifen 11 while in other studies 
mutations were not related to tamoxifen treatment benefit 12, or were associated with 
shorter survival 13. 
Since preclinical models have identified cross-talks between ER and 
PI3K/AKT/mTOR pathways as mechanism of endocrine therapy resistance, therapies 
combining endocrine treatment with PI3K inhibitors have also been evaluated in 
clinical settings. In these studies, PIK3CA mutations might not only relate with 
response to endocrine therapy but also to PI3K-inhibitor therapy. One of the first 
reported a neo-adjuvant study which demonstrated significant increased 
antiproliferative responses when patients received mTOR inhibitor (everolimus) plus 
AI (letrozole) compared to AI alone. This antiproliferative response for the combination 
therapy was also seen in a small number of patients with PIK3CA exon 9 mutations, 
but not for patients with exon 20 mutations 14. Evaluation of this combination therapy 
in MBC within the BOLERO-2 study, a phase 3 trial, demonstrated a two times longer 
progression-free survival for the addition of everolimus to AI 15. Additionally, the 
BELLE-2 study also suggests that PIK3CA mutations detected in the primary tumor 
as well as in ctDNA may help select patients who benefit from adding a pan-PI3K 
inhibitor (buparlisib) to SERD endocrine therapy (fulvestrant). Patients carrying the 
PIK3CA mutation showed to increase from 4.0 to 6.8 months PFS 16.  Unfortunately, 
buparlisib showed some serious adverse events precluding further development of 
this drug.  17. On the opposite, Loi et al. have shown that PIK3CA mutations do not 
correlate with better neoadjuvant mTOR inhibitor (everolimus) treatment outcome 
when added to AI (letrozole). Instead, they showed their PI3K gene expression 
signature can predict better treatment outcome after neoadjuvant AI 18.  Schmid et al. 
(not in refs )also showed in the neoadjuvant setting, that regardless of PIK3CA 
mutation status in luminal B primary BC, the PI3K inhibitor (pictilisib) appears to 
9,,
9,,,
9,
9
,9
,,,
,,
,
9,,
9,,,
9,
9
,9
,,,
,,
,
128 | Chapter VII  

suppress tumor cell proliferation significantly when added to AI (anastrozole) 19. As 
suggested by both Loi et al. and Schmid et al. and in line with our study design from  
chapter III onwards, the PIK3CA mutation alters genes that are related with tumor 
aggressiveness. This might explain why treatment with PI3K inhibitors improves the 
outcomes of BC patients regardless of the PIK3CA mutation status. We proposed that 
genes related to the PIK3CA mutation, like the above mentioned PI3K signature, can 
predict better than PIK3CA genotype treatment outcome after adding PI3K inhibitors 
to AI treatment.    
Finally, the PIK3CA genotype of primary breast tumors was not prognostic in our 
cohort, which is in line with the findings by others 18,20,21. For example, Kim et al. have 
shown that PIK3CA mutations did not affect OS in metastatic BC regardless of ER 
status 20. Moreover, unlike TP53 mutations, PIK3CA mutations do not affect its own 
gene expression level 9,20.  
Our observed association of the PIK3CA mutation with aromatase inhibitors, but not 
with tamoxifen might suggest a difference in the mechanism of action for these two 
types of drugs, which could teach us more about hormonal resistance. The 
mechanism of action for aromatase inhibitors prevents estrogen synthesis, 
consequently depriving the receptor from their natural ligand. Tamoxifen is a selective 
estrogen receptor modulator (SERM), which competes with the natural ligand for 
binding to the estrogen receptor. 
Aromatase inhibitors reduce considerably the presence of estrogens. However, AI 
does not interact with the ER and does not induce conformational changes. Therefore, 
it is not expected that AI alters ER functionality. That is why the majority of aromatase 
inhibitors resistant tumors still express functional ER as it has been described 
by Patani, et al. 22.  
7DPR[LIHQELQGVWR(5ĮDQGSHUPLWVUHFHSWRUGLPHUL]DWion, but induce conformational 
changes which differ to those induced by estrogens. Therefore, more ER functional 
changes are expected to be altered after tamoxifen use 23,24.  
To evaluate PIK3CA genotype for its prognostic and predictive value properly, we 
should have analyzed  patient samples with and without treatment in the same clearly 
defined clinical setting using randomized clinical trials (RCT) as explained by Beelen 
et al.8. However, due to the retrospective nature of collected data from our cohort of 
patients, we were not able to analyze both prognostic and predictive value in the 
similar sets of patients for both disease and treatment outcome (in the adjuvant 
setting). Ideally, we could have done randomized clinical trials (RCT) to ensure that 
the potential predictive value of PIK3CA genotype was correct. Nevertheless, it is 
currently not standard of care to have RCT including placebo groups without adjuvant 
systemic treatment 8. 
In conclusion, there is an urgent need to verify the relationship for PIK3CA genotype 
with disease and treatment outcome in prospective more clearly defined clinical trials 
to determine its potential as prognostic and predictive biomarker established in above 
mentioned retrospective studies25. One such randomized phase III trial comparing AI 
versus tamoxifen followed by AI, however, was inconclusive with regard to PIK3CA 
mutations and treatment outcome (Sabine, Crozier et al., JCO 2014).  
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Genes, microRNAs and proteins related to PIK3CA mutations and endocrine 
treatment outcome  
 
In the era of personalized medicine, not only the mutation of PIK3CA is of importance 
but even more downstream affected targets and pathways. This will further aid in the 
discovery of predictive biomarkers and of novel targets for therapy. To find potential 
biomarkers for sensitivity to AI in MBC patients based on their relationship with 
PIK3CA genotype, we have studied mRNA (gene) and microRNA expression profiles 
in chapter III. The goal was to identify mRNAs and microRNAs related to AI treatment 
and to PIK3CA genotype. In contrast to the standard procedures, i.e. mostly using 
one discovery and one validation cohort of patients, and aiming at a lower false rates 
we have used in this chapter two discovery cohorts. We reasoned that biomarkers 
identified in two independent cohorts, are certainly more informative at the moment of 
validation in a third independent cohort.  
In each discovery set, expression of several mRNAs and miRs were related with the 
PIK3CA genotype,  including LRG1, PLCL1, FAM81B, CCNO, NEK10, PGR, 
SERPINA3, SORBS2, VTCN1, hsa-miR-449a, hsa-miR-301a-3p, and hsa-miR-205-
5p as overlapping biomarkers. Of these common genes and miRs, only LRG1 
expression was shown to be related with AI treatment outcome, and 
independent from luminal subtype. Others have demonstrated that LRG1 plays a 
role in protein-protein interaction, signal transduction, and cell adhesion and 
development 26. Moreover, LRG1 is expressed during granulocyte differentiation 26. 
Interestingly for liquid biopsies, LRG1 mRNA is detectable in whole blood using qPCR, 
whereas LRG1 protein can be measured in plasma by ELISA 27 or by an 
electrochemical sensor at lower costs. This mLRG1-sensor has been designed for 
diagnosing adenoma-carcinoma transition in colon cancer 28. Further studies are 
needed to explore and apply such a sensor for LRG1 in plasma of ER positive breast 
cancer patients and verify our observed relation with aromatase inhibitors response. 
Our findings in chapter III demonstrated high LRG1 expression levels in primary 
breast cancer with PIK3CA mutations and response on AI treatment.  
Importantly to mention is the fact that we always want to show associations with 
PIK3CA genotype after correction for well-known confounders such as molecular 
subtype. In that way, biomarkers related to the PIK3CA mutation status, have a higher 
likelihood to be related to genotype and not just have been identified by chance or 
due to confounders. 
Based on gene expression related in silico data, we aimed in chapter IV to identify 
cancer related proteins of signalling pathways (including the ones of the 
PI3K/AKT/mTOR pathway). These proteins were investigated for altered expression 
or phosphorylation in luminal breast cancer with PIK3CA mutations. We here showed 
that an enhanced MAPK1/3 phosphorylation is related to PIK3CA mutated 
luminal breast cancer in an exon specific manner. The enhancement was also 
associated with favorable metastasis-free survival especially when located in the 
nuclei of tumor cells. Others reported previously contrasting findings on the 
relationship between MAPK1/3 phosporylation and endocrine treatment outcome.  
Some studies showed no significant findings for adjuvant tamoxifen 29,30 whereas 
others demonstrated increased MAPK1/3 phosphorylation with better outcome in 
especially tamoxifen-treated cases 31,32 or resistance to neo-adjuvant AI 33. Using the 
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in❏silico RPPA data we showed an enhanced MAPK1/3 phosphorylation in luminal 
P I K 3C A mutated tumors. In our own clinical data we were not able to confirm this 
relationship, probably due to a small sample size, since for only 95 out of 721 FFPE 
samples sufficient DNA could be retrieved. The enhanced MAPK1/3 phoshorylation 
in luminal P I K 3C A mutated tumors, however, was also seen by Beelen when 
analysing TMAs of 563 ER-positive breast tumors for MAPK1/3 phosphorylation and 
PIK3CA exon 9 and exon 20 mutation status 12. Moreover Wang et al. have shown 
already an incremented MAPK1/3 phosphorylation after the knock-in of P I K 3C A 
mutations human breast epithelial cells 34. Nevertheless, this cell line model might not 
explain completely our found association since breast epithelial cells are not breast 
cancer cells. New technologies such as for example Crisper/Cas strategies might 
enable functional studies including the knock-in of P I K 3C A exon-specific mutations in 
different luminal P I K 3C A wild-type cell lines. The insertion of the mutation will confirm 
whether MAPK1/3 phosphorylation will increase after introducing specific P I K 3C A 
genetic alterations in already luminal breast cancer cell lines.  
Endocrine therapy resistance and breast cancer phenotype  
 
The next aim was to contextualize ER-positive inflammatory breast cancer with 
P I K 3C A mutation. With the era of immunotherapy it is of importance not only to look 
at the tumor itself but also at the tumor micro-environment. As envisioned every time 
we make new subgroups, we are trying to find new features, which can give us insights 
on treatment resistance. Previously, we found that the P I K 3C A mutation was related 
to AI-first line sensitivity. Later, we used these insight to go beyond and to find 
biomarkers based on this initial observation. Our collaborators Van Laere et al. from 
the translational Cancer Research Unit, GZA Hospitals St-Augustinus, in Antwerp, 
Belgium observed in their cohort of inflammatory breast cancer (IBC), an aggressive 
tumor phenotype, that a subgroup of patients (ER+ IBC) exhibited resistance to 
endocrine therapy compared to ER+ non-IBC patients. Based on this, we used in 
chapter V, this cancer phenotype with worse outcome as alternative approach to 
identify biomarkers for endocrine therapy resistance.  
As for non-IBC, P I K 3C A mutations have been also described in 28% of IBC cases 35. 
Moreover, P I K 3C A mutations have also been identified (13%) in single circulating 
tumor cells isolated from blood of IBC patients 36. The P I K 3C A mutation frequencies 
for IBC and for non-IBC, however, were not significant different 37. 
In chapter V RXU DQDO\VHV UHYHDOHG WKDW WKH ³(5 ,%&-OLNH´ metagene ( A B A T , 
ADAMDEC1, CLEC7A, ETS1, ITK and STC2), as well as its classifier genes ABAT, 
and STC2 are associated with endocrine treatment resistance but not with 
prognosis.  
In line with our findings, down-regulation of STC2 has been identified by Parris et al. 
as critical gene for breast cancer initiation and progression 38. Moreover, STC2 gene 
expression has been associated with shorter disease-free survival 39. Interestingly, we 
find another piece of the puzzle, to better understand endocrine response in chapter 
III, we observed that primary tumors of ER-positive MBC patients treated with first-
line AI have a longer PFS and increased PLCL1. Thus, PLCL1 gene expression 
was proposed as biomarker of AI-first line sensitivity. PLCL1 encodes for 
phospholipase Clike1 (PRIP), a protein that regulates the phosphorylation and 
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activation of the gamma-aminobutyric acid (GABA) receptor 40, 41. Therefore, 
increased PLCL1 levels might result in reduced GABA receptor activity. On the 
other hand, in chapter V, low ABAT gene expression was associated with shorter 
PFS after anti-hormonal therapy (tamoxifen and first-line AI) in ER-positive IBC 
patients when compared to ER-positive non-IBC patients. ABAT encodes for the 4-
aminobutyrate aminotransferase (ABAT) responsible for catabolism of GABA. 
Therefore, low ABAT gene expression levels might result in enhanced GABA 
receptor downstream activity since more GABA is available to interact with the 
GABA receptor. 
In chapter V, we showed that expression of ABAT protein was not informative with 
regard to treatment outcome. However, Budczies et al., have shown that Low ABAT 
mRNA expression was associated with low ABAT protein expression. Most 
importantly, they also observed an association between low ABAT expression and 
recurrence-free survival in ER+ and ER- breast cancer patients 42. 
This brings me to hypothesise that resistant tumor cells proliferate not only via 
estradiol and estrogen receptors but might also use GABA and GABA receptors 
for this purpose. Moreover, estradiol and GABA might cooperate in this proliferation 
process since it has been shown by Maggi et al., that estrogens may increase the 
number of GABA binding sites by direct interaction with the GABA receptor gene or 
genes involved in the metabolism of GABA receptor 43. It has also been shown that 
GABA as estradiol regulates most of the same neural functions 44. Therefore, GABA 
receptor and estrogen receptor (the corresponding receptors for GABA and estradiol) 
might have a huge similarity. Future studies are needed to verify all this and to test 
above mentioned hypothesis for its validity.  
Liquid biopsy biomarkers for endocrine therapy resistance  
 
Nowadays, circulating biomarkers including circulating tumor cells (CTCs) and cell-
free DNA are being widely studied since they can be isolated from several body fluids 
LQFOXGLQJEORRGEHFRPLQJDXVHIXODOWHUQDWLYH WRJHWD ³OLTXLGELRSV\´ LQDQDOPRVW
non-invasive manner. In breast cancer, these promising tools can be potentially used 
in diagnosis, prognosis, prediction and monitoring of treatment response. Moreover, 
the study of these biomarkers will lead researchers to a better understanding of the 
complexity and dissemination of breast cancer biology as well as treatment resistance 
45,46
. 
Previously in Chapter II, we observed no association between ❑IK3CA mutations and 
first-line tamoxifen treatment outcome, most likely due to differences between primary 
tumor and metastases as it has already been shown by Dupont Jensen et al. 47. 
Therefore, next we aimed to identify PIK3CA mutations as well as additional tumor-
specific mutations in serum cell-free DNA potentially related to first-line tamoxifen 
outcome in metastatic breast cancer patients (Chapter VI). 
Tumor-specific mutations including PIK3CA mutations were detected in minute 
amounts of serum cell-free DNA (Chapter VI). Cell-free DNA was extracted using 
serum samples collected during therapy and stored for over 18 years. To discover 
specific mutations in cfDNA, we demonstrated that targeted ion-PGM sequencing can 
be used as shown in chapter VI and by Weerts et al. 48. However, more sensitive 
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detection methods such digital PCR are required for mutation detection in blood then 
in tissue biopsies, since in blood only trace amounts of mutated circulating tumor DNA 
are often present.  
For further liquid biopsy discovery studies more sensitive methods next to digital PCR 
are needed, including OnTarget assays to enrich for mutant alleles or deep 
sequencing with unique molecule identifiers used for instance in Oncomine cfDNA 
assays. These assays enable the simultaneous evaluation of many mutations, 
whereas digital PCR can analyse in general only one mutation 49,50. Again the optimal 
standardization of pre-analytical conditions, i.e. collection of blood samples, is key 50. 
Methods must be selected based on its highest detection sensitivity and low cost, 
which facilitates a real time monitoring on disease progression.   
We confirmed with additional techniques (re-sequencing and digital PCR) only the 
missense identified mutations because of their putative biological relevance. As yet, 
not studied in detail, the synonymous mutations might also have biological relevance, 
as it has been reviewed by Gotea V. et al. They presented evidence supporting the 
direct impact of synonymous mutations on gene function via gene splicing; mRNA 
stability, folding, and translation; protein folding; and miRNA-based regulation of 
expression. Their results highlight the functional contribution of synonymous 
mutations to oncogenesis and the need to further investigate their detection and 
validation 51. 
In chapter II, we showed the association between PIK3CA mutations and first-line AI 
treatment outcome in metastatic breast cancer patients. However, for the 
retrospective exploratory study in chapter VI, blood samples from patients treated with 
first-line AI were scarce and unfortunately not available for the study.  
Liquid biopsy ± Future of Circulating blood biomarkers  
CTCs and cell-free DNA as circulating blood biomarkers can complementary provide 
real-time information. Given the heterogeneity of breast cancer cells, this changes 
over time and is affected by treatment pressure. Moreover, since metastatic sites are 
often of restrictive access, liquid biopsies might potentially become surrogates for 
tissue-based already existing biomarkers. In addition, these are suitable to closely 
follow the patients over time, which will impact the management of patients and will 
lead to a more accurate personalized therapy 52. 
Moreover, new emerging breast cancer clones can be monitored in real-time for 
molecular characterization, which will allow a more accurate follow up of the evolution 
of the tumor and therefore offer the patient an individualized treatment 53. Breast 
cancer is well characterized by accumulation of several mutations. Hence, 
identification of gain or loss of mutations in metastatic tumors not previously identified 
in the primary tumors is not surprising. A clear example of this has recently been 
shown by Segal et al., who compiled recent studies comparing the frequency of ESR1 
mutations in metastatic and primary ER-positive breast tumors and concluded that 
ESR1 mutations hardly identified in the primary tumors can go up to 37% in metastatic 
specimens, especially in luminal A and PIK3CA-mutated tumors 54.  Thus current anti-
estrogen treatments remain partially effective for these tumors harbouring ESR1 
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mutations. Nevertheless, alternative therapies capable to target the remaining 
resistant clones will be required 55.   
Other type of mutations (including PIK3CA, TP53, ARID1A, PTEN, AKT1, NF1, 
FBXW7 and FGFR3) have been also shown to be discordant between primary and 
recurrent breast tumors as well as, copy number alterations ( as in MCL1, CCND1, 
FGFR1, MYC, IGF1R, MDM2, MDM4, AKT3, CDK4, AKT2) 56. This evidences the 
need of developing profiles capable to identify new features of metastatic clones and 
therefore better predict treatment response. For example a CTC 8-gene signature in 
MBCP to distinguish between poor and good outcome after first-line AI treatment was 
recently developed and further validated in an independent set 57.  
Certainly, isolation of CTCs compared to cell-free DNA is more expensive and 
challenging since CTCs are less frequent present in blood 58. However, unlike plasma 
cell-free DNA, CTCs can offer wider information not only DNA-related but also at other 
kind of levels, including proteomics, metabolomics, epigenetics. Additionally, ex-vivo 
culture of CTCs is a better strategy to identify the right treatment for the right breast 
cancer patient over the course of the disease. CTCs in the blood can be captured in 
viable form and used to improve drug screening 59. This especially of importance for 
metastatic disease where the characteristics of the primary tumor will differ from the 
metastasis and will aid in discovery and discrimination between driver and passenger 
gene mutations/alterations. Future studies will reveal the most cost-effective way to 
better use these (novel) tools in the clinical practice. 
General recommendations and future perspectives 
Retrospective studies have the limitation of lack of optimal control groups. Thereby, 
to better raise firm conclusions, results obtained from these kind of studies must be 
confirmed in prospective clinical trials including appropriate randomized controls. An 
accurate study design must be considered based on the current wide knowledge on 
tumor cell heterogeneity. Patient inclusion criteria should contemplate most 
comparable group of patients. Since the PIK3CA mutation is already known to have 
a different effect based on subtype, the groups´ comparisons should be based on 
subtypes in relation to the outcome of the study, for example, in relation to anti-
hormonal therapy response.  
If we consider that cells are individual entities even though they keep inter-
communication with neighbour cells, different tumor clones are present in a tumor 
tissue. Hence, not only the percentage of tumor cells present in the primary tumor 
sample but its insight into the temporal and spatial heterogeneity may lead us to 
adequate conclusions.  
In the future, technology advances, including the promising circulating biomarkers 
such as (profiling of) circulating tumor cells (CTCs) and cell-free (mutant) DNA 
obtained from liquid biopsies, currently under study in many labs, will lead us to have 
a closer follow up of the patients considering different possible present clones in the 
patient. Moreover, timing and frequency of analysis to better prognosticate and predict 
the outcome of treatment will be also determined more accurately by the study of this 
biomarkers.  
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The pathways interaction complexity will be better understood by selecting 
xenographs and culture of circulating tumor cells, and based on all the variables 
already known that should be controlled at the moment of study treatment response 
such as genetic, metabolomic, and proteomic alterations present in the cell, above 
and beyond the tumor environment, which already has been shown to play a key role 
in tumor development and its evolution. Moreover, if we consider that pathway 
analysis has been usually done based on primary tumor samples in which the tumor 
percentage might drastically differ from one sample to another, the use of circulating 
biomarkers based on a cell individual approach will help overcoming clonally related 
issues.  
The future scenario for patients´ follow up and treatment will therefore consider a 
multidisciplinary approach, namely, not only important known features such as 
subtypes will be taken into account but also new technologies that will let us have 
access to real time information carried in circulating biomarkers. This will boost the 
knowledge about the tumor evolution making it easier to find biomarkers capable to 
pick the right patient for the right treatment. Later on, in the era of 
personalized/precision medicine, once the biomarkers have been validated, the goal 
will be to pick the right treatment for the right breast cancer patient.    
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SUMMARY 

Breast cancer, which is the most common type of cancer in women and second most 
common cancer worldwide, is a heterogeneous disease. Guidelines to treat this 
disease are based on prognostic and predictive clinicopathological factors and tumor 
biomarkers, such as estrogen receptor (ER), progesterone receptor (PR) and HER2 
receptor. Most breast cancers are ER-positive (75-80%), for which three types of anti-
hormonal therapies are used: selective estrogen receptor modulators (SERMs), -
degraders (SERDs) and aromatase inhibitors (AI). Tamoxifen, a SERM, has been a 
key treatment for (premenopausal) women for 40 years now. Aromatase inhibitors 
(AI), used for over 20 years, prevent estrogen synthesis. AI have been mostly 
effectively used in postmenopausal women. Finally, SERDs like Fulvestrant are 
nowadays more often used as therapy for patients with acquired resistance to AI 
treatment due to gained mutations in the ligand binding domain of ER.   
Important for the aims of this thesis is the fact that the objective response rate to anti-
hormonal therapy for ER-positive metastatic breast cancer (MBC) is only 20-40% with 
a median duration of approximately 8-14 months. This shows a clear and urgent need 
for biomarkers which are able to identify patients who will or will not benefit from the 
therapy. As such, for those patients, unnecessary exposure to undesirable adverse 
events of (anti-hormonal) therapy can be avoided. 
The aim of this thesis was to find potential biomarkers which are able to predict anti-
hormonal treatment responsiveness and/or resistance in mainly advanced ER-
positive breast cancer patients. To reach this goal different research approaches were 
followed. Since mutations in PIK3CA are the most prevalent mutations in luminal 
tumors and occur in maximum 45% (see introduction) of the ER-positive breast 
cancers, the thesis was mainly focused on the relationship between PIK3CA genotype 
and PI3K pathway with treatment outcome.   
First, in chapter II, we studied the effect of the PIK3CA mutation in relation to 
progression-free survival (PFS) in primary tumors of 531 MBC patients after first-line 
AI or tamoxifen treatment. We found that patients with a PIK3CA mutation have 
significantly longer PFS after first-line AI therapy when compared to wild-type tumors. 
Therefore, we proposed the PIK3CA mutation as a potential predictive biomarker for 
first-line AI sensitivity. Moreover, no association with treatment outcome was found 
after first-line tamoxifen therapy. Thus, the PIK3CA mutation has no predictive 
value for first-line tamoxifen sensitivity nor resistance. We also studied the 
mutation in relation to metastasis-free survival (MFS) in 342 LNN (neo)adjuvant 
systemic therapy naïve patients and demonstrated that the PIK3CA mutation has no 
value as a prognostic biomarker.  
In chapter III, we investigated mRNAs and miRs expression profiles as potential 
predictive biomarkers correlated with PIK3CA genotype and AI therapy outcome. 
First, expression of mRNAs and miRs from primary breast tumors was investigated 
for the relation with PIK3CA genotype in two independent discovery sets. One set 
included 286 luminal samples from in silico data of the TCGA consortium. The second 
dataset included 84 ER-positive samples of MBC patients treated with first-line AI. 
Expression of 9 mRNAs (CCNO, FAM81B, LRG1, NEK10, PLCL1, PGR, SERPINA3, 
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▲ORB▲2 , VTCN1) and 3 miRs (miR-449a, miR-205-5p, miR-301a-3p) was related to 
the PIK3CA mutation status in both sets. Further analyses revealed that LRG1 and 
PLCL1 expression related to longer PFS after first-line AI therapy, independent 
of luminal subtype and traditional predictive factors. Next, these 9 mRNAs and 3 miRs 
were evaluated in a publicly available in silico dataset of 25 breast cancer patients 
who received neo-adjuvant AI. Expression levels of 3 genes (LRG1, PGR, 
SERPINA3) were shown to decrease significantly after neo-adjuvant AI treatment in 
patients with clinical response. Based on all these findings, we proposed LRG1 as 
potential luminal subtype independent biomarker related to the PIK3CA 
genotype and AI therapy outcome.  
We next, in chapter IV, aimed to identify cancer related proteins of signalling 
pathways with altered expression or phosphorylation in luminal breast cancer 
harbouring PIK3CA mutations. For that purpose, in silico data from 361 primary 
tumors of breast cancer patients of the TCGA consortium were used. Here we showed 
that enhanced phosphorylation of MAPK1/3, p38 and YAP and decreased expression 
of p70S6K and 4E-BP1 in luminal breast cancer related to PIK3CA mutations. 
Phosphorylated MAPK1/3, as most significant upregulated protein for PIK3CA exon 
specific mutations, was further explored in tissue microarrays containing 721 primary 
breast cancer specimens including a subset of 290 luminal tumors from systemic 
untreated LNN patients, to evaluate its relationship with metastasis free survival.  We 
showed that especially nuclear MAPK1/3 phosphorylation has a potential value as a 
prognostic biomarker. Our findings indicate that phosphorylation of MAPK1/3 and 
its subcellular localization associate with a favourable disease outcome.  
Until this chapter, PIK3CA mutation had been our starting point to find biomarkers with 
potential prognostic or predictive value after anti-hormonal treatment. In the epoch of 
immune therapy, in chapter V, we evaluated a subgroup of patients with inflammatory 
breast cancer (ER-positive IBC) who are more often resistant to anti-hormonal therapy 
compared to ER-positive non-IBC patients. PIK3CA mutations are also present in IBC, 
however, no significant differences in prevalence have been observed between IBC 
and non-IBC. Based on this and since anti-hormonal therapy resistance might depend 
also on cancer phenotype we now compared IBC with non-IBC samples. We 
identified a metagene of six genes (ABAT, ADAMDEC1, CLEC7A, ETS1, ITK and 
STC2) that distinguished IBC from non-IBC. This metagene and its individual 
genes were further evaluated in 6 independent in silico datasets and validated by qRT-
PCR in a cohort of MBC patients receiving first-line tamoxifen. It was shown that the 
metagene, ABAT and STC2 were not prognostic, that decreased expression of 
ABAT and STC2 was associated with poor anti-hormonal therapy outcome in 
MBC and that only ABAT expression was related to outcome in patients receiving 
adjuvant tamoxifen.  
Finally in chapter VI, in the current era of liquid biopsies and personalized/precision 
medicine, we aimed at the characterization of tumor-specific mutations in cell-free 
DNA (cfDNA) from sequential sera taken from MBC patients while on tamoxifen 
treatment. As a proof of principle, we demonstrated that mutations can be detected in 
minute amounts of serum cell-free DNA by next generation sequencing (NGS) using 
a targeted ion-PGM gene panel. Moreover, cfDNA can be analyzed in blood samples 
stored for almost two decades. In this exploratory study, we identified mutations in 
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PIK 3 C A , TP53, AKAP9, CREBBP and S M AD4 which, (except AKAP9) were 
present in both primary tumor as well as in serum cfDNA taken at disease 
progression. In most cases, however, these mutations were not detected in sera 
preceding progression, not even using deeper re-sequencing. Interestingly, one case 
had a PIK3CA mutation which was traced back in cfDNA of serum taken two years 
before diagnosis of metastatic lesions. It was detected in only a few reads by NGS, 
but confirmed by digital PCR.        
In conclusion, in this thesis we showed that PIK3CA mutations detected in primary 
breast tumors have a predictive value for AI response in the advanced disease setting, 
but not for tamoxifen nor for prognosis. Related to this PIK3CA genotype we 
demonstrated in primary breast tumors that expression of LRG1 can be used as 
potential biomarker for AI therapy outcome, which upon neo-adjuvant AI treatment 
showed decreased levels in patients with clinical response. At the proteomic level, 
MAPK1/3 phosphorylation levels in luminal breast cancer was shown to be related 
with PIK3CA exon specific mutations. This MAPK1/3 phosphorylation, especially 
when localized in the nuclei, has also prognostic value in breast cancer. Next, using 
an alternative approach to discover biomarkers for endocrine therapy resistance, we 
constructed a metagene to identify ER-positive breast cancers with an IBC phenotype. 
This metagene and its individual genes ABAT and STC2  were shown to be predictive 
for tamoxifen and AI therapy resistance in the advanced disease setting. In the 
adjuvant setting only ABAT was related to tamoxifen resistance. Finally, we explored 
the potential of tumor-specific mutations in serum cfDNA as biomarkers for tamoxifen 
resistance in MBC patients. Mutations in PIK3CA, TP53, AKAP9, CREBBP and 
SMAD4 were shown in serum cfDNA taken at disease progression and all mutations 
except for AKAP9 also in the primary tumor. 
All above potential biomarkers described in this thesis hopefully will improve the 
identification of patients who will or will not benefit from anti-hormonal therapy. For 
these patients, undesirable adverse effects due to unnecessary exposure to therapy 
might be avoided. Thus, today with these biomarkers we are able to better pick the 
right patient for the right endocrine treatment. Promisingly in the near future, when 
the biomarkers are more extensively validated by others, we will finally be able to pick 
the right treatment for the right breast cancer patient. 
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SAMENVATTING 
 
Borstkanker, de meest voorkomende vorm van kanker bij vrouwen en de tweede 
meest voorkomende kanker wereldwijd, is een heterogene ziekte. Richtlijnen voor de 
behandeling van deze ziekte zijn gebaseerd op klinische pathologische factoren en 
tumorbiomarkers zoals oestrogeen receptor (ER), progesteron receptor (PR) en 
HER2 receptor. De meeste borstkankers zijn ER-positief (75-80%), waarvoor drie 
soorten anti-hormonale therapieën bekend zijn: selectieve oestrogeenreceptor 
modulatoren (SERM's) en -degraders (SERD's) en aromatase-remmers (AI). 
Tamoxifen, een SERM, is al 40 jaar een belangrijk medicijn voor de behandeling van 
(premenopauzale) vrouwen. Aromatase remmers (AI), nu al meer dan 20 jaar in 
gebruik, voorkomen oestrogeen synthese. AI worden voornamelijk effectief gebruikt 
bij postmenopauzale vrouwen. Tenslotte worden SERD's, zoals Fulvestrant, vaker 
gebruikt als therapie voor patiënten met verworven resistentie tegen AI-behandeling 
als gevolg van mutaties in het ligand bindende domein van de ER. 
 
Belangrijk voor de doelstellingen van dit proefschrift is het feit dat de objectieve 
response voor anti-hormonale therapie bij ER-positieve uitgezaaide borstkanker 
(MBC) slechts 20-40% bedraagt, met een mediane duur van ongeveer 8-14 maanden. 
Dit laat een duidelijke en dringende behoefte aan biomarkers zien die in staat zijn om 
die patiënten te identificeren die wel of niet op de therapie zullen reageren. Als 
zodanig kan voor deze patiënten onnodige blootstelling aan ongewenste bijwerkingen 
van (anti-hormonale) therapie worden voorkomen. 
 
Het doel van dit proefschrift was het vinden van potentiële biomarkers die in staat zijn 
het effect van anti-hormonale therapie, responsiviteit dan wel resistentie, in 
voornamelijk uitgezaaide ER-positieve borstkankerpatiënten te voorspellen. Om in 
ons onderzoek dit doel te bereiken, werden verschillende  benaderingen gevolgd. 
Aangezien mutaties in PIK3CA de meest voorkomende mutatie in deze luminale 
tumoren zijn, in maximaal 45% van de ER-positieve borstkanker, was het proefschrift 
vooral gericht op de relatie tussen PIK3CA genotype en PI3K signaalpaden en de 
behandelingsuitkomst. 
 
In het eerste hoofdstuk II, bestudeerden we het effect van PIK3CA mutaties in relatie 
tot progressie-vrije overleving (PFS) in primaire tumoren van 531 MBC patiënten na 
eerste lijn AI- of tamoxifen behandeling. We hebben vastgesteld dat patiënten met 
een PIK3CA mutatie een significant langere PFS hebben na de eerste lijns AI therapie 
in vergelijking met wild-type tumoren. Daarom hebben we de PIK3CA mutatie 
aangedragen als een potentiële predictieve biomarker voor de eerste lijn AI 
gevoeligheid. Bovendien werd geen associatie met de behandelingsuitkomst 
gevonden na eerste lijns tamoxifen therapie. Dus heeft de PIK3CA mutatie geen 
voorspellende waarde voor de eerste lijns tamoxifen gevoeligheid of 
resistentie. We hebben ook de mutatie bestudeerd in relatie tot metastase-vrij 
overleving (MFS) bij 342 LNN (neo) adjuvante systemische therapie naïeve patiënten 
en aangetoond dat de PIK3CA mutatie geen waarde heeft als prognostische 
biomarker. 
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In hoofdstuk III onderzochten we mRNAs en miRs expressieprofielen, die 
gecorreleerd waren met PIK3CA genotype en AI therapie uitkomst, als potentiële 
predictieve biomarkers. Ten eerste werd de expressie van mRNA's en miR's in 
primaire borsttumoren onderzocht voor de relatie met PIK3CA-genotype in twee 
onafhankelijke data sets. Een set omvatte 286 luminale borstkanker weefsels uit de 
in silico data set van het TCGA consortium. De tweede dataset omvatte 84 ER-
positieve weefsels van MBC patiënten die waren behandeld met eerste lijn AI. 
Expressie van 9 mRNA's (CCNO, FAM81B, LRG1, NEK10, PLCL1, PGR, SERPINA3, 
SORBS2, VTCN1) en 3 miRs (miR-449a, miR-205-5p, miR-301a-3p) toonden een 
verband met de PIK3CA mutatie status in beide data sets. Uit verdere analyses bleek 
ook dat LRG1 en PLCL1 expressie gerelateerd was met een langer PFS na eerste 
lijn AI therapie, en dit was onafhankelijk van het luminale subtype en de traditionele 
predictieve factoren. Vervolgens werden deze 9 mRNAs en 3 miRs geëvalueerd in 
een publiek beschikbare in silico data set van 25 borstkankerpatiënten die neo-
adjuvante AI hadden kregen. Expressie niveaus van 3 genen (LRG1, PGR, 
SERPINA3) bleken significant af te nemen na neo-adjuvante AI behandeling bij 
patiënten met klinische respons. Op basis van al deze bevindingen hebben we LRG1 
voorgesteld als potentiële luminale subtype onafhankelijke biomarker die 
verband houdt met het PIK3CA genotype en AI therapie uitkomst.  
 
Vervolgens hebben we in hoofdstuk IV geprobeerd om kanker gerelateerde eiwitten 
met gewijzigde expressie dan wel fosforylering of signaal routes te identificeren bij 
luminale borstkankers die PIK3CA mutaties bevatten. Daartoe werden in silico data, 
van het TCGA consortium, gebruikt van 361 primaire tumoren van patiënten met 
borstkanker. Hieruit bleek dat verhoogde fosforylering van MAPK1/3, p38 en YAP en 
verlaagde expressie van p70S6K en 4E-BP1 bij luminale borstkanker in verband kon 
worden gebracht met PIK3CA mutaties. Het gefosforyleerde MAPK1/3, het meest 
significant verhoogde eiwit voor PIK3CA exon specifieke mutaties, werd verder 
bestudeerd in weefselmicroarrays van 721 primaire borstkanker weefsels. In een 
subset van 290 luminale tumoren met systemisch onbehandelde LNN patiënten is de 
relatie met metastase vrij overleving geevalueerd. We laten zien dat vooral nucleaire 
localisatie van MAPK1/3 fosforylering een potentiële waarde heeft als een 
prognostische biomarker. Onze bevindingen wijzen erop dat fosforylering van 
MAPK1/3 en de subcellulaire lokalisatie ervan associeert met een gunstige 
ziekte-uitkomst. 
 
Tot aan dit hoofdstuk was PIK3CA mutatie ons uitgangspunt om biomarkers te vinden 
met potentiële prognostische of voorspelling op anti-hormonale behandeling. In het 
tijdperk van immuuntherapie, hebben we in hoofdstuk V een subgroep patiënten met 
inflammatoire borstkanker geevalueerd (ER-positieve IBC) die juist vaker resistent 
zijn tegen anti-hormonale therapie in vergelijking met ER-positieve niet-IBC-patiënten. 
Ook hier zijn PIK3CA mutaties aanwezig in IBC, en er zijn geen significante 
verschillen in prevalentie waargenomen tussen IBC en niet-IBC. Gebaseerd op dit en 
daar anti-hormonale therapie ook afhankelijk kan zijn van kankerfenotype, hebben we 
deze IBC met niet-IBC-weefsels vergeleken. We hebben een metagen van zes 
genen (ABAT, ADAMDEC1, CLEC7A, ETS1, ITK en STC 2) geïdentificeerd die IBC 
kan onderscheiden van niet-IBC. Dit metagen en de individuele genen werden 
verder bestudeerd in 6 onafhankelijke in silico datasets en gevalideerd met behulp 
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van qRT-PCR in een cohort van MBC patiënten die eerste lijns tamoxifen kregen. Er 
werd aangetoond dat het metagen, en de afzonderlijke genen ABAT en STC2 niet 
prognostisch waren. De verlaagde expressie van ABAT en STC2 was 
geassocieerd met een slechte anti-hormonale therapie-uitkomst in MBC en dat 
alleen ABAT-expressie was gerelateerd aan de uitkomst bij patiënten die adjuvante 
tamoxifen kregen. 
 
In het huidige tijdperk van ▼◆quid b io p sies en persoonsgerichte/precisie geneeskunde, 
richtten wij ons in hoofdstuk VI op de karakterisatie van tumor-specifieke mutaties in 
celvrij DNA (cfDNA) die uit sequentiële sera die van MBC-patiënten werden verkregen 
tijdens de behandeling met tamoxifen. We hebben aangetoond dat mutaties kunnen 
worden gedetecteerd in kleine hoeveelheden serum waaruit het celvrij DNA werd 
geisoleerd. Dit werd middels next generation sequencing (NGS) met behulp van een 
gerichte ion-PGM genpaneel geanalyseerd. Bovendien is cfDNA stabiel en kan 
worden geanalyseerd in bloedmonsters die bijna twee decennia zijn opgeslagen. In 
deze verkennende studie hebben we mutaties geïdentificeerd in PIK3CA, TP53, 
AKAP9, CREBBP en SMAD4, die (behalve AKAP9) aanwezig waren in zowel de 
primaire tumor als in het serum cfDNA verkregen bij ziekteprogressie. In de 
meeste gevallen werden deze mutaties echter niet gedetecteerd in de sera 
voorafgaand aan progressie van de ziekte, ook niet na meer gevoeligere re-sequentie 
bepalingen. Interessant was dat één casus een PIK3CA-mutatie had, die werd 
teruggevonden in cfDNA van serum dat twee jaar voor de diagnose uitzaaiing werd 
genomen. Het werd in lage frequentie gedetecteerd door NGS, maar bevestigd door 
digitale PCR. 
 
Concluderend, in dit proefschrift laat ik zien dat PIK3CA mutaties gedetecteerd in 
primaire borsttumoren wel een voorspellende waarde hebben voor AI respons van 
uitgezaaide ziekte, maar niet voor tamoxifen behandeling noch voor prognose. 
Gerelateerd aan dit PIK3CA genotype hebben we in primaire borsttumoren 
aangetoond dat de expressie van LRG1 kan worden gebruikt als potentiële biomarker 
voor AI therapie uitkomst, en ook dat LGR1 verlaagd was bij neo-adjuvante AI 
behandelde patiënten met klinische respons. Op het proteoom niveau liet ik zien dat 
de MAPK1/3 fosforyleringsniveaus bij luminale borstkanker gerelateerd zijn met 
PIK3CA exon specifieke mutaties. Deze MAPK1/3 fosforylering, met name 
gelokaliseerd in de kernen, heeft ook een prognostische waarde in borstkanker. 
Daarnaast is met behulp van een alternatieve benadering om biomarkers te 
ontdekken voor resistentie tegen endocriene therapie, een metagen geconstrueerd 
om ER-positieve borstkanker te identificeren met een IBC-fenotype. Dit metagen en 
de individuele genen ABAT en STC2 bleken voorspellend te zijn voor de resistentie 
tegen tamoxifen en AI in de uitgezaaide ziekte. Bij de adjuvante behandeling was 
alleen ABAT gerelateerd aan tamoxifen resistentie. Tenslotte hebben we de waarde 
van tumor-specifieke mutaties in serum cfDNA verkend als mogelijke biomarkers voor 
tamoxifen resistentie bij uitgezaaide (MBC) patiënten. Mutaties in PIK3CA, TP53, 
AKAP9, CREBBP en SMAD4 werden in de primaire tumor getoond en in de meeste 
gevallen alleen in serum cfDNA afgenomen bij progressie van de ziekte. 
 
Alle bovenstaande potentiële biomarkers die in dit proefschrift worden beschreven, 
zullen hopelijk de selectie van patiënten verbeteren die al dan niet van anti-hormonale 
9,,
9,,,
9,
9
,9
,,,
,,
,
9,,
9,,,
9,
9
,9
,,,
,,
,
146 | Chapter VIII  

therapie profijt mogen hebben. Bij deze patiënten kunnen ongewenste bijwerkingen 
als gevolg van onnodige blootstelling aan therapie vermeden worden. Zo kunnen we 
met deze biomarkers beter de juiste patiënt kiezen voor de juiste endocriene 
behandeling. Hoopvol voor de nabije toekomst, wanneer deze biomarkers meer 
uitgebreid worden gevalideerd door anderen, zullen we uiteindelijk de juiste 
behandeling voor de juiste borstkankerpatiënt kunnen kiezen. 
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RESUMEN 

El cáncer de mama, una enfermedad heterogénea, es el tipo de cáncer más común 
en mujeres y el segundo más común en todo el mundo. Guías de tratamiento para 
esta enfermedad se basan en factores clínico-patológicos pronósticos y predictivos 
al igual que en biomarcadores tumorales tales como receptor de estrógenos (ER), 
receptor de progesterona (PR) y receptor HER2. La mayoría de los cánceres de 
mama son ER-positivo (75-80%). Para su tratamiento se usan tres tipos de terapia 
anti-hormonal: Moduladores selectivos del receptor de estrógenos (SERMs), 
degradadores selectivos del receptor de estrógenos (SERDs) e inhibidores de 
aromatasa (AI). El tamoxifeno, un SERM, ha sido por más de 40 años el tratamiento 
clave para mujeres pre-menopáusicas. Por otro lado, los AI que previenen la síntesis 
de estrógenos, han sido usados por algo más de 20 años y han sido principalmente 
efectivos para tratar a mujeres posmenopáusicas. Finalmente, los SERDs como el 
fulvestran, son usados hoy en día como terapia para pacientes con resistencia 
adquirida a los AI debido a mutaciones adquiridas en el dominio de unión al ER.     
Es importante para los objetivos de esta tesis, que las tasas de respuesta objetiva a 
la terapia anti-hormonal para pacientes de cáncer de mama metastásico es solo 20-
40%, con una duración media de aproximadamente 8-14 meses. Esto muestra una 
necesidad clara y urgente de encontrar biomarcadores capaces de identificar 
pacientes que se beneficiarán o no de la terapia; de este modo se podrá evitar la 
exposición innecesaria a efectos adversos no deseados en los pacientes en quienes 
la terapia anti-hormonal no surtirá efecto. 
El objetivo de la presente tesis fue encontrar biomarcadores con potencial, capaces 
de predecir respuesta y/o resistencia al tratamiento anti-hormonal, principalmente en 
pacientes de cáncer de mama ER avanzado. Para lograr este objetivo, se usaron 
diferentes estrategias, teniendo en cuenta que las mutaciones PIK3CA son las más 
prevalentes en tumores luminales y ocurren hasta en un 45% de los cánceres de 
mama ER positivo (ver introducción), el enfoque se centró básicamente en la relación 
entre el genotipo PIK3CA y la ruta PI3K con el resultado del tratamiento.   
Primero, en el capítulo II, se estudió el efecto de la mutación PIK3CA en relación con 
la supervivencia libre de progresión (PFS) en tumores primarios de 531 pacientes 
MBC luego de seguir la primera línea de tratamiento con AI o tamoxifeno. Se encontró 
que pacientes con la mutación PIK3CA comparados con los silvestres tienen una PFS 
significativamente más larga luego de seguir la terapia de primera línea con AI. Por 
lo que la mutación PIK3CA fue propuesta como biomarcador potencial de predicción 
para la primera línea de tratamiento con AI. Adicionalmente, no se encontró dicha 
asociación tras la primera línea de tratamiento con tamoxifeno. Por lo tanto, la 
mutación PIK3CA no tiene valor predictivo de respuesta ni resistencia para la 
primera línea de tratamiento con tamoxifeno. Dicha mutación también se estudió 
en relación con la supervivencia sin metástasis (MFS) en 342 pacientes con ganglio 
linfático negativo sin terapia sistémica neo-adyuvante y se demostró que la mutación 
PIK3CA no tiene valor como biomarcador pronóstico.  
En el capítulo III, se investigó el perfil de expresión de ARN mensajeros (mRNAs) y 
micro ARNs (miRs) como biomarcadores potenciales de predicción correlacionados 
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con el genotipo PIK3CA y con el resultado tras la terapia. En primer lugar, la expresión 
de mRNAs y miRs de tumores primarios de mama fue investigada en relación con el 
genotipo PIK3CA en dos grupos de descubrimiento independientes. Un grupo incluyó 
286 muestras luminales de datos in silico del consorcio TCGA, mientras que el 
segundo grupo de datos incluyó 84 muestras ER-positivas de pacientes MBC tratados 
con la primera línea de AI. La expresión de 9 mRNAs (CCNO, FAM81B, LRG1, 
NEK10, PLCL1, PGR, SERPINA3, SORBS2, VTCN1) y 3 miRs (miR-449a, miR-205-
5p, miR-301a-3p) se encontró relacionada con el estatus de la mutación PIK3CA en 
ambos grupos. Análisis posteriores revelaron que la expresión de LRG1 y PLCL1 
está relacionada con una PFS más larga tras la terapia de primera línea con AI, 
independientemente del subtipo luminal y de factores tradicionales de predicción. 
Posteriormente, estos 9 mRNAs y 3 miRs fueron evaluados en una base de datos in 
silico pública de 25 pacientes de cáncer de mama quienes recibieron AI neo-
adyuvante. Se observó que en pacientes con respuesta clínica, los niveles de 
expresión de 3 genes (LRG1, PGR, SERPINA3) mostraron disminuir 
significativamente después del tratamiento neo-adyuvante con AI. Con base en estos 
hallazgos, LRG1 fue propuesto como biomarcador potencial independiente del 
subtipo luminal relacionado con el genotipo PIK3CA y el resultado tras la 
terapia con AI.  
A continuación, en el capítulo IV, el objetivo fue identificar proteínas de vías de 
señalización asociadas con cáncer cuya expresión o fosforilación estuviese alterada 
en cáncer de mama luminal con mutaciones PIK3CA. Para ello, se utilizaron datos in 
silico de 361 tumores primarios de pacientes de cáncer de mama tomados del 
consorcio TCGA. Aquí se mostró que una fosforilación aumentada de MAPK1/3, p38 
y YAP y una expresión disminuida de p70S6K y 4E-BP1 en cáncer de mama luminal, 
se relaciona con la mutación PIK3CA. La proteína MAPK1/3 fosforilada, la cual fue 
encontrada sobre regulada en tumores con mutaciones PIK3CA exón específicas, 
fue estudiada con mayor detalle haciendo uso de microarreglos de tejidos de 721 
especímenes de cáncer de mama, incluyendo un subgrupo de 290 tumores tipo 
luminal de pacientes con ganglio linfático negativo no tratados sistémicamente, para 
evaluar su relación con la supervivencia sin metástasis. Se mostró que especialmente 
la fosforilación MAPK1/3 nuclear tiene un valor potencial como biomarcador 
pronóstico. Estos resultados indican que la fosforilación de MAPK1/3 y su 
localización subcelular están asociadas con un desenlace favorable de la 
enfermedad. 
Hasta este capítulo, la mutación PIK3CA había sido el punto de partida para encontrar 
biomarcadores con valor potencial pronóstico y predictivo luego del tratamiento anti-
hormonal. En la época de la inmunoterapia, en el capítulo V, se evaluó un subgrupo 
de pacientes con cáncer de mama inflamatorio (IBC ER-positivo), quienes son 
resistentes con mayor frecuencia a la terapia anti-hormonal comparados con los 
pacientes ER-positivo no-IBC. Las mutaciones PIK3CA están presentes también en 
IBC; sin embargo, no se han observado diferencias significativas entre IBC y no-IBC. 
Con base en esto y teniendo en cuenta que la resistencia a la terapia anti-hormonal 
dependerá también del fenotipo del cáncer, se compararon especímenes de IBC con 
no-IBC. Se identificó un metagen de seis genes (ABAT, ADAMDEC1, CLEC7A, 
ETS1, ITK y STC2), el cual es capaz de distinguir IBC de no-IBC. Este metagen, 
así como sus genes individuales fueron posteriormente evaluados en seis bases de 
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datos in silico independientes y validados usando qRT-PCR en una cohorte de 
pacientes MBC, quienes habían recibido tamoxifeno como primera línea de 
tratamiento. Se mostró, que el metagen, al igual que los genes individuales ABAT y 
STC2 no tienen valor pronóstico, además que la expresión disminuida de ABAT 
y STC2 se asocia con un desenlace desfavorable luego de la terapia anti-
hormonal en pacientes MBC. Se mostró también que solo la expresión de ABAT se 
relacionó con el resultado en pacientes que recibieron tamoxifeno como terapia 
adyuvante. 
Finalmente en el capítulo VI, en la era de las biopsias líquidas y medicina 
personalizada, el objetivo fue caracterizar mutaciones tumor-específicas en ADN libre 
de células (cfDNA) a partir de suero tomado secuencialmente de pacientes MBC 
mientras estaban bajo tratamiento con tamoxifeno. Como prueba de concepto, se 
demostró que diferentes mutaciones pueden ser detectadas en cantidades ínfimas 
de AND en suero libre de células usando secuenciación de nueva generación (NGS) 
con un panel gen dirigido mediante el uso de la tecnología ion-PGM. Adicionalmente, 
el cfDNA puede ser analizado en muestras de sangre almacenadas por casi dos 
décadas. En este estudio exploratorio, se identificaron mutaciones en PIK3CA, 
TP53, AKAP9, CREBBP y SMAD4, las cuales (excepto AKAP9) estuvieron 
presentes tanto en el tumor primario como en el suero cfDNA tomado durante 
la progresión de la enfermedad. Sin embargo, en la mayoría de los casos, estas 
mutaciones no fueron detectadas en sueros precedentes a la progresión, ni siquiera 
tras una re-secuenciación más profunda. Cabe notar que en un caso con presencia 
de la mutación PIK3CA, se rastreó el cfDNA en suero tomado dos años antes del 
diagnóstico de lesiones metastásicas y se logró detectar la mutación en unas pocas 
lecturas usando NGS, aunque no fue confirmada con PCR digital. 
En conclusión, en esta tesis se mostró que las mutaciones PIK3CA detectadas en 
tumores primarios de mama tienen un valor predictivo de respuesta a AI en estado 
avanzo de la enfermedad. Por el contrario, no tienen valor predictivo de respuesta a 
tamoxifeno, ni tampoco valor pronóstico. En relación con el genotipo PIK3CA, se 
demostró que en tumores primarios de mama, la expresión del gen LRG1 puede ser 
usada como un biomarcador potencial de respuesta a la terapia con AI. Dicho 
biomarcador mostró disminuir sus niveles en pacientes con respuesta clínica bajo 
tratamiento neo-adyuvante con AI. A nivel proteómico, el grado de fosforilación de 
MAPK1/3 en cáncer de mama de tipo luminal mostró estar relacionado con 
mutaciones PIK3CA exón específicas. La MAPK1/3 fosforilada, especialmente 
cuando se localiza en el núcleo, también tiene un valor pronóstico en cáncer de 
mama. El siguiente paso fue descubrir biomarcadores de resistencia a la terapia 
endocrina mediante una estrategia alternativa, para lo cual fue construido un metagen 
capaz de identificar cáncer de mama ER-positivo con un fenotipo IBC. Este metagen 
y sus genes individuales ABAT y STC2 mostraron ser capaces de predecir resistencia 
a las terapias con AI y tamoxifeno en pacientes con enfermedad avanzada. Mientras 
que en el contexto adyuvante, solo ABAT, se encontró relacionado con resistencia a 
tamoxifeno. Finalmente, se exploraron mutaciones tumor-específicas en suero cfDNA 
como biomarcadores potenciales de resistencia a tamoxifeno en pacientes MBC. 
Mutaciones en PIK3CA, TP53, AKAP9, CREBBP y SMAD4, fueron identificadas en 
suero cfDNA tomado durante la progresión de la enfermedad. Todas las mutaciones 
(excepto AKAP9) fueron halladas también en el tumor primario. 
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Cabe esperar que todos los biomarcadores potenciales descritos anteriormente en 
esta tesis, mejoren la identificación de pacientes quienes se beneficiarán o no de la 
terapia anti-hormonal. Para estos últimos pacientes quienes no se beneficiarán del 
tratamiento, los efectos adversos no deseados debidos a exposición innecesaria a la 
terapia podrán evitarse. De este modo, con estos biomarcadores hoy podemos 
seleccionar el paciente adecuado para el tratamiento endocrino adecuado, con 
la promesa que en un futuro no muy lejano, una vez los biomarcadores estén más 
extensamente validados por otros, sea posible finalmente seleccionar el 
tratamiento adecuado para el paciente de cáncer de mama adecuado. 

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ZUSAMMENFASSUNG 
Brustkrebs, die am häufigsten auftretende Krebsart bei Frauen und die zweithäufigste 
weltweit, ist eine sehr heterogene Krankheit. Richtlinien zur Behandlung basieren auf 
prognostischen und prädiktiven Faktoren, sowie Tumor-Biomarkern wie zum Beispiel 
Östrogenrezeptor (ER), Progesteronrezeptor (PR) und HER2-Rezeptor. Die meisten 
Mammakarzinome sind ER-positiv (75-80%), für die es drei verschiedene Arten der 
antihormonellen Therapie gibt: selektive Östrogenrezeptormodulatoren (SERMs), 
selektive Östrogenrezeptorabbauer (SERDs) und Aromataseinhibitoren (AIs). 
Tamoxifen, ein SERM, ist seit 40 Jahren das Schlüsselelement der Therapie bei 
prämenopausalen Frauen. Aromataseinhibitoren, welche seit 20 Jahren genutzt 
werden, verhindern die Östrogensynthese und wurden am effektivsten bei 
postmenopausalen Frauen zur Therapie genutzt. SERDs wie Fulvestrant werden 
heutzutage vor allem bei Patienten genutzt, die eine Resistenz auf AIs, aufgrund von 
erworbenen Mutationen in der ER-Bindungsdomäne entwickelt haben. 
Für die Ziele dieser Dissertation war die Tatsache wichtig, dass ER-positive, 
metastasierende Mammakarzinome (MBC) nur in 20-40% der Fälle auf eine 
antihormonelle Therapie ansprechen und dann auch nur mit einer medianen Dauer 
von 8-14 Monaten. Dies zeigt die Notwendigkeit Biomarker zu finden, welche es 
ermöglichen, Patienten die von der Therapie profitieren oder nicht profitieren würden, 
zu identifizieren. Somit könnten die Patienten, die nicht von einer Behandlung 
profitieren, vor den negativen Folgen einer unnötigen (antihormonellen) Therapie und 
ihren unerwünschten Nebenwirkungen geschützt werden. 
Das Ziel dieser Dissertation war es, potenzielle Biomarker vor allem für 
fortgeschrittene ER-positive Mammakarzinome zu finden, die das Ansprechen oder 
die Resistenz auf antihormonelle Therapien besser vorhersagen können. Zu diesem 
Zweck wurden mehrere verschiedene Forschungsansätze verfolgt. Da Mutationen 
des PIK3CA-Gens die vorherrschenden Mutationen bei luminalen Tumoren sind und 
in bis zu 45% der ER-positiven Tumoren vorkommen (siehe Einleitung), konzentriert 
sich diese Dissertation auf die Beziehung zwischen dem PIK3CA-Genotyp und dem 
PI3K-Signalweg in Bezug auf das Therapieergebnis. 
Im zweiten Kapitel untersuchten wir den Effekt der PIK3CA-Mutation in 
Primärtumoren auf das progressionsfreie Überleben von 531 MBC-Patienten, nach 
einer Erstlinientherapie von AIs oder Tamoxifen. Es zeigte sich, dass Patienten mit 
einer PIK3CA-Mutation ein deutlich längeres progressionsfreies Überleben hatten, 
wenn sie mit AIs therapiert wurden als bei Wildtyptumoren. Daher schlugen wir die 
PIK3CA-Mutation als potenziellen prädiktiven Biomarker für die Sensitivität der AI-
Erstlinientherapie vor.  
Im Gegensatz dazu wurde kein Zusammenhang mit dem Ergebnis bei einer 
Erstlinientherapie mit Tamoxifen gefunden. Dementsprechend hat die PIK3CA-
Mutation keinen prädiktiven Wert für die Resistenz oder Sensitivität auf die 
Tamoxifen-Erstlinientherapie. Wir untersuchten die Mutation auch in Bezug auf das 
metastasenfreie Überleben (MFS) in 342  systemischen (neo-) adjuvanten-Therapie-
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naiven LNN-Patienten und zeigten, dass die PIK3CA-Mutation keinen Nutzen als 
prognostischer Biomarker darstellt. 
 
Im dritten Kapitel untersuchten wir ob mRNA- und miR-Expressionsprofile als 
potenzielle prädiktive Biomarker mit dem PIK3CA-Genotyp und dem AI-
Therapieergebnis korrelieren. Zuerst wurde die Expression von mRNAs und miRs in 
primären Mammakarzinomen, im Zusammenhang mit dem PIK3CA-Genotyp, in zwei 
unabhängigen Versuchskohorten untersucht. Die erste Kohorte enthielt 286 luminale 
Proben aus in silico Datensätzen des TCGA-Konsortiums. Die zweite enthielt 84 ER-
positive Proben von MBC-Patienten, die mit einer AI-Erstlinientherapie behandelt 
wurden. In beiden Kohorten konnte ein Zusammenhang zwischen dem PIK3CA-
Mutationsstatus und der Expression von neun mRNAs (CCNO, FAM8 1 B, L RG1 , 
NEK1 0 , PL CL 1 , PGR, SERPINA3, SORBS2, VTCN1) sowie drei miRs (miR-449a, 
miR-205-5p, miR-301a-3p) nachgewiesen werden. Weitere Analysen zeigten, dass 
die Expression von LRG1 und PLCL1 mit einem längeren progressionsfreien 
Überleben nach AI-Erstlinientherapie assoziierten, unabhängig vom luminalen 
Subtyp und traditionellen prädiktiven Parametern. Als nächstes wurden diese neun 
mRNAs und drei miRs in einem öffentlich zugänglichen in silico Datenset von 25 
Mammakarzinompatienten, die mit neoadjuvanter AI-Therapie behandelt wurden, 
geprüft. Hier zeigte sich, dass die Expression von drei Genen (LRG1, PGR, 
SERPINA3) nach neoadjuvanter AI-Therapie signifikant abgenommen hatte in 
Patienten, die auf die Therapie ansprachen. Basierend auf diesen Ergebnissen 
schlugen wir LRG1 als potenziellen, luminal-subtypunabhängigen, Biomarker für 
den PIK3CA-Genotyp und das AI-Therapieergebnis vor. 
Im vierten Kapitel wollten wir tumorassoziierte Proteine der Signalkaskaden mit 
veränderter Expression oder Phosphorylierung in luminalem Brustkrebs mit PIK3CA-
Mutationen detektieren. Hierfür nutzten wir Proben eines in silico Datensatzes von 
361 Primärtumoren von Brustkrebspatienten des TCGA-Konsortiums. Eine verstärkte 
Phosphorylierung von MAPK1/3, p38 und YAP, sowie eine verringerte Expression von 
p70S6K und 4E-BP1 in luminalen Brustkrebsproben im Zusammenhang mit PIK3CA-
Mutationen konnte nachgewiesen werden. Phosphoryliertes MAPK1/3, das am 
signifikantesten hochregulierte Protein assoziiert mit PIK3CA-Exonmutationen, wurde 
in einer weiteren Testreihe mit Gewebemikroarrays aus 721 primären, luminalen 
Mammakarzinomen, einschließlich einer Subgruppe von 290 luminalen Tumoren von 
systemisch-unbehandelten LNN-Patienten, untersucht, um den Bezug zum 
metastasenfreien Überleben zu evaluieren. Wir konnten zeigen, dass vor allem die 
nukleare MAPK1/3-Phosphorylierung einen potenziellen Wert als prognostischer 
Biomarker hat. Unsere Ergebnisse zeigen, dass die Phosphorylierung und 
subzelluläre Lokalisierung von MAPK1/3 mit einer besseren Prognose 
assoziieren. 
In den bisherigen Kapiteln stand immer die Mutation des PIK3CA-Gens als Startpunkt 
im Fokus, um Biomarker mit potenziellem prognostischem oder prädiktivem Wert 
nach Antihormontherapie zu finden. In den Zeiten der Immuntherapie, untersuchten 
wir in Kapitel fünf eine Untergruppe von Patienten mit inflammatorischem 
Mammakarzinom (ER-positiver IBC), welche deutlich häufiger therapieresistent auf 
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antihormonelle Therapien reagieren, im Vergleich zu ER-positiven non-IBC-
Patienten. 
PIK3CA-Mutationen kommen auch bei diesem Karzinomtyp vor, ein signifikanter 
Unterschied in der Prävalenz zwischen IBC und Non-IBC konnte allerdings nicht 
gefunden werden. Aufgrund dieser Beobachtung und da die antihormonelle 
Therapieresistenz auch vom Krebsphänotyp abhängig sein könnte, verglichen wir 
Proben von IBC-Patienten mit Non-IBC-Patienten. Wir identifizierten ein Metagen 
aus sechs Genen (ABAT, ADAMDEC1, CLEC7A, ETS1, ITK und STC2), welches 
sich zwischen IBC und Non-IBC unterschied. Dieses Metagen und seine 
individuellen Gene wurden in 6 unabhängigen in silico Datensätzen evaluiert und 
durch qRT-PCR in einer Kohorte von MBC-Patienten mit Tamoxifen als 
Erstlinientherapie validiert.  Hierbei konnte gezeigt werden, dass das Metagen, 
ABAT und STC2 keinen prognostischen Wert hatten, eine reduzierte Expression 
von ABAT und STC2 mit einem schlechteren antihormonellen Therapieergebnis 
in MBC assoziierte und dass nur die Expression von ABAT bei Patienten mit 
adjuvanter Tamoxifentherapie relevant in Bezug auf das Therapieergebnis war. 
 
In der heutigen Ära der Liquid-Biopsy-Analytik und der personalisierten 
Medizin/Präzisionsmedizin  charakterisierten wir im sechsten Kapitel, 
tumorspezifische Mutationen in zellfreier DNA (cfDNA) aus den konsekutiv 
entnommenen Seren von MBC-Patienten, die unter Tamoxifentherapie standen. In 
einer Pilotstudie, zeigten wir, dass es möglich ist, Mutationen in geringen Mengen 
zellfreier, aus Serum gewonnener, DNA unter Verwendung eines Targeted-Ion PGM 
Genpanels mittels "Next generation sequencing" (NGS) nachzuweisen. Des Weiteren 
kann cfDNA auch in fast zwanzig Jahre alten Blutproben untersucht werden. In dieser 
explorativen Studie identifizierten wir Mutationen in PIK3CA, TP53, AKAP9, 
CREBBP und SMAD4, die (mit Ausnahme von AKAP9) sowohl im Primärtumor 
als auch in der, beim Fortschreiten der Erkrankung gewonnenen, Serum-cfDNA 
auftraten. In den meisten Fällen konnten die Mutationen allerdings nicht in den Seren 
vor der Tumorprogression nachgewiesen werden, dies war auch nicht der Fall bei 
tiefergehender Re-Sequenzierung. Interessanterweise wurde allerdings in einem Fall 
eine PIK3CA-Mutation, in cfDNA aus Serum, das 2 Jahre vor dem Nachweis von 
Metastasen abgenommen wurde gefunden. Diese Mutation wurde nur in wenigen 
NGS-Reads detektiert, aber konnte mit digitaler PCR bestätigt werden. 
Zusammenfassend wurde in dieser Dissertation gezeigt, dass PIK3CA-Mutationen in 
primären Mammakarzinomen einen prädiktiven Nutzen für die 
Aromataseinhibitortherapie bei fortgeschrittener Erkrankung haben, aber jedoch 
keine Aussagekraft in Bezug auf Tamoxifentherapie oder Prognose besitzen. Im 
Zusammenhang mit dem PIK3CA-Genotyp konnte auch in primären 
Mammakarzinomen gezeigt werden, dass die Expression von LRG1 als potenzieller 
Biomarker für den AI-Therapieerfolg genutzt werden kann, da LRG1 im Rahmen einer 
neoadjuvanten Therapie geringere Expression zeigte, wenn die Therapie auch 
klinisch anschlug. Auf Proteinebene konnten wir für luminalen Brustkrebs 
nachweisen, dass der MAPK1/3-Phosphorylierungsgrad in Zusammenhang mit 
PIK3CA-spezifischen Exonmutationen steht. Diese Phosphorylierung von MAPK1/3 
hat auch einen prognostischen Wert für Brustkrebs, vor allem, wenn sie in den 
Zellkernen auftritt.  
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Im Rahmen einer alternativen Herangehensweise um Biomarker für eine Resistenz 
bei der endokrinen Therapie zu finden, konstruierten wir ein Metagen um ER-positive 
Mammakarzinome mit IBC-Phänotyp zu identifizieren.  
Dieses Metagen und seine Einzelgene ABAT und STC2 waren prädiktiv für 
Therapieresistenz gegen Tamoxifen oder AIs im fortgeschrittenen Krankheitsstadium. 
Im Fall der adjuvanten Therapie war nur ABAT mit Tamoxifenresistenz assoziiert. 
Zuletzt untersuchten wir das Potenzial von tumorspezifischen Mutationen in Serum-
cfDNA als Biomarker für Tamoxifenresistenz bei MBC-Patienten. Mutationen in 
PIK3CA, TP53, AKAP9, CREBBP und SMAD4 konnten sowohl im Serum bei 
Tumorprogression als auch, mit Ausnahme von AKAP9, im Primärtumor 
nachgewiesen werden.  
 
Alle in dieser Dissertation beschriebenen potenziellen Biomarker können hoffentlich 
die Identifikation von Patienten verbessern, die von einer antihormonellen Therapie 
profitieren oder nicht profitieren. Für Patienten, die nicht von einer Behandlung 
profitieren würden, könnten dann unerwünschte Nebenwirkungen, die durch eine 
unnötige Therapie entstehen, vermieden werden.  
So können wir heute mithilfe dieser Biomarker den richtigen Patienten für die 
richtige endokrine Therapie auswählen, und hoffentlich in naher Zukunft, wenn 
diese Biomarker auch von Anderen ausführlich validiert worden sind, das richtige 
Therapiekonzept für jeden Brustkrebspatienten individuell bestimmen. 
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